U.S. patent number RE47,770 [Application Number 15/158,543] was granted by the patent office on 2019-12-17 for recombinant production of mixtures of antibodies. This patent grant is currently assigned to Merus N.V.. The grantee listed for this patent is Merus N.V.. Invention is credited to Abraham Bout, Ronald Hendrik Brus, Ton Logtenberg, Patricius H. C. Van Berkel.
United States Patent | RE47,770 |
Van Berkel , et al. | December 17, 2019 |
Provided is methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields.
Inventors: | Van Berkel; Patricius H. C. (Berkel en Rodenrijs, NL), Brus; Ronald Hendrik (Voorschoten, NL), Logtenberg; Ton (Utrecht, NL), Bout; Abraham (Leiden, NL) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Applicant: |
|
||||||||||
Assignee: | Merus N.V. (Utrecht,
NL) |
||||||||||
Family ID: | 68807854 | ||||||||||
Appl. No.: | 15/158,543 | ||||||||||
Filed: | May 18, 2016 |
Application Number | Filing Date | Patent Number | Issue Date | ||
---|---|---|---|---|---|
12221021 | Apr 19, 2011 | 7927834 | |||
11593279 | Sep 30, 2008 | 7429486 | |||
11039767 | Aug 28, 2007 | 7262028 | |||
PCT/EP03/07690 | Jul 15, 2003 | ||||
60397066 | Jul 18, 2002 | ||||
Reissue of: | 12932719 | Mar 4, 2011 | 9303081 | Apr 5, 2016 | |
Current U.S. Class: | 1/1 |
Current CPC Class: | C07K 16/30 (20130101); C07K 16/2851 (20130101); C07K 16/32 (20130101); C07K 16/2833 (20130101); C07K 16/10 (20130101); C07K 16/00 (20130101); C07K 16/2851 (20130101); C07K 16/2803 (20130101); C07K 16/32 (20130101); C07K 16/30 (20130101); A61K 39/39558 (20130101); C07K 16/10 (20130101); C12P 21/005 (20130101); C07K 16/2896 (20130101); C07K 16/2803 (20130101); C07K 16/2833 (20130101); C07K 16/00 (20130101); C07K 2317/515 (20130101); C12N 2795/00041 (20130101); C07K 2317/31 (20130101); C07K 2317/622 (20130101); C07K 2317/626 (20130101); C07K 2317/732 (20130101); Y02P 20/582 (20151101); C07K 2317/21 (20130101); C07K 2319/30 (20130101); C07K 2317/73 (20130101); C07K 2317/12 (20130101); C07K 2317/31 (20130101); C07K 2317/734 (20130101); C07K 2317/51 (20130101); C07K 2317/50 (20130101); C07K 2317/56 (20130101); A61K 2039/507 (20130101) |
Current International Class: | C07K 16/18 (20060101); C07K 16/32 (20060101); C07K 16/28 (20060101); A61K 39/395 (20060101); C12P 21/00 (20060101); C07K 16/10 (20060101); C07K 16/30 (20060101); C07K 16/00 (20060101) |
Field of Search: | ;424/130.1,133.1,134.1,135.1,141.1,801,809 ;530/387.1,387.3,866,867 ;435/69.6 |
4399216 | August 1983 | Axel et al. |
4599311 | July 1986 | Kawasaki |
4634665 | January 1987 | Axel et al. |
4801687 | January 1989 | Ngo |
4816567 | March 1989 | Cabilly et al. |
4868103 | September 1989 | Stavrianopoulos et al. |
4937190 | June 1990 | Palmenberg et al. |
5030002 | July 1991 | North |
5137809 | August 1992 | Loken et al. |
5151504 | September 1992 | Croze |
5179017 | January 1993 | Axel et al. |
5223409 | June 1993 | Ladner et al. |
5385839 | January 1995 | Stinski |
5627037 | May 1997 | Ward et al. |
5631169 | May 1997 | Lakowicz et al. |
5641640 | June 1997 | Hanning |
5667988 | September 1997 | Barbas et al. |
5667998 | September 1997 | Dougherty et al. |
5733779 | March 1998 | Reff |
5770429 | June 1998 | Lonberg et al. |
5772997 | June 1998 | Hudziak et al. |
5783186 | July 1998 | Arakawa et al. |
5789208 | August 1998 | Sharon |
5789215 | August 1998 | Berns et al. |
5827690 | October 1998 | Meade et al. |
5830698 | November 1998 | Reff et al. |
5834237 | November 1998 | Jacobs et al. |
5849500 | December 1998 | Breitling et al. |
5885827 | March 1999 | Wabl et al. |
5888789 | March 1999 | Rodriguez |
5939598 | August 1999 | Kucherlapati et al. |
5965371 | October 1999 | Marasco et al. |
6004940 | December 1999 | Marasco et al. |
6054297 | April 2000 | Carter et al. |
6080560 | June 2000 | Russell et al. |
6114598 | September 2000 | Kucherlapati et al. |
6180357 | January 2001 | Young et al. |
6207446 | March 2001 | Szostak et al. |
6265150 | July 2001 | Terstappen et al. |
6291740 | September 2001 | Bremel et al. |
6303341 | October 2001 | Hiatt et al. |
6335163 | January 2002 | Sharon |
6570061 | May 2003 | Rajewsky et al. |
6586251 | July 2003 | Economides et al. |
6596541 | July 2003 | Murphy et al. |
7067284 | June 2006 | Barbas et al. |
7105348 | September 2006 | Murphy et al. |
7183076 | February 2007 | Arathoon et al. |
7262028 | August 2007 | Van Berkel et al. |
7329530 | February 2008 | Houtzager et al. |
7429486 | September 2008 | Van Berkel et al. |
7491516 | February 2009 | Collinson et al. |
7579446 | August 2009 | Bakker et al. |
7642228 | January 2010 | Carter et al. |
7696330 | April 2010 | Meulen et al. |
7740852 | June 2010 | Bakker et al. |
7777010 | August 2010 | Logtenberg |
7858086 | December 2010 | Geuijen et al. |
7901919 | March 2011 | Houtzager et al. |
7919257 | April 2011 | Hoogenboom et al. |
7927834 | April 2011 | Van Berkel et al. |
7932360 | April 2011 | Van Berkel et al. |
7960518 | June 2011 | Throsby et al. |
7968092 | June 2011 | Throsby et al. |
8052974 | November 2011 | Throsby et al. |
8106170 | January 2012 | Ter Meulen et al. |
8148497 | April 2012 | Bakker et al. |
8192927 | June 2012 | Van Den Brink et al. |
8211431 | July 2012 | Throsby et al. |
8241631 | August 2012 | Throsby et al. |
8268756 | September 2012 | Logtenberg et al. |
8470327 | June 2013 | Throsby et al. |
8592562 | November 2013 | Kannan et al. |
8911738 | December 2014 | Throsby et al. |
9012371 | April 2015 | Logtenberg et al. |
9248181 | February 2016 | De Kruif et al. |
9248182 | February 2016 | De Kruif et al. |
9303081 | April 2016 | Van Berkel et al. |
9358286 | June 2016 | De Kruif et al. |
9738701 | August 2017 | Hoogenboom et al. |
2002/0088016 | July 2002 | Bruggeman |
2002/0138857 | September 2002 | Ghayur |
2003/0039958 | February 2003 | Holt et al. |
2003/0077739 | April 2003 | Simmons et al. |
2003/0091561 | May 2003 | van de Winkel et al. |
2003/0093820 | May 2003 | Green et al. |
2003/0096225 | May 2003 | Logtenberg |
2003/0194403 | October 2003 | van de Winkel et al. |
2003/0207346 | November 2003 | Arathoon et al. |
2003/0215914 | November 2003 | Houtzager et al. |
2003/0219829 | November 2003 | Logtenberg et al. |
2003/0224408 | December 2003 | Hoogenboom et al. |
2005/0014261 | January 2005 | Houtzager et al. |
2005/0037001 | February 2005 | Germeraad et al. |
2005/0037427 | February 2005 | Houtzager et al. |
2005/0170398 | August 2005 | Van Berkel et al. |
2006/0015949 | January 2006 | Lonberg |
2006/0015957 | January 2006 | Lonberg |
2006/0088520 | April 2006 | Germeraad et al. |
2006/0117699 | June 2006 | Di Trapani |
2006/0160184 | July 2006 | Hoogenboom et al. |
2006/0177437 | August 2006 | Houtzager et al. |
2006/0205077 | September 2006 | Schwenk et al. |
2006/0257397 | November 2006 | Throsby et al. |
2006/0292634 | December 2006 | Houtzager et al. |
2007/0054362 | March 2007 | Van Berkel et al. |
2007/0059766 | March 2007 | Logtenberg |
2007/0178552 | August 2007 | Arathoon et al. |
2007/0280945 | December 2007 | Stevens et al. |
2008/0070799 | March 2008 | Bakker et al. |
2008/0241166 | October 2008 | Tomlinson et al. |
2009/0017521 | January 2009 | Houtzager et al. |
2009/0054254 | February 2009 | Throsby et al. |
2009/0130652 | May 2009 | Throsby et al. |
2009/0181855 | July 2009 | Vasquez et al. |
2009/0182127 | July 2009 | Kjaergaard et al. |
2009/0263864 | October 2009 | Van Berkel et al. |
2010/0015133 | January 2010 | Igawa et al. |
2010/0069614 | March 2010 | Houtzager et al. |
2010/0146647 | June 2010 | Logtenberg et al. |
2010/0172917 | July 2010 | Ter Meulen et al. |
2010/0286374 | November 2010 | Kannan et al. |
2010/0297153 | November 2010 | Geuijen et al. |
2010/0310572 | December 2010 | Bakker et al. |
2010/0310586 | December 2010 | Dolcetti et al. |
2010/0331527 | December 2010 | Davis et al. |
2011/0177073 | July 2011 | Van Berkel et al. |
2011/0195454 | August 2011 | McWhirter et al. |
2011/0268739 | November 2011 | Throsby et al. |
2012/0021409 | January 2012 | McWhirter et al. |
2012/0039898 | February 2012 | Throsby et al. |
2012/0058907 | March 2012 | Logtenberg et al. |
2012/0076794 | March 2012 | Throsby et al. |
2012/0093823 | April 2012 | Van Den Brink et al. |
2012/0141493 | June 2012 | Throsby et al. |
2012/0177637 | July 2012 | Hoogenboom et al. |
2012/0192300 | July 2012 | Babb et al. |
2012/0276115 | November 2012 | Van Den Brink et al. |
2012/0315278 | December 2012 | Throsby et al. |
2013/0115208 | May 2013 | Ho et al. |
2013/0145484 | June 2013 | Logtenberg et al. |
2013/0336981 | December 2013 | de Kruif et al. |
2014/0072579 | March 2014 | De Kruif et al. |
2014/0120096 | May 2014 | Bakker et al. |
2014/0140999 | May 2014 | De Kruif et al. |
2014/0314755 | October 2014 | Logtenberg et al. |
2014/0317766 | November 2014 | Logtenberg et al. |
2015/0139996 | May 2015 | De Kruif et al. |
2015/0196637 | July 2015 | De Kruif et al. |
2016/0238600 | August 2016 | Hoogenboom et al. |
2016/0319320 | November 2016 | Van Berkel et al. |
2018/0094289 | April 2018 | Van Berkel et al. |
2018/0112247 | April 2018 | Van Berkel et al. |
2003250074 | Feb 2004 | AU | |||
2 405 961 | Nov 2001 | CA | |||
2405961 | Nov 2001 | CA | |||
1341364 | Jun 2002 | CA | |||
2445255 | Oct 2002 | CA | |||
2114353 | Jan 2006 | CA | |||
0120694 | Oct 1984 | EP | |||
0314161 | May 1989 | EP | |||
0402029 | Dec 1990 | EP | |||
0445625 | Sep 1991 | EP | |||
0 469 897 | Feb 1992 | EP | |||
0469025 | Feb 1992 | EP | |||
0469897 | Feb 1992 | EP | |||
0481790 | Apr 1992 | EP | |||
171142 | Jul 1992 | EP | |||
0523949 | Jan 1993 | EP | |||
469025 | Aug 1995 | EP | |||
0814159 | Dec 1997 | EP | |||
0724639 | Jan 2001 | EP | |||
666868 | Apr 2002 | EP | |||
1349234 | Oct 2003 | EP | |||
1399575 | Mar 2004 | EP | |||
1439234 | Nov 2004 | EP | |||
1 325 932 | Apr 2005 | EP | |||
1325932 | Apr 2005 | EP | |||
1870459 | Dec 2007 | EP | |||
2147594 | Jan 2010 | EP | |||
2817875 | Jun 2002 | FR | |||
5-68599 | Mar 1993 | JP | |||
8116978 | May 1996 | JP | |||
2001523971 | Nov 2001 | JP | |||
2004008214 | Aug 2003 | JP | |||
20048218 | Jan 2004 | JP | |||
2004-524841 | Aug 2004 | JP | |||
2006-109711 | Apr 2006 | JP | |||
2006-515503 | Jun 2006 | JP | |||
2008-538912 | Nov 2008 | JP | |||
2010-505418 | Feb 2010 | JP | |||
2010-512749 | Apr 2010 | JP | |||
2011508604 | Mar 2011 | JP | |||
2011-525808 | Sep 2011 | JP | |||
2013004215 | Jan 2013 | JP | |||
5749161 | May 2015 | JP | |||
2236127 | Sep 2004 | RU | |||
9002809 | Mar 1990 | WO | |||
WO 90/02809 | Mar 1990 | WO | |||
9004036 | Apr 1990 | WO | |||
9012878 | Nov 1990 | WO | |||
9100906 | Jan 1991 | WO | |||
9100906 | Jan 1991 | WO | |||
9108216 | Jun 1991 | WO | |||
9117271 | Nov 1991 | WO | |||
9201047 | Jan 1992 | WO | |||
9203918 | Mar 1992 | WO | |||
9209690 | Jun 1992 | WO | |||
9215679 | Sep 1992 | WO | |||
9218619 | Oct 1992 | WO | |||
9220791 | Nov 1992 | WO | |||
9301288 | Jan 1993 | WO | |||
9312227 | Jun 1993 | WO | |||
9402602 | Feb 1994 | WO | |||
9402610 | Feb 1994 | WO | |||
9404667 | Mar 1994 | WO | |||
9423046 | Oct 1994 | WO | |||
9425591 | Nov 1994 | WO | |||
9517085 | Jun 1995 | WO | |||
9517500 | Jun 1995 | WO | |||
9520401 | Aug 1995 | WO | |||
9627011 | Sep 1996 | WO | |||
9630498 | Oct 1996 | WO | |||
9742313 | Nov 1997 | WO | |||
9747739 | Dec 1997 | WO | |||
9815627 | Apr 1998 | WO | |||
9815833 | Apr 1998 | WO | |||
9839416 | Sep 1998 | WO | |||
9841645 | Sep 1998 | WO | |||
9824893 | Nov 1998 | WO | |||
9824923 | Nov 1998 | WO | |||
9850431 | Nov 1998 | WO | |||
9852976 | Nov 1998 | WO | |||
9920749 | Apr 1999 | WO | |||
99156894 | Apr 1999 | WO | |||
9923221 | May 1999 | WO | |||
9926569 | Jun 1999 | WO | |||
9936569 | Jul 1999 | WO | |||
WO 99/26569 | Jul 1999 | WO | |||
9945962 | Sep 1999 | WO | |||
1999050657 | Oct 1999 | WO | |||
9964582 | Dec 1999 | WO | |||
44777 | Aug 2000 | WO | |||
0063403 | Oct 2000 | WO | |||
0070023 | Nov 2000 | WO | |||
0071694 | Nov 2000 | WO | |||
WO 00/71694 | Nov 2000 | WO | |||
0076310 | Dec 2000 | WO | |||
WO 00/76310 | Dec 2000 | WO | |||
0100245 | Jan 2001 | WO | |||
0119394 | Mar 2001 | WO | |||
0127279 | Apr 2001 | WO | |||
0132901 | May 2001 | WO | |||
0148485 | Jul 2001 | WO | |||
0164929 | Sep 2001 | WO | |||
0188132 | Nov 2001 | WO | |||
188132 | Nov 2001 | WO | |||
0218948 | Mar 2002 | WO | |||
236789 | May 2002 | WO | |||
0243478 | Jun 2002 | WO | |||
0246233 | Jun 2002 | WO | |||
WO 02/43478 | Jun 2002 | WO | |||
WO 02/46233 | Jun 2002 | WO | |||
2059297 | Aug 2002 | WO | |||
02066630 | Aug 2002 | WO | |||
02074969 | Sep 2002 | WO | |||
WO 02/074969 | Sep 2002 | WO | |||
02096948 | Dec 2002 | WO | |||
WO 02/096948 | Dec 2002 | WO | |||
03002609 | Jan 2003 | WO | |||
03004704 | Jan 2003 | WO | |||
WO 03/004704 | Jan 2003 | WO | |||
WO 03/0026909 | Jan 2003 | WO | |||
03016501 | Feb 2003 | WO | |||
WO 03/016501 | Feb 2003 | WO | |||
3033670 | Apr 2003 | WO | |||
00048306 | Jun 2003 | WO | |||
03046560 | Jun 2003 | WO | |||
WO 03/046560 | Jun 2003 | WO | |||
WO 03/048306 | Jun 2003 | WO | |||
03102157 | Dec 2003 | WO | |||
3106674 | Dec 2003 | WO | |||
03106684 | Dec 2003 | WO | |||
WO 03/0102157 | Dec 2003 | WO | |||
WO 03/106684 | Dec 2003 | WO | |||
2004009618 | Jan 2004 | WO | |||
2004061104 | Jul 2004 | WO | |||
2004003211 | Aug 2004 | WO | |||
2004106375 | Dec 2004 | WO | |||
2004106375 | Dec 2004 | WO | |||
2005068622 | Jul 2005 | WO | |||
WO 2005/068622 | Jul 2005 | WO | |||
2005118635 | Dec 2005 | WO | |||
2006028936 | Mar 2006 | WO | |||
2006106905 | Oct 2006 | WO | |||
2006117699 | Nov 2006 | WO | |||
2006117699 | Nov 2006 | WO | |||
2007110205 | Oct 2007 | WO | |||
2007117410 | Oct 2007 | WO | |||
2007147901 | Dec 2007 | WO | |||
2008054606 | May 2008 | WO | |||
2008076379 | Jun 2008 | WO | |||
2008119353 | Oct 2008 | WO | |||
2009051974 | Apr 2009 | WO | |||
2009080251 | Jul 2009 | WO | |||
2009080252 | Jul 2009 | WO | |||
2009080253 | Jul 2009 | WO | |||
2009089004 | Jul 2009 | WO | |||
2009098596 | Aug 2009 | WO | |||
2009157771 | Dec 2009 | WO | |||
2010084197 | Jul 2010 | WO | |||
2010129304 | Nov 2010 | WO | |||
2011028952 | Mar 2011 | WO | |||
2011028953 | Mar 2011 | WO | |||
2011097603 | Aug 2011 | WO | |||
2011143545 | Nov 2011 | WO | |||
2012020096 | Feb 2012 | WO | |||
2012023053 | Feb 2012 | WO | |||
2012058768 | May 2012 | WO | |||
2012131555 | Oct 2012 | WO | |||
2012141798 | Oct 2012 | WO | |||
AL. Joyner, Gene Targeting: A Practical Approach, The Practical Approach Series, 2005, (196 pages), Second Edition, Oxford University Press. cited by applicant . Abstract dated Jul. 9, 2012, EP12175544. cited by applicant . Abstract, "Recombinant Production of Mixtures of Antibodies", Reference No. P61090EP20, at least as early as Oct. 1, 2010, 1 page. cited by applicant . Allen, Ligand-targeted therapeutics in anticancer therapy, Nat. Rev. Cancer, 2002, 2:750-783, Abstract only. cited by applicant . Almagro et al., Humanization of antibodies, Frontiers in Bioscience, Jan. 1, 2008, pp. 1619-1633, vol. 13. cited by applicant . Appeal Brief under 37 C.F.R. .sctn. 41.37 filed by Brenda Herschbach Jarrell, U.S. Appl. No. 13/948,818, dated Jul. 20, 2015, 26 pages. cited by applicant . U.S. Appl. No. 11/645,238, sharing common inventors, available on the U.S. Patent Office website. cited by applicant . Annexes in respect of a request for a change from Merus B.V. to Merus N.V. dated May 19, 2016 (English version). cited by applicant . Annexes in respect of a request for a change from Merus B.V. to Merus N.V. dated May 27, 2016 (Dutch version). cited by applicant . Acknowledgement of receipt from European Patent Office for EP 10186063.3 dated May 20, 2016. cited by applicant . Acknowledgement of receipt of European Patent Office regarding EP 10186063.3 dated Jun. 6, 2016, 2 pages. cited by applicant . Amendment, Australian patent application No. 2009263082, Jan. 23, 2014, 22 pages. cited by applicant . Advice of receipt to Fritz Lahrtz of Isenbruck Bosl Hoschler LLP, Registration No. of item RD119029438NL, Mar. 14, 2016, one page. cited by applicant . Advice of receipt to Fritz Lahrtz of Isenbruck Bosl Hoschler LLP, Registration No. of item RD118911257NL, May 25, 2016, one page. cited by applicant . Auxiliary Request 13 with annotations, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, Five pages. cited by applicant . Auxiliary Request 13, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages. cited by applicant . Auxiliary Request 14 with annotations, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, Five pages. cited by applicant . Auxiliary Request 14, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages. cited by applicant . Auxiliary Request 2 with annotations, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, Five pages. cited by applicant . Auxiliary Request 2, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages. cited by applicant . Auxiliary Request 3 with annotations, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, Five pages. cited by applicant . Auxiliary Request 3, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages. cited by applicant . Auxiliary Request 4 with annotations, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, Five pages. cited by applicant . Auxiliary Request 4, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages. cited by applicant . Auxiliary Request 5 with annotations, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, Five pages. cited by applicant . Auxiliary Request 5, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages. cited by applicant . Auxiliary Request 6 with annotations, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, Five pages. cited by applicant . Auxiliary Request 6, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages. cited by applicant . Auxiliary Request 7 with annotations, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, seven pages. cited by applicant . Auxiliary Request 7, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages. cited by applicant . Auxiliary Request 8 with annotations, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, seven pages. cited by applicant . Auxiliary Request 8, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages. cited by applicant . Auxiliary Request 9 with annotations, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, nine pages. cited by applicant . Auxiliary Request 9, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages. cited by applicant . Aya Jakobovits, The long-awaited magic bullets: therapeutic human monoclonal antibodies from transgenic mice, Exp. Opin. Invest. Drugs, 1998, pp. 607-614, vol. 7, No. 4, Ashley Publications Ltd. cited by applicant . U.S. Appl. No. 15/090,505, sharing common inventors, available on the U.S. Patent Office website. cited by applicant . Approved Judgement in Regeneron Pharmaceuticals Inc.vs Kymab Limited and Novo Nordisk A/S, Case No: HP-2013-000001/HP-2014-000001 for Hearing dates: Nov. 18-20, 23-27,30 and Dec. 7 & 8, 2015. cited by applicant . Arai et al., Antibody responses induced by immunization with a Japanese rabies vaccine detennined by neutralization test and enzyme-linked immunosorbert assay, Vaccine, Jun. 2002, pp. 2448-2453, vol. 7, No. 20(19-20). cited by applicant . Attaelmannan, Mohammed et al., "Understanding and Identifying Monoclonal Gammopathies," Clinical Chemistry, vol. 46(88):1230-1238 (2000). cited by applicant . Atwell et al., Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library1, J. Mol. Biol., Jul. 4, 1997, pp. 26-35, vol. 270, Issue 1, Abstract only. cited by applicant . Aucouturier et al., Monoclonal lg L Chain and L Chain V Domain Fragment Crystallization in Myeloma-Associated Fanconi's Syndrome, The Journal of Immunology, Apr. 15, 1993, pp. 3561-3568, vol. 150, No. 8. cited by applicant . Auerbach et al., Angiogenesis Assays: A Critical Overview, Clin. Chemistry, Jan. 2003, pp. 32 40, vol. 49, No. 1. cited by applicant . Australian Office Action for Application No. 2009263082, 8 pages, dated Mar. 18, 2014. cited by applicant . Auxiliary Request 1 with annotations, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, Five pages. cited by applicant . Auxiliary Request 1, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages. cited by applicant . Auxiliary Request 10 with annotations, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, nine pages. cited by applicant . Auxiliary Request 10, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages. cited by applicant . Auxiliary Request 11 with annotations, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, Five pages. cited by applicant . Auxiliary Request 11, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, three pages. cited by applicant . Auxiliary Request 12 with annotations, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, Five pages. cited by applicant . Auxiliary Request 12, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, three pages. cited by applicant . Auxiliary request 5, EP Application No. 09075279.1, Reference No. P85261EP00, Apr. 23, 2013, three pages. cited by applicant . Auxiliary request 1, EP Application No. 09075279.1, Reference No. P85261EP00, Apr. 23, 2013, three pages. cited by applicant . Auxiliary request 2, EP Application No. 09075279.1, Reference No. P85261EP00, Apr. 23, 2013, three pages. cited by applicant . Auxiliary request 3, EP Application No. 09075279.1, Reference No. P85261EP00, Apr. 23, 2013, three pages. cited by applicant . Auxiliary request 6, EP Application No. 09075279.1, Reference No. P85261EP00, Apr. 23, 2013, three pages. cited by applicant . Arnold et al., Development of B-1 Cells: Segregation of Phosphatidyl Choline-specific B Cells to the B-1 Population Occurs After Immunoglobulin Gene Expression, J. Exp. Med., May 1994, pp. 1585-1595, vol. 179, The Rockfeller University Press. cited by applicant . Auxiliary request 4, EP Application No. 09075279.1, Reference No. P85261EP00, Apr. 23, 2013, three pages. cited by applicant . Auxiliary request 1 (amendments indicated), EP Application No. 09075279.1, Reference No. P85261EP00, Apr. 23, 2013, three pages. cited by applicant . Auxiliary request 2 (amendments indicated), EP Application No. 09075279.1, Reference No. P85261EP00, Apr. 23, 2013, three pages. cited by applicant . Auxiliary request 3 (amendments indicated), EP Application No. 09075279.1, Reference No. P85261EP00, Apr. 23, 2013, three pages. cited by applicant . Auxiliary request 5 (amendments indicated), EP Application No. 09075279.1, Reference No. P85261EP00, Apr. 23, 2013, three pages. cited by applicant . Auxiliary request 6 (amendments indicated), EP Application No. 09075279.1, Reference No. P85261EP00, Apr. 23, 2013 three pages. cited by applicant . Auxiliary request 4 (amendments indicated), EP Application No. 09075279.1, Reference No. P85261EP00, Apr. 23, 2013, three pages. cited by applicant . Campbell et al., Sheep cloned by nuclear transfer from a cultured cell line, Nature, Mar. 7, 1996, pp. 64-66, vol. 380, Nature Publishing Group. cited by applicant . Birchmeier et. al., Met, metastasis, motility and more, Nat. Rev. Mol. Cell Biol., Dec. 2003, pp. 915-925, vol. 4, Abstract only. cited by applicant . Bogen, Bjarne et al., "A rearranged lambda 2 light gene chain retards but does not exclude kappa and lambda 1 expression," Eur. J. Immunol., vol. 21:2391-2395 (1991). cited by applicant . Brady et al., Rapid specific amplification of rat antibody cDNA from nine hybridomas in the presence of myeloma light chains, Journal of Immunological Methods, Aug. 31, 2006, pp. 61-67, vol. 315. cited by applicant . Bruggemann et al., A Repertoire of Monoclonal Antibodies with Human Heavy Chains from Transgenic Mice, Proc. Natl. Acad. Sci., Sep. 1989, pp. 6709-6713, vol. 86, USA. cited by applicant . Burger et al., An integrated strategy for the process development of a recombinant antibody-cytokine fusion protein expressed in BHK cells, Appl. Microbiol. Biotechnol., Sep. 1999, pp. 345-353, vol. 52, Issue 3, Abstract only. cited by applicant . Brief communication in opposition proceedings for EP application 10186063.3 dated May 31, 2016, one page. cited by applicant . Brief communication in Opposition proceedings in EP 10186063.3 dated May 26, 2016. cited by applicant . Communication from the European Patent Office to Isenbruck Bosl Forschler LLP regarding change to Merus N.V. dated Jun. 7, 2016. cited by applicant . Brief Communication from European Patent Office to Isenbruck Bosl Forschler LLP regarding EP 10186063.3 dated Jun. 13, 2016. cited by applicant . Brief Communication from European Patent Office to JA Kemp regarding EP 10186063.3 dated Jun. 13, 2016. cited by applicant . Brief Communication from European Patent Office to JA Kemp regarding EP 10186063.3 dated Jun. 7, 2016. cited by applicant . Brief Communication from European Patent Office to Isenbruck Bosl Forschler LLP regarding EP 10186063.3 dated Jun. 10, 2016 about Oral proceedings on Jun. 22, 2016. cited by applicant . Brief communication from European Patent Office to JA Kemp about Opposition--Oral proceedings on Jun. 22, 2016. cited by applicant . Correspondence from A. Bentham of J A Kemp to The European Patent Office regarding the reply to the Patentees response to Opposition, EP Application No. 09075279.1, Aug. 20, 2015, eight pages. cited by applicant . Cao et al., Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models, Proc. Natl. Acad. Sci. U.S.A., Jun. 19, 2001, pp. 7443-7448, vol. 98, No. 13. cited by applicant . Carmack et al, Influence of a Vkappa8 L Chain Transgene on Endogenous Rearrangements and the Immune Response to the HA(SB) Determinant on Influenza Virus The Journal of Immunology, 1991, vol. 147, No. 6, pp. 2024-2033. cited by applicant . Carter et al., Humanization of anti-p185her2 antibody for human cancer therapy, PNAS, 1992, pp. 4285-4289, vol. 89. cited by applicant . Carter, Paul, "Bispecific human lgG by design," Journal of Immunological Methods, vol. 248:7-15 (2001). cited by applicant . Cho et al., Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab, Nature, Feb. 13, 2003, pp. 756-760, vol. 421, Abstract only. cited by applicant . Chothia, et al., Canonical Structures for the Hypervariable Regions of Immunoglobulins, J. Mol. Biol., Aug. 20, 1987, pp. 901-917, vol. 196, Issue 4. cited by applicant . Casellas et al., Contribution of Receptor Editing to the Antibody Repertoire, Science, Feb. 23, 2001, pp. 1541-1544, vol. 291, Issue 5508. cited by applicant . Castelli et al., HLA-DP4, the Most Frequent HLA II Molecule, Defines a New Supertype of Peptide-Binding Specificity, J. Immunol., Dec. 15, 2002, pp. 6928-6934, vol. 169, No. 12. cited by applicant . Cherrington et al., New paradigms for the treatment of cancer: The role of anti-angiogenesis agents, Adv. Cancer. Res., 2000, pp. 1-38, vol. 79, Abstract only. cited by applicant . Cheung et al., A recombinant human Fab expressed in Escherichia coli neutralizes rabies virus, J. Virol., Nov. 1992, pp. 6714-6720, vol. 66, No. 11. cited by applicant . Christophe Sirac; Sirac et al. (2006) Role of the monoclonal kappa chain V domain and reversibility of renal damage in a transgenic model of acquired Fanconi syndrome, Blood 108:536-543. cited by applicant . Claims dated Jul. 9, 2012, EP12175544. cited by applicant . Claims, Replacement pp. 125-129, Reference No. P61090EP20, at least as early as Oct. 1, 2010, 5 pages. cited by applicant . Conn et al., Purification of a glycoprotein vascular endothelial cell mitogen from a rat glioma-derived cell line, Proc. Natl. Acad. Sci. U.S.A., Feb. 1, 1990, pp. 1323-1327, vol. 87, No. 4. cited by applicant . Correspondence from C.M. Jansen of V.O. to the European Patent Office regarding change of correspondence, EP Application No. 10186063.3 and EP Patent No. 2314629, Dec. 17, 2015, one page. cited by applicant . Correspondence from Dr. Fritz Lahrtz of Isenbruck Bosl Forschler LLP to the European Patent Office regarding change of correspondence, EP Application No. 10186063.3 and EP Patent No. 2314629, Jan. 8, 2016, one page. cited by applicant . Correspondence from Dr. Fritz Lahrtz of Isenbruck Bosl Forschler LLP to the European Patent Office regarding the Oral Proceedings on Jun. 22, 2016, EP Application No. 10186063.3 and EP Patent No. 2314629, Feb. 16, 2016, one page. cited by applicant . Correspondence from A Bentham of J A Kemp to The European Patent Office regarding inquiry on status of opposition, EP Application No. 09075279.1, Nov. 17, 2015, one page. cited by applicant . Correspondence from C.M. Jansen of V.O. to European Patent Office regarding the Registration of the Association and change of address, reference No. RvE/E100EPEP, Sep. 29, 2015, one page. cited by applicant . Correspondence from A. Bentham of J A Kemp to The European Patent Office regarding request to change date of Oral Proceedings, EP Patent No. 2147594, Jan. 29, 2016, two pages. cited by applicant . Correspondence from Fritz Lahrtz of Isenbruck Bosl Hoschler LLP to European Patent Office regarding request for Postponement of Oral Proceedings, EP Application No. 09075279.1 and EP Patent No. 2147594, Feb. 1, 2016, two pages. cited by applicant . Correspondence from A. Bentham of J A Kemp to The European Patent Office regarding possible dates for Oral Proceedings, EP Patent No. 2147594, Feb. 15, 2016, one page. cited by applicant . Correspondence from Dr. Fritz Lahrtz of Isenbruck Bosl Forschler LLP to the European Patent Office regarding change of name for Proprietor, EP Application No. 09075279.1 and EP Patent No. 2147594, May 30, 2016, one page. cited by applicant . Bitter et al., Expression and Secretion Vectors for Yeast, in Methods in Enzymology, Ed. Wu & Grossman, Acad. Press, N.Y. 153:516 544 (1987) Abstract only. cited by applicant . Correspondence from Dr. Fritz Lahrtz of Isenbruck Bosl Forschler LLP to the European Patent Office regarding change of representation, EP Application No. 09075279.1 and EP Patent No. 2147594, Jan. 8, 2016, one page. cited by applicant . Cascalho et al., A Quasi-Monoclonal Mouse, Science, Jun. 14, 1996, pp. 1649-1652, vol. 272. cited by applicant . Claims (amendments indicated), European Patent Application No. 09075279.1, Dec. 22, 2011, Reference No. P85231EP00, five pages. cited by applicant . Correspondence from A Bentham of J A Kemp to European Patent Office regarding an opposition, EP Patent No. 2147594, Aug. 11, 2014, one page. cited by applicant . Correspondence from C.M. Jansen of V.O. to European Patent Office regarding change of representation, EP Patent No. 2147594, Dec. 17, 2015, one page. cited by applicant . EP Priority Document of EP Application No. 02077953.4, "Recombinant Production of Mixtures of Antibodies", submitted in International Application No. PCT/EP03/07690, Sep. 5, 2003, 140 pages. cited by applicant . EP Priority Document of International Application No. PCT/EP03/50201, "Recombinant Production of Mixtures of Antibodies", submitted in International Application No. PCT/EP03/07690, Sep. 1, 2003, 168 pages. cited by applicant . EP Priority Document of International Application No. PCT/EP2003/07690, "Recombianant Production of Mixtures of Antibodies", Oct. 25, 2010, 186 pages. cited by applicant . EPO Acknowledgement of receipt dated Aug. 20, 2012, EP12175544.1. cited by applicant . EPO Acknowledgement of receipt dated Dec. 17, 2015, EP12175544.1. cited by applicant . EPO Acknowledgement of receipt dated Jul. 9, 2012, Application No. EP12175544.1. cited by applicant . EPO Acknowledgement of Receipt of the Notice of Opposition against EP Application No. 10186063.3 and EP Patent No. 2314629, date of receipt Jul. 15, 2014, three pages. cited by applicant . EPO Acknowledgement of Receipt of the submission by the proprietor, EP Application No. 10186063.3 and EP Patent No. 2314629, date of receipt Feb. 24, 2015, one page. cited by applicant . EPO Acknowledgement of Receipt of the submission by the proprietor, EP Application No. 10186063.3 and EP Patent No. 2314629, date of receipt Oct. 16, 2014, one page. cited by applicant . EPO Acknowledgement of receipt, Acknowledgement of Receipt, Application No. 10186063.3 and EP Patent No. 2314629, Nov. 27, 2015, one page. cited by applicant . EPO Acknowledgement of receipt, request, Application No. 10186063.3, Dec. 17, 2015, one page. cited by applicant . EPO Annexes in respect of a request for a change dated May 30, 2016, EP12175544.1. cited by applicant . EPO Brief Communication regarding the Opposition against EP Application No. 10186063.3 and EP Patent No. 2314629, Feb. 27, 2015, EPO Form 2911O 01.12, one page. cited by applicant . EPO Brief Communication regarding the Opposition againts EP Application No. 10186063.3 and EP Patent No. 2314629, Oct. 24, 2014, EPO Form 2911O 01.12, one page. cited by applicant . EPO Client Database System--clean up dated Apr. 23, 2013, EP12175544.1. cited by applicant . EPO Communication concerning the registration of amendments relating to entries pertaining to the applicant/the proprietor dated Jun. 20, 2016, EP12175544.1. cited by applicant . EPO Communication of a notice of opposition (R. 79(1) EPC), EP Application No. 10186063.3 and EP Patent No. 2314629, Aug. 22, 2014, EPO Form 2317A, 12.07, one page. cited by applicant . EPO Communication of a notice of opposition for EP Application No. 10186063.3 and EP Patent No. 2314629, Jul. 21, 2014 EPO Form 2316, 01.12, one page. cited by applicant . EPO Communication of amended entries concerning the representation dated Dec. 23, 2015, EP12175544.1. cited by applicant . EPO Communication of amended entries concerning the representative (R. 143(1)(h) EPC), EP Application No. 10186063.3 and EP Patent No. 2314629, Oct. 8, 2015, EPO Form 2548, 08.13, one page. cited by applicant . EPO Communication of amended entries concerning the representative (R. 143(1)(h) EPC), EP Application No. 039075279.1 and Patent No. 2147594, Oct. 8, 2015, EPO Form 2548 08.13, one page. cited by applicant . EPO Communication of further notices of opposition pursuant to Rule 79(2) EPC, EP Application No. 10186063.3 and EP Patent No. 2314629, Aug. 22, 2014, EPO Form 2318, 01.12, one page. cited by applicant . EPO Acknowledgement of receipt of letter regarding request for extension of time, EP Application No. 09075279.1, date of receipt Oct. 16, 2014, one page. cited by applicant . EPO Brief Communication regarding the Opposition, EP Application No. 09075279.1 and Patent No. 2147594, Oct. 22, 2014, EPO Form 2911O 01.12, one page. cited by applicant . EPO Acknowledgement of receipt of letter regarding reply to opposition, EP Application No. 09075279.1 and Patent No. 2147594, date of receipt Apr. 2, 2015, one page. cited by applicant . EPO Brief Communication regarding the Opposition, EP Application No. 09075279.1 and Patent No. 2147594, Apr. 13, 2015, EPO Form 2911O 01.12, one page. cited by applicant . EPO Acknowledgement of receipt of letter regarding reply patentee's response to opposition, EP Application No. 09075279.1 and Patent No. 02147594, date of receipt Aug. 20, 2015, one page. cited by applicant . EPO Acknowledgement of receipt of letter regarding in vivo data, EP Application No. 09075279.1, date of receipt Jun. 13, 2013, one page. cited by applicant . EPO Brief Communication regarding the Opposition, EP Application No. 09075279.1 and Patent No. 2147594, Aug. 25, 2015, EPO Form 2911O 01.12, one page. cited by applicant . EPO Brief Communication to Fritz Lahrtz of Isenbruck Bosl Hoschler LLP regarding the telephone conversation on the Opposition, EP Application No. 09075279.1 and Patent No. 2147594, Mar. 16, 2016, EPO Form 2911O 01.12, one page. cited by applicant . EPO Acknowledgement of receipt of request to change date of oral proceedings, EP Application No. 09075279.1 and Patent No. 2147594, date of receipt Jan. 29, 2016, one page. cited by applicant . EPO Authorization of Johan Renew regarding Oral Proceedings, EP Application No. 09075279.1, Dec. 2, 2015, one page. cited by applicant . EPO Brief Communication to Fritz Lahrtz of Isenbruck Bosl Hoschler LLP regarding the Opposition and Oral Proceedings, EP Application No. 09075279.1 and Patent No. 2147594, Feb. 9, 2016, EPO Form 2911O 01.12, one page. cited by applicant . EPO Brief Communication to Andrew Bentham of J A Kemp regarding the Opposition and Oral Proceedings, EP Application No. 09075279.1 and Patent No. 2147594, Feb. 9, 2016, EPO Form 2911O 01.12, one page. cited by applicant . EPO Acknowledgement of receipt of possible dates for oral proceedings, EP Application No. 09075279.1 and Patent No. 2147594, date of receipt Feb. 15, 2016, one page. cited by applicant . EPO Brief Communication to Andrew Bentham of J A Kemp regarding the telephone conversation on the Opposition, EP Application No. 09075279.1 and Patent No. 2147594, Mar. 16, 2016, EPO Form 2911O 01.12, one page. cited by applicant . EPO Brief Communication to Fritz Lahrtz of Isenbruck Bosl Hoschler LLP regarding the Oral Proceedings on Oct. 13, 2016, EP Application No. 09075279.1 and Patent No. 2147594, Mar. 22, 2016, EPO Form 2310A 12.07, one page. cited by applicant . EPO Brief Communication to Andrew Bentham of J A Kemp regarding the Oral Proceedings on Oct. 13, 2016, EP Application No. 09075279.1 and Patent No. 2147594, Mar. 22, 2016, EPO Form 2310A 12.07, one page. cited by applicant . EPO Acknowledgement of receipt of executed acknowledgment, EP Application No. 09075279.1 and Patent No. 2147594, date of receipt Apr. 12, 2016, one page. cited by applicant . EPO Brief Communication to Andrew Bentham of J A Kemp regarding the Opposition, EP Application No. 09075279.1 and Patent No. 2147594, Jun. 14, 2016, EPO Form 2911O 01.12, one page. cited by applicant . EPO Acknowledgement of receipt of letter of inquiry, EP Application No. 09075279.1 and Patent No. 2147594, date of receipt Nov. 17, 2015, one page. cited by applicant . EPO Brief Communication regarding the Opposition, EP Application No. 09075279.1 and Patent No. 2147594, Dec. 9, 2015, EPO Form 2911O 01.12, one page. cited by applicant . EPO Acknowledgement of receipt of change of representation, EP Application No. 09075279.1 and Patent No. 2147594, date of receipt Dec. 17, 2015, one page. cited by applicant . EPO Acknowledgement of receipt of Notice of Opposition, EP Application No. 09075279.1 and EP Patent No. 2147594, date of receipt Aug. 11, 2014, two pages. cited by applicant . EPO Communication of a Notice of Opposition, EP Application No. 09075279.1 and EP Patent No. 2147594, Aug. 20, 2014, EPO Form 2316 01.12, one page. cited by applicant . EPO Acknowledgement of receipt of claim requests, EP Application No. 09075279.1, date of receipt Apr. 23, 2013, two pages. cited by applicant . EPO Acknowledgement of receipt of written submissions, EP Application No. 09075279.1, date of receipt Apr. 24, 2013, one page. cited by applicant . EP Application No. 09075279.1 with annotations, Aug. 3, 2010, 170 pages. cited by applicant . EPO Acknowledgement of receipt of letter regarding French and German translated claims, EP Application No. 09075279.1, date of receipt Sep. 2, 2013, one page. cited by applicant . EPO Acknowledgement of receipt of letter regarding request to hold application, EP Application No. 09075279.1, date of receipt Sep. 3, 2013, one page. cited by applicant . EPO communication to Fritz Lahrtz of Isenbruck Bosl Hoschler LLP, Brief Communication regarding Oral proceedings on Jun. 22, 2016 at 10:00 in S2.1, EP Application No. 10186063.3 and EP Patent No. 2314629, Apr. 26, 2016, EPO Form 2911O 01.12, one page. cited by applicant . EPO communication to Fritz Lahrtz of Isenbruck Bosl Hoschler LLP, Communication of amended entries concerning the representative (R. 143(1)(h) EPC), EP Application No. 10186063.3 and EP Patent No. 2314629, Jan. 12, 2016, EPO Form 2548 08.13, one page. cited by applicant . EPO Communication to J A Kemp, Acknowledgement of receipt of EPO Forms 2310 and 2043, EP Application No. 10186063.3 and EP Patent No. 2314629, Nov. 19, 2015, EPO Form 2936 08.10, one page. cited by applicant . EPO Communication to V.O., Acknowledgement of receipt of EPO Forms 2310 and 2043, EP Application No. 10186063.3 and EP Patent No. 2314629, Nov. 19, 2015, EPO Form 2936 08.10, one page. cited by applicant . EPO Communication under rule 71(3) EPC, EP Application No. 10186063.3, Jun. 17, 2013, EPO Form 2004C, 04.12TRI, 196 pages. cited by applicant . EPO Communication, Annex to EPO Form 2004, Communication pursuant to Rule 71(3) EPC, Bibliographical data of EP Application No. 10186063.3, Jun. 5, 2013, EPO Form 2056, 11.08, 1 page. cited by applicant . EPO Communication pursuant to Article 94(3) EPC, Application No. 10186063.3, Dec. 12, 2011, EPO Form 2001, 12.10CSX, 5 pages. cited by applicant . EPO Communication pursuant to Article 94(3) EPC, Application No. 10186063.3, Jun. 11, 2012, EPO Form 2001, 12.10CSX, 3 pages. cited by applicant . EPO Communication pursuant to Rule 55 EPC, EP Application No. 10186063.3, Nov. 25, 2010, EPO Form 1047A, 11.09, 1 page. cited by applicant . EPO Communication pursuant to Rules 70(2) and 70a(2) EPC and reference to Rule 39(1) EPC, EP Application No. 10186063.3, May 2, 2011, EPO Form 1082, 04.10, 2 pages. cited by applicant . EPO Communication pursuant to the Decision of the President of the European Patent Office on the filing of priority document, EP Application No. 10186063.3, Oct. 21, 2010, EPO Form 1195, 04.09 PRIO, 1 page. cited by applicant . EPO Communication regarding Applicant Address Change, EP Application No. 10186063.3, Jan. 26, 2012, EPO FOrm 2544, 04.10, 1 page. cited by applicant . EPO Communication regarding important information concerning oral proceedings, at least as early as Nov. 19, 2015, EPO Form 2043 02.09, three pages. cited by applicant . EPO Communication regarding opposition, EP Application No. 10186063.3, Nov. 19, 2015, EPO Form 2906 01.91TRI, 11 pages. cited by applicant . EPO Communication regarding The oral proceedings dated Jun. 22, 2016, EP Application No. 10186063.3, EPO Form 2341 09.14, one page. cited by applicant . EPO Communication regarding the preparation for oral proceedings--Instructions to Support Service dated Nov. 11, 2015, EP Application No. 10186063.3 and EP Patent No. 2314629, EPO Form 2040 12.01TRI, two pages. cited by applicant . EPO communication to Andrew Bentham of J A Kemp, Brief Communication regarding EPO Form 2548 of Jan. 12, 2016, EP Application No. 10186063.3 and EP Patent No. 2314629, Jan. 12, 2016, EPO Form 29100O 01.12, two pages. cited by applicant . EPO communication to Andrew Bentham of J A Kemp, Brief Communication regarding Oral Proceedings on Jun. 22, 2016 and the Letter from the proprietor of the patent of Feb. 16, 2016, EP Application No. 10186063.3 and EP Patent No. 2314629, Mar. 7, 2016, EPO Form 2310A 12.07, two pages. cited by applicant . EPO communication to Andrew Bentham of J A Kemp, Brief Communication regarding Oral Proceedings on Jun. 22, 2016 at 10:00 in S2.1., EP Application No. 10186063.3 and EP Patent No. 2314629, Feb. 25, 2016, EPO Form 29100O 01.12, one page. cited by applicant . EPO communication to Fritz Lahrtz of Isenbruck Bosl Hoschler LLP, Brief Communication regarding letter dated Feb. 16, 2016, EP Application No. 10186063.3 and EP Patent No. 2314629, Mar. 7, 2016, EPO Form 2310A 12.07, one page. cited by applicant . EPO Communication of further notices of opposition Rule 79(2) EPC, EP Application No. 09075279.1 and Patent No. 2147594, Sep. 25, 2014, EPO Form 2318 01.12, one page. cited by applicant . EPO Communication regarding Submission in opposition proceedings, Request for extension of time, EP Application No. 09075279.1 and Patent No. 2147594, Oct. 16, 2014, two pages. cited by applicant . EPO Communication regarding Extension of time limit pursuant to Rule 132 EPC, EP Application No. 09075279.1 and Patent No. 2147594, Oct. 22, 2014, one page. cited by applicant . EPO Communication regarding Submission in opposition proceedings, Reply of the patent proprietor to the notice(s) of opposition, EP Application No. 09075279.1 and Patent No. 2147594, Apr. 2, 2015, two pages. cited by applicant . EPO communication to Andrew Bentham of J A Kemp, Brief Communication regarding EPO Form 2548 of Jan. 12, 2016, EP Application No. 09075279.1 and EP Patent No. 2147594, Jan. 12, 2016, EPO Form 29100O 01.12, two pages. cited by applicant . EPO Communication regarding important information concerning oral proceedings, at least as early as Jan. 19, 2016, EPO Form 2043 02.09, three pages. cited by applicant . EPO Communication regarding Preliminary, Non-binding Opinion of the Opposition Division, EP Application No. 09075279.1, Jan. 19, 2016, EPO Form 2906 01.91TRI, 11 pages. cited by applicant . EPO Communication to Fritz Lahrtz of Isenbruck Bosl Hoschler LLP, Acknowledgement of receipt of EPO Forms 2310 and 2043, EP Application No. 09075279.1 and EP Patent No. 2147594,Jan. 19, 2016, EPO Form 2936 08.10, one page. cited by applicant . EPO Communication, After communication under Rule 71(3) EPC (IGRA) but before decision to grant (EPO Form 2006A), EP Application No. 09075279.1, Sep. 5, 2013, EPO Form 2092C 04.12, two pages. cited by applicant . EPO Communication pursuant to Rule 114(2) EPC, EP Application No. 09075279.1, Oct. 10, 2013, EPO Form 2022 12.07, one page. cited by applicant . EPO Communication pursuant to Rule 114(2) EPC, EP Application No. 09075279.1 and Patent No. 2147594, May 8, 2012, EPO Form 2022 12.07, one page. cited by applicant . EPO Communication pursuant to Rule 114(2) EPC, EP Application No. 09075279.1 and Patent No. 2147594, Jun. 14, 2013, EPO Form 2022 12.07, one page. cited by applicant . EPO Communication pursuant to Rule 114(2) EPC, EP Application No. 09075279.1 and Patent No. 2147594, Jul. 2, 2013, EPO Form 2022 12.07, one page. cited by applicant . EPO Communication to Andrew Bentham of J A Kemp, Acknowledgement of receipt of EPO Forms 2310 and 2043, EP Application No. 09075279.1 and EP Patent No. 2147594, Jan. 19, 2016, EPO Form 2936 08.10, one page. cited by applicant . EPO Communication regarding the cancelling of the Summons for Oral Proceedings dated Oct. 13, 2016, EP Application No. 09075279.1, Mar. 17, 2016, EPO Form 2088 06.14, one page. cited by applicant . EPO Communication regarding important information concerning oral proceedings, at least as early as Mar. 22, 2016, EPO Form 2043 02.09, three pages. cited by applicant . EPO Communication to Fritz Lahrtz of Isenbruck Bosl Hoschler LLP, Acknowledgement of receipt of EPO Forms 2310 and 2043, EP Application No. 09075279.1 and EP Patent No. 2147594, Mar. 22, 2016, EPO Form 2936 08.10, one page. cited by applicant . EPO Communication to Andrew Bentham of J A Kemp, Acknowledgement of receipt of EPO Forms 2310 and 2043, EP Application No. 09075279.1 and EP Patent No. 2147594, Mar. 22, 2016, EPO Form 2936 08.10, one page. cited by applicant . EPO Communication regarding the entries pertaining to the applicant / the proprietor (R. 143(1)(f) EPC), EP Application No. 09075279.1 and EP Patent 2147594, Jun. 13, 2016, EPO Form 2544 03.14, two pages. cited by applicant . EPO Communication to Fritz Lahrtz of Isenbruck Bosl Forschler LLP, Refund of fees, EP Application No. 09075279.1 and Patent No. 2147594, Jun. 15, 2016, EPO Form 2907 04.14, one page. cited by applicant . EPO communication to Fritz Lahrtz of Isenbruck Bosl Hoschler LLP, Communication of amended entries concerning the representative (R. 143(1)(h) EPC), EP Application No. 09075279.1 and EP Patent No. 2147594, Jan. 12, 2016, EPO Form 2548 08.13, one page. cited by applicant . EPO Communication under Rule 71(3) EPC, EP Application No. 09075279.1, Sep. 2, 2013, EPO Form 2004C 06.13TRI, five pages. cited by applicant . EPO Communication, Annex to EPO Form 2004, Communication pursuant to Rule 71(3) EPC, EP Application No. 09075279.1, Sep. 2, 2013, EPO Form 2056, two pages. cited by applicant . EPO Communication of notices of opposition (R. 79(1) EPC), EP Application No. 09075279.1 and Patent No. 2147594, Sep. 25, 2014, EPO Form 2317A 12.07, one page. cited by applicant . EPO Communication pursuant to Article 94(3) EPC, EP Application No. 09075279.1, Jun. 29, 2012, EPO Form 2001 12.10CSX, six pages. cited by applicant . EPO Communication pursuant to Rule 114(2) EPC, EP Application No. 09075279.1 and Patent No. 2147594, Nov. 5, 2012, EPO Form 2022 12.07, one page. cited by applicant . EPO Communication regarding Preparation for oral Proceeding--Instructions to Support Service, EP Application No. 09075279.1, Feb. 5, 2013, EPO Form 2040 12.07TRI, two pages. cited by applicant . EPO Communication to Martin Hatzmann of Vereenigde, Summons to attend oral proceedings pursuant to Rule 115(1) EPC, EP Application No. 09075279.1, Mar. 6, 2013, EPO form 2008 12.12, one page. cited by applicant . EPO Communication to Martin Hatzmann of Vereenigde, Acknowledgement of receipt of the document specified above, EP Application No. 09075279.1, Mar. 6, 2013, EPO Form 2936 08.10, one page. cited by applicant . EPO communication to Martin Hatzmann of V.O., Brief Communication regarding the letter of Apr. 23, 2013, EP Application No. 09075279.1 and EP Patent No. 2147594, May 22, 2013, EPO Form 2008A 12.07, one page. cited by applicant . EPO communication, Client Database System (CDS)--clean up, EP Application No. 10186063.3, Apr. 23, 2013, EPO Form 2596C, 04.08, 1 page. cited by applicant . EPO Communication, EP Application No. 10186063.3, Mar. 3, 2011, EPO Form 1507N, 08.10, 1 page. cited by applicant . EPO communication, Maintenance / Change of date / Cancellation of oral proceedings arranged for: Jun. 22, 2016 at 10.00 hrs, EP Application No. 10186063.3 and EP Patent No. 2314629, Feb. 22, 2016, EPO Form 2088 06.14, two pages. cited by applicant . EPO Communication, Summons to J A Kemp to attend oral proceedings pursuant to Rule 115(1) EPC, EP Application No. 10186063.3 and EP Patent No. 2314629, Nov. 19, 2015, EPO Form 2310 12.14, one page. cited by applicant . EPO Communication, Summons to V.O. to attend oral proceedings pursant to Rule 115(1) EPC, EP Application No. 10186063.3 and EP Patent No. 2314629, Nov. 19, 2015, EPO Form 2310 12.14, one page. cited by applicant . EPO Decision to grant a European patent pursuant to Article 97(1) EPC, EP Application No. 10186063.3, Sep. 19, 2013, EPO Form 2006A, 12.07, 2 pages. cited by applicant . EPO Extension of time limit pursuant to Rule 132 EPC, EP Application No. 10186063.3 and EP Patent No. 2314629, Oct. 24, 2014, EPO Form 2944C, 06.12, one page. cited by applicant . EPO General enquiry dated Jun. 16, 2016, EP12175544.1. cited by applicant . EPO Information on Search Strategy dated Jun. 30, 2016, EP12175544.1. cited by applicant . EPO Invitation to remedy deficiencies dated Aug. 31, 2012, EP12175544.1. cited by applicant . EPO Invitation to remedy deficiencies pursuant to Rule 30(3) EPC / Rule 163(3) EPC, EP Application No. 10186063.3, Nov. 23, 2010, EPO Form 1128, 05.10, 3 pages. cited by applicant . EPO Letter accompanying subsequently filed items dated Aug. 20, 2012, EP12175544.1. cited by applicant . EPO Letter accompanying subsequently filed items dated Dec. 17, 2015, EP12175544.1. cited by applicant . EPO Letter accompanying subsequently filed items, Document concerning representation filed by C.M. Jansen of V. O., .EP Application No. 10186063.3, Dec. 17, 2015, one page. cited by applicant . EPO Letter accompanying subsequently filed items, Documents filed during examination procedure and Letter dealing with Oral proceedings filed by David Power of J A Kemp, EP Application No. 10186063.3, May 20, 2016, one page. cited by applicant . EPO Model-Sheet dated Oct. 29, 2012, EP12175544.1. cited by applicant . EPO Notification of European Publication Number and Information on the application of Article 67(3) EPC, EP Application No. 10186063.3, dated Mar. 3, 2011, EPO Form 1133, 05.10, 1 page. cited by applicant . EPO Notification of European publication number dated Jan. 16, 2013, EP12175544.1. cited by applicant . EPO Partial description filed in response to formal objections dated Aug. 20, 2012, EP12175544.1. cited by applicant . EPO communication, Preparation for oral proceedings--Instruction to Support Service, EP Application No. 09075279.1 and EP Patent No. 2147594, Jan. 14, 2016, EPO Form 2040 12.07TRI, two pages. cited by applicant . EPO Communication, Summons to Fritz Lahrtz of Isenbruck Bosl Hoschler LLP to attend oral proceedings pursuant to Rule 115(1) EPC, EP Application No. 09075279.1 and EP Patent No. 2147594, Jan. 19, 2016, EPO Form 2310 12.14, one page. cited by applicant . EPO Communication, Summons to Andrew Bentham of J A Kemp to attend oral proceedings pursuant to Rule 115(1) EPC, EP Application No. 09075279.1 and EP Patent No. 2147594, Jan. 19, 2016, EPO Form 2310 12.14, one page. cited by applicant . EPO Communication, Consultation by telephone with the applicant / representative, EP Application No. 09075279.1, Oct. 9, 2013, EPO Form 2036 12.07TRI, one page. cited by applicant . EPO Communication, Result of consultation, EP Application No. 09075279.1, Oct. 14, 2013, EPO Form 2049A 12.07TRI, two pages. cited by applicant . EPO Communication, Decision to grant a European patent pursuant to Article 97(1) EPC, EP Application No. 09075279.1, Oct. 17, 2013, EPO Form 2006A 12.07, two pages. cited by applicant . EPO Communication, Transmission of the certificate for a European patent pursuant to Rule 74 EPC, EP Application No. 09075279.1, Nov. 13, 2013, EPO Form 2047 12.07, one page. cited by applicant . EPO Communication, Notice of Opposition to a European Patent, EP Application No. 09075279.1 and EP Patent No. 2147594, Aug. 11, 2014, EPO Form 2300E, eight pages. cited by applicant . EPO Request for change of applicant's representation dated Dec. 17, 2015, EP12175544.1. cited by applicant . EPO Request for change of applicant's representation dated Dec., 22, 2015, EP12175544.1. cited by applicant . EPO Request for change of applicant's representative dated Sep. 29, 2015, EP12175544.1. cited by applicant . EPO Request for grant of a European patent dated Jul. 9, 2012, Application No. EP12175544.1. cited by applicant . EPO Request for recordation of a transfer dated May 30, 2016, EP12175544.1. cited by applicant . EPO Request for recording a change in name of representative dated Apr. 2, 2013, EP12175544.1. cited by applicant . EPO Search has started dated Jun. 15, 2016, EP12175544.1. cited by applicant . EPO Sequence Listing dated Oct. 29, 2012, EP12175544.1. cited by applicant . EPO Communication, Minutes of the oral proceedings before the Examining Division, EP Application No. 09075279.1 and Patent No. 2147594, May 23, 2013, EPO Form 2009.1 12.07TRI, two pages. cited by applicant . EPO Communication, Provision of a copy of the minutes in accordance with Rule 124(4) EPC, EP Application No. 09075279.1, Aug. 8, 2013, EPO Form 2042 12.07TRI, one page. cited by applicant . EPO communication, Maintenance / Change of date / Cancellation of oral proceedings arranged for: Jun. 22, 2016 at 10.00 hrs, EP Application No. 09075279.1 and EP patent No. 2147594, Feb. 4, 2016, EPO Form 2088 06.14, two pages. cited by applicant . EPO Communication, Summons to Fritz Lahrtz of Isenbruck Bosl Hoschler LLP to attend oral proceedings pursuant to Rule 115(1) EPC, EP Application No. 09075279.1 and EP Patent No. 2147594, Mar. 22, 2016, EPO Form 2310 12.14, one page. cited by applicant . EPO Communication, Summons to Andrew Bentham of J A Kemp to attend oral proceedings pursuant to Rule 115(1) EPC, EP Application No. 09075279.1 and EP Patent No. 2147594, Mar. 22, 2016, EPO Form 2310 12.14, one page. cited by applicant . EPO Payment of fees and expenses dated May 30, 2016, EP12175544.1. cited by applicant . EPO Payment of fees and expenses dated Oct. 29, 2012, EP12175544.1. cited by applicant . EPO Reply to the invitation to remedy deficiencies dated Oct. 29, 2012, EP12175544.1. cited by applicant . EPO Communication, Minutes, EP Application No. 09075279.1, Aug. 8, 2013, EPO Form 2906 01.91TRI, 25 pages. cited by applicant . EPO communication, Maintenance / Change of date / Cancellation of oral proceedings arranged for: May 23, 2013 at 10.00 hrs, EP Application No. 19075279.1, Apr. 25, 2013, EPO Form 2088 04.10, two pages. cited by applicant . EPO Communication, Annex to Summons to attend oral proceedings pursuant to Rule 115(1) EPC, EP Application No. 09075279.1, Mar. 6, 2013, EPO form 2906 01.91TRI, six pages. cited by applicant . EPO communication, Client Database System (CDS)--clean up, EP Application No. 19075279.1, Apr. 23, 2013, EPO Form 2596C, 04.08, 1 page. cited by applicant . EPO communication, Executed Maintenance / Change of date / Cancellation of oral proceedings arranged for: May 23, 2013 at 10.00 hrs, EP Application No. 19075279.1, May 14, 2013, EPO Form 2088 04.10, two pages. cited by applicant . EPO communication, EP Application No. 19075279.1, at least as early as May 22, 2013, EPO Form 2906 01.91TRI, one page. cited by applicant . Fussenegger et al., Genetic optimization of recombinant glycoprotein production by mammalian cells, Reviews, Tibtech, Jan. 1999, pp. 35-42, vol. 17. cited by applicant . European Patent Office Communication for Application No. 09075279.1 dated Nov. 5, 2012. cited by applicant . EPO Submission in opposition proceedings, Acknowledgement of Receipt filed by David Power of J A Kemp, EP Application No. 10186063.3 and EP Patent No. 2314629, Nov. 20, 2015, two pages. cited by applicant . EPO Submission in opposition proceedings, Reply of the patent proprietor to the notice(s) of opposition, EP Application No. 10186063.3 and EP Patent No. 2314629, Feb. 24, 2015, two pages. cited by applicant . EPO Submission in opposition proceedings, Request for extension of time, EP Application No. 10186063.3 and EP Patent No. 2314629, Oct. 16, 2014, two pages. cited by applicant . EPO Transmission of the certificate for a European patent pursuant to Rule 74 EPC, EP Application No. 10186063.3, Oct. 18, 2013, EPO Form 2047, 12.07, 1 page. cited by applicant . Esposito. Gloria et al.. "Phage display of a human antibody against Clostridium tetani toxin," Gene, vol. 148:167-168 (1994). cited by applicant . European Search Opinion, EP Application No. 10186063.3, at least as early as Mar. 24, 2011, EPO Form 1703, 01,91TRI, 3 pages. cited by applicant . GenBank Accession No. ABA26122.1, Immunoglobulin light chain variable region, partial [Homo sapiens], 2005, 1 page. cited by applicant . European Search Report for EP Application No. 10186063, Mar. 16, 2011, EPO Form 1503, 03.82 (P04CO1), 2 pages. cited by applicant . Ewert et al., Biophysical properties of human antibody variable domains, J. Mol. Biol., Jan. 17, 2003, pp. 531-553, vol. 325, Iss. 3. cited by applicant . F.T. Wunderlich (2004), "Generation of inducible Cre systems for conditional gene inactivation in mice," Inauguraldissertation zur Erlangung des Doktorgrades der Mathematisch Naturwissenschaftlichen Fakultat der Universitat zu Koln; on the World Wide Web at deposit.ddb.de/cgi.bin/dokserv?idn=97557230x&dok_var=d1&dok_ext=pdf&filen- ame= 97557230x.pd. cited by applicant . Fecteau, Jessie F. et al., "A New Memory CD27 IgG+ B Cell Population in Peripheral Blood Expressing VH Genes with Low Frequency of Somatic Mutation," The Journal of Immunology, vol. 177:3728-3736 (2006). cited by applicant . Fendly et al., Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product, Cancer Research, Mar. 1, 1990, pp. 1550-1558, vol. 50. cited by applicant . Ferrara, N., Vascular endothelial growth factor: molecular and biological aspects., Curr. Top. Microbiol. Immunol., 1999, 237:1-30. cited by applicant . Flavell et al., "Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin", British Journal of Cancer, vol. 84, No. 4, 2001, pp. 571-578. cited by applicant . Folkman, Angiogenesis in cancer, vascular, rheumatoid and other disease, J. Nat. Med., 1995, pp. 27-31, vol. 1, Abstract only. cited by applicant . Franklin et al., Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex, Cancer Cell, Apr. 2004, pp. 317-328, vol. 5, issue 4. cited by applicant . Giddings et al., Transgenic plants as factories for biopharmaceuticals, Nature Biotechnology, 2000, pp. 1151-1155, vol. 18, Nature America Inc. cited by applicant . G. Neufeld et al., Vascular endothelial growth factor (VEGF) and its receptors, FASEB J., Jan. 1999, pp. 9-22, vol. 13, No. 1. cited by applicant . Galun et al., Clinical evaluation (Phase I) of a combination of two human monoclonal antibodies to HBV: Safety and antiviral properties., Hepatology, Mar. 2002, pp. 673-679, vol. 35, Issue 3. cited by applicant . Gascan et al., Human B cell clones can be induced to proliferate and to switch to IgE and IgG4 synthesis by Interleukin-4 and a signal provided by activated CD4C T cell clones. J Exp Med. 1991;173:747-750. cited by applicant . GenBank Accession No. M87478, "Human rearranged IgK mRNA VJC region," 1 page. (1994). cited by applicant . Gerbert et al., Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation, J Biol. Chem., Nov. 13, 1998, pp. 30336-30343, vol. 273. cited by applicant . Gerstner et al., Sequence Plasticity in the Antigen-binding Site of a Therapeutic Anti-HER2 Antibody, J. Mol. Biol., Aug. 30 2002, pp. 851-862, vol. 321, issue 5, Elsevier, Abstract only. cited by applicant . Fritz Lahrtz of Isenbruck Bosl Hoschler LLP communication to EPO, Executed Acknowledgement, EP Application No. 09075279.1 and EP Patent No. 2147594, Jan. 25, 2016, EPO Form 2936 08.10, one page. cited by applicant . Fritz Lahrtz of Isenbruck Bosl Hoschler LLP communication to EPO, Executed Acknowledgement, EP Application No. 09075279.1 and EP Patent No. 2147594, Mar. 29, 2016, EPO Form 2936 08.10, one page. cited by applicant . Gluzman, SV40-transformed simian cells support the replication of early SV40 mutants, Cell, Jan. 1981, pp. 175-182, vol. 23, Issue 1, Abstract only. cited by applicant . Gonzales-Fernandez et al., Analysis of somatic hypennutation in mouse Peyer's patches using immunoglobulin K lightchain transgenes, Proc. Natl. Acad. Sci., Nov. 1993, pp. 9862-9866, vol. 90. cited by applicant . Goyenechea et al., Modifying the sequence of an immunoglobulin V -gene alters the resulting pattern of hypermutation, Proc. Natl. Acad. Sci. 1996, pp. 13979-13984, vol. 93. cited by applicant . Goyenechea, Beatriz et al., "Cells strongly expressing Igk transgenes show clonal recruitment of hypermutation: a role for both MAR and the enhancers," The EMBO Journal, vol. 16(13):3987-3994 (1997). cited by applicant . Green et al., Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs, Nat. Genet., 1994, pp. 13-21, vol. 7, Abstract only. cited by applicant . Griffiths et al., Isolation of high affinity human antibodies directly from large synthetic repertoires, EMBO J., Jul. 15, 1994, pp. 3245-3260, vol. 13, No. 14. cited by applicant . Hochedlinger, Konrad et al., "Monoclonal mice generated by nuclear transfer from mature B and T donor cells," Nature, vol. 415:1 035-1 038 (2002). cited by applicant . Holliger et al., "Diabodies": Small bivalent and bispecitic antibody fragments, Proc. Natl. Acad. Sci., Jul. 1993, pp. 5444-5448, vol. 90. cited by applicant . Homig-Holzel et al., Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-kappaB pathway and promotes lymphomagenesis, J. Exp. Med., 2008, pp. 1317-1329, vol. 205, No. 6. cited by applicant . Griffiths, et al., Human anti-self antibodies with high specificity from phage display libraries, EMBO J., Feb. 1993, pp. 725-734, vol. 12, No. 2. cited by applicant . Heintges et al., Cloning, Bacterial Expression and Sequencing of Human Antibody Fragments Against Hepatitis C Virus NS3 by Phage Display of a Combinatorial Phagemid Library, Hepatology, 1998, p. 497, vol. 28, No. 4. cited by applicant . Hengstschlager et al., A lambda 1 trans gene under the control of a heavy chain promoter and enhancer does not undergo somatic hypennutation, Eur. J. Immunol. 1994, pp. 1649-1656, vol. 24. cited by applicant . Hiatt et al., "Production of antibodies in transgenic plants", Department of Molecular Biology, Letters to Nature, vol. 342, Nov. 2, 1989, pp. 76-78. cited by applicant . Hardy et al., B Cell Development Pathways, Annu. Rev. Immunol., 2001, pp. 595-621, vol. 19. cited by applicant . German Translation of claims for EP Application No. 09075279.1, at least as early as Sep. 2, 2013, four pages. cited by applicant . French Translation of claims for EP Application No. 09075279.1, at least as early as Sep. 2, 2013, three pages. cited by applicant . Executed Acknowledgement of receipt of the document specified above, EP Application No. 09075279.1, Mar. 7, 2013, EPO Form 2936 08.10, one page. cited by applicant . Letter accompanying subsequently filed items regarding translations of claims, EP Application No. 10186063.3, Sep. 6, 2013, 13 pages. cited by applicant . Letter from Mr. Andrew Bentham of JA Kemp to European Patent Office dated Jul. 15, 2014, accompanying subsequently filed items, one page. cited by applicant . Letter from Mr. C.M. Jansen of V.O. Patents & Trademarks to European Patent Office, Regarding Registration of the Association and change of address, Sep. 29, 2015, one page. cited by applicant . Letter from Mr. T.J. Elmore of V.O. Patents & Trademarks to European Patent Office, at least as early as Oct. 16, 2014, accompanying subsequently filed items, one page. cited by applicant . Li et al., Stable expression of three genes from a tricistronic retroviral vector containing a picornavirus and 9-nt cellular internal ribosome entry site elements, J. Virol. Methods, Feb. 2004, pp. 137-144, vol. 115, Issue 2. cited by applicant . Lie, Y.S. et al., "Advances in quantitative PCR technology: 5' nuclease assays," Curr. Opin. Biotechnol., vol. 9 (1):43-48 (1998). cited by applicant . Lindhofer et al., Preferential Species-Restricted Heavy/Light Chain Pairing in Rat/Mouse Quadromas, Journal of Immunology, 1995, pp. 219-225, vol. 155. cited by applicant . Letter from European Patent Office to Mr. Andrew Bentham of JA Kemp dated Jun. 6, 2016, accompanying subsequently filed items, one page. cited by applicant . Letter regarding the opposition procedure (no time limit) dated Jun. 20, 2016 from Isenbruck Bosl Forschler LLP to European Patent Office, 1 page. cited by applicant . Letter from JA Kemp to The European Patent Office regarding Oral Proceedings scheduled for Jun. 22, 2016. cited by applicant . List of references in Opposition to Merus B.V.'s EP 2 314 29 B1, Consolidated List of Documents, undated, one page. cited by applicant . Letter submitting declarations of Peter Hudson and Robert Brink dated Jun. 2, 2015, Australian Application No. 2009263082, 1 page. cited by applicant . Letter accompanying subsequently filed items regarding revocation procedure, EP Application No. 09075279.1, Aug. 20, 2015, one page. cited by applicant . Letter accompanying subsequently filed items regarding examination, EP Application No. 09075279.1, Jun. 13, 2013, one page. cited by applicant . Main Request with annotations, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages. cited by applicant . Main Request, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages. cited by applicant . Mao, Xiaohong et al., "Activation of EGFP expression by ere-mediated excision in a new ROSA26 reporter mouse strain," Blood, vol. 97(1 ):324-326 (2001). cited by applicant . Marks et al., By-passing immunization: Human antibodies from V-gene libraries displayed on phage, J. Mol. Biol., Dec. 5, 1991, pp. 581-597, vol. 222, Issue 3, Abstract only. cited by applicant . Marvin, J.S., et al., Recombinant approaches to IgG-like bispecific antibodies, Acta Pharmacologica Sinica, Jun. 2005, pp. 649-658, vol. 26. cited by applicant . Little et al., Human antibody libraries in Escherichia coli, Journal of Biotechnology, 1995, pp. 187-195, vol. 41, Elsevier. cited by applicant . McCafferty et al., Antibody Engineering, PAS, 2002, 178 pages, Oxford University Press. cited by applicant . Melvyn Little, Antibodies for Immunotherapy, Cambridge University Press, 2009. 23 pages. cited by applicant . Mendel et al., The Angiogenesis Inhibitor SU5416 Has Long-lasting Effects on Vascular Endothelial Growth Factor Receptor Phosphorylation and Function, Clin. Cancer Res., Dec. 2000, pp. 4848-4858, vol. 6. cited by applicant . Mendez et al., Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice, Nature Genetics. 1997. pp. 146-156. vol. 15. cited by applicant . Merus, "MeMo--the ingenious mouse, for improved antibody therapeutics," www.merus.nl, 3 pages (2011). cited by applicant . Meyer et al., the Igk 3'-enhancer triggers gene expression in early B lymphocytes but its activity in enhanced on B cell activation, Int. Immunol., 1996, pp. 1561-1568, vol. 8, No. 10. cited by applicant . Main request, EP Application No. 09075279.1, Reference No. P85261EP00, Apr. 23, 2013, three pages. cited by applicant . Lofgren et al., Comparing Elisa and Surface Plasmon Resonance for Assessing Clinical Immunogenicity of Panitumumab, .J Immunol., 2007, pp. 7467-7472, vol. 178. cited by applicant . Lonberg et al., Human antibodies from transgenic animals, Nature Biotechnology, Sep. 1, 2005, pp. 1117-1125, vol. 23, No. 9, Nature Publishing Group, New York, NY, US. cited by applicant . Lonberg, Nils et al., "Antigen-specific human antibodies from mice comprising four distinct genetic modificaitons," Nature, vol. 368:856-859 (1994). cited by applicant . Lu et al., Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2, J. Immunol. Methods, Nov. 19, 1999, pp. 159-171, vol. 230. cited by applicant . Lu et al., Complete Inhibition of Vascular Endothelial Growth Factor (VEGF) Activities with a Bifunctional Diabody Directed against Both VEGF Kinase Receptors, fms-like Tyrosine Kinase Receptor and Kinase Insert Domain-containing Receptor, Cancer Res., Oct. 1, 2001, pp. 7002-7008, vol. 61. cited by applicant . Lu et al., Identification of the Residues in the Extracellular Region of KDR Important for Interaction with Vascular Endothelial Growth Factor and Neutralizing Anti-KDR Antibodies, J. Biol. Chem., May 12, 2000, pp. 14321-14330, vol. 275. cited by applicant . Ma et al., Assembly of monoclonal antibodies with IgG1 and IgA heavy chain domains in transgenic tobacco plants, Eur. J. Immunol., 1994, p. 131-138, vol. 24. cited by applicant . Macdonald et al., Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes, PNAS, 2013, (6 Pages), Early Edition. cited by applicant . Letter accompanying subsequently filed items regarding Document concerning representation, EP Application No. 09075279.1, Submitted by C.M. Jansen of V.O., Dec. 17, 2015, one page. cited by applicant . Meyer, Kerstin B. et al., "The importance of the 3'-enhancer region in immunoglobulin kappa gene expression," Nucleic Acids Research, vol. 18(19):5609-5615 (1990). cited by applicant . Middendorp et al., Cellular Maturation Defects in Bruton's Tyrosine Kinase-Deficient Immature B Cells Are Amplified by Premature B Cell Receptor Expression and Reduced by Receptor Editing, J. Immunol., Feb. 1, 2004, pp. 1371-1379, vol. 172, No. 3. cited by applicant . Middendorp et al., Impaired Precursor B Cell Differentiation in Bruton's Tyrosine Kinase-Deficient Mice, J. Immunol., Mar. 15, 2002, pp. 2695-2703, vol. 168 No. 6. cited by applicant . Letter accompanying subsequently filed items regarding acknowledgement, EP Application No. 09075279.1, Submitted by David Power of J A Kemp, Apr. 12, 2016, one page. cited by applicant . Letter accompanying subsequently filed items regarding German and French translation of the claims, EP Application No. 09075279.1, Sep. 2, 2013, two pages. cited by applicant . Letter disclosing in vivo data dated Jun. 13, 2013, European patent application No. 09075279.1, 2 pages. cited by applicant . Letter accompanying subsequently filed items regarding oral proceedings, EP Application No. 09075279.1, Apr. 24, 2013, one page. cited by applicant . Letter accompanying subsequently filed items regarding documents filed during examination procedure, EP Application No. 09075279.1, Sep. 3, 2013, one page. cited by applicant . Letter accompanying subsequently filed items regarding amended claims with clean and annotated copies, EP Application No. 09075279.1, Apr. 23, 2013, 2 pages. cited by applicant . Peeters et al., Production of antibodies and antibody fragments in plants, Vaccine, Mar. 21, 2001, pp. 2756-2761, vol. 19, Issues 17-19, Elsevier. cited by applicant . Pelanda et al., a prematurely expressed Ig(kappa) transgene, but not V(kappa)J(kappa) gene segment targeted into the Ig(kappa) locus, can rescue B cell development in lambdaS-deficient mice, Immunity, Sep. 1996, pp. 229-239, vol. 5, No. 3. cited by applicant . Peled, Jonathan U. et al., "The Biochemistry of Somatic Hypermutation," Annu. Rev. Immunol., vol. 26:481-511 (2008). cited by applicant . Perrin et al., In vitro rabies vaccine potency appraisal by Elisa: advant of the immunocapture method with a neutralizing anti-glycoprotein monoclonal antibody, Biologicals, Oct. 1990, pp. 321-330, vol. 18(4). cited by applicant . Persic, L. et al. An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries, Gene, Mar. 10, 1997, pp. 9-18, vol. 187, Issue 1. cited by applicant . Pollock et al., "Transgenic milk as a method for the production of recombinant antibodies", Elsevier, Journal of Immunological Methods, 231 (1999), pp. 147-157. cited by applicant . Popov, Andrei V. et al., "A Human Immunoglobulin lambda Locus Is Similarly Well Expressed in Mice and Humans," J. Exp. Med., vol. 189(10):1611-1619 (1999). cited by applicant . Presta et al., Engineering of therapeutic antibodies to minimize immunogenicity and optimize function, Advanced Drug Delivery Reviews, Aug. 7, 2006, pp. 640-656, vol. 58, No. 5-6, Elsevier BV, Amsterdam, NL. cited by applicant . Opposition Filed Against European Patent No. EP 2 314 629 B1 (European Patent Application No. 10186063.3) in the Name of Merus B.V., Declaration of Dr. Joel Martin, May 18, 2016, 13 pages. cited by applicant . Padlan et al., A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties, Mol. Immunol., 1991, pp. 489-498, vol. 28, Abstract only. cited by applicant . Pasqualucci et al., BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci, Proc. Natl. Acad. Sci. USA, Sep. 1998, pp. 11816-11821, vol. 95. cited by applicant . Pau et al, The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines, Vaccine, 2001, pp. 2716-2721, vol. 19. cited by applicant . Paul Carter, "Bispecific human IgG by design", Elsevier, Journal of Immunological Methods, vol. 248, 2001, pp. 7-15. cited by applicant . PCT International Preliminary Examination Report, PCT/EP03/07690, dated Nov. 29, 2004. cited by applicant . PCT International Preliminary Report on Patentability, PCT/NL2009/050381 dated Jan. 5, 2011. cited by applicant . PCT International Search Report, PCT/NL2009/050381 dated Dec. 7, 2009. cited by applicant . Payment of fees and expenses for EP Application No. 10186063.3 dated May 27, 2016, one page. cited by applicant . Phelps et al., Expression and Characterization of a Chimeric Bifunctional Antibody with Therapeutic Applications, The Journal of Immunology, Aug. 15, 1990, pp. 1200-1204, vol. 145, No. 4. cited by applicant . Notice of Opposition, Australian application No. 2009263082, Jun. 20, 2014, 1 page. cited by applicant . Opposition Summary, Australian Application No. 2009263082, May 18, 2015, 11 pages. cited by applicant . Nicholson et al., Antibody Repertoires of Four- and Five-Feature Translocus Mice Carrying Human Immunoglobulin Heavy Chain and kappa and lambda Light Chain Yeast Artificial Chromosomes, The Journal of Immunology, 1999, pp. 6898-6906, vol. 163. cited by applicant . Nissim et al., Antibody fragments from a `single pot` phage display library as immunochemical the reagents, The EMBO Journal, 1994, pp. 692-698, vol. 13. No. 3. cited by applicant . Norderhaug et al., Balanced expression of single subunits in a multisubunit proteins, achieved by cell fusion of individual transfectants, European Journal of Biochemistry, 2002, pp. 3205-3210, vol. 269. cited by applicant . Notice of Opposition dated Jul. 8, 2016, EP2264163 10010741.6. cited by applicant . Notice of Opposition to a European patent, EP Patent No. 2314629, EP Application No. 10186063.3, Jul. 14, 2014, EPO Form 2300E, Q40114EP, 8 pages. cited by applicant . Notification to EPO regarding Applicant Address Change, EP Application No. 10186063.3, Jan. 4, 2012, 1 page. cited by applicant . Notification to EPO regarding Request for recording a change in name of representative, EP Application No. 10186063.3, Mar. 23, 2013, 3 pages. cited by applicant . Novobrantseva et al., Rearrangement and expression of immunoglobulin light chain genes can precede heavy chain expression during normal B cell development in mice, J. Exp. Med., Jan. 4, 1999, pp. 75-88, vol. 189, No. 1. cited by applicant . Nowakowski et al., Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody, PNAS, Aug. 20, 2002, pp. 11346-11350, vol. 99, No. 17. cited by applicant . Odegard et al., Targeting of somatic hypermutation, Nature Reviews, Immunology, Aug. 2006, pp. 573-583, vol. 6, No. 8. cited by applicant . NCBI, Aucouturier et al., Monoclonal IgL Claim and L chain V domain fragment crystallization in myeloma-associated Fanconi's syndrome, <http://www.ncbi.nlm.nib/gov/nuccore/M87478, at least as early as Apr. 25, 2012. cited by applicant . Nemazee, David, "Receptor editing in lymphocyte development and central tolerance," Nature, vol. 6(10):728-740 (2006). cited by applicant . Neuberger, M.S. et al., "Isotype exclusion and transgene down-regulation in immunoglobulin-lambda transgenic mice," Nature, vol. 338:350-352 (1989). cited by applicant . Ngo, T.-H., et al, Identification of functional synergism between monoclonal antibodies. Application to the enhancement of plasminogen activator inhibitor-1 neutralizing effects, FEBS Letters, 1997, pp. 373-376, vol. 416. cited by applicant . Min Soo Kim et al., Comparative Analyses of Complex Formation and Binding Sites between Human Tumor Necrosis Factor-alpha and its Three Antagonists Elucidate their Different Neutralizing Mechanisms, JMB, Dec. 14, 2007, pp. 1374-1388, vol. 374, Issue 5. cited by applicant . Mirick et al., A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies: not four letter words, Q. Nucl. Med. Mol. Imaging, Dec. 2004, pp. 251-257, vol. 48, No. 4. cited by applicant . Morimoto et al., High level expression of a human rabies virus-neutralizing monoclonal antibody by a rhabdovirus-based vector, J. Immunol. Methods, Jun. 2001, pp. 199-206, vol. 1, No. 252(1-2). cited by applicant . Morrison et al., Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains, Proc. Natl. Acad. Sci. USA, Nov. 1, 1984, pp. 6851-6855, vol. 81, No. 21. cited by applicant . Mostoslavsky et al., "Asynchronous replication and allelic exclusion in the immune system," Nature (2001) 414:221-225, Abstract only. cited by applicant . Murphy et al., Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice, PNAS, 2013, 6 pages, Early Edition. cited by applicant . Murphy, "Chapter 8: The Development and Survival of Lymphocytes", Janeway's Immunobiology, Eight Edition, Jul. 24, 2011, pp. 275-290. cited by applicant . Nagle, "Regeneron helps make Sanofi Velcolmmue to its `weak` pipline", Outsourcing-Pharma.com, Dec. 3, 2007, two pages, William Reed Business Media SAS. cited by applicant . Nahta et al., The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells, Cancer Research, Apr. 1, 2004, pp. 2343-2346, vol. 64. cited by applicant . Prak, Eline Lunning, Light Chain Replacement: a new model for antibody gene rearrangement, J. Exp. Med., Aug. 1995, pp. 541-548, vol. 182, the Rockefeller University Press. cited by applicant . Statement of Fact and Argument in Support of Opposition filed against EP Patent No. 2314629, at least as early as Jul. 15, 2014, 30 pages. cited by applicant . Priority Document dated Oct. 27, 2009, EP12175544. cited by applicant . Queen et al., A humanized antibody that binds to the interleukin 2 receptor, Proc. Natl. Acad. Sci. U.S.A., Dec. 1, 1989, pp. 10029-10033, vol. 86, No. 24. cited by applicant . Spillner et al., Paratope-based protein identification by antibody and peptide phage display, Analytical Biochemistry, 2003, pp. 96-104, vol. 321, Academic Press. cited by applicant . Radic et al., Ig H and L chain contributions to autoimmune specificities, The Journal of Immunology, Jan. 1, 1991, pp. 176-182, vol. 146, No. 1, The American Association of Immunologists. cited by applicant . Rajewsky et al., Conditional gene targeting, J Clin Invest, Aug. 1, 1996, pp. 600-603, vol. 98, No. 3. cited by applicant . Refund of Fees, EP Application No. 10186063.3, Jun. 4, 2011, EPO Form 2907, 12.07, 1 page. cited by applicant . Refund of Fees, EP Application No. 10186063.3, Nov. 17, 2010, EPO Form 2907, 12.07, 1 page. cited by applicant . Reply to Communication under Rule 79(1) EPC, EP Application No. 101860633 and EP Patent No. 2314629, Feb. 24, 2015, 20 pages. cited by applicant . Request for Grant of a European Patent for EP Application No. 101860633, Oct. 1, 2010, 6 pages. cited by applicant . Response to Communication pursuant to Article 94(3) EPC, EP Application No. 10186063.3, Dec. 21, 2011, 13 pages. cited by applicant . Response to Communication pursuant to Article 94(3) EPC, EP Application No. 10186063.3, Jul. 19, 2012, 45 pages. cited by applicant . Response to the Summons to attend Oral Proceedings dated Nov. 29, 2015 and in preparation of the Hearing of Jun. 22, 2016, from Isenbruck Bosl Forschler LLP to European Patent Office dated May 20, 2016. cited by applicant . Request for recordal of change of Proprietor from Merus B.V. to Merus N.V. filed by Isenbruck Bosl Forschler LLP with European Patent Office dated May 27, 2016, 2 pages. cited by applicant . Second Declaration by David Tarlington dated Oct. 15, 2015, Australian patent application No. 2009263082, 24 pages. cited by applicant . Second Declaration of Anthony L. DeFranco dated Oct. 18, 2015, Australian application No. 2009263082, 31 pages. cited by applicant . Sirac et al., "Toward Understanding Renal Fanconi Syndrome: Step by Step Advances through Experimental Models", Contributions to Nephrology, Experimental Models of Renal Fanconi Syndrome, vol. 169, 2011, pp. 247-261. cited by applicant . Sanger et al., DNA sequencing with chain-terminating inhibitors, PNAS, Dec. 1, 1997, pp. 5463-5467, vol. 74, No. 12. cited by applicant . Sasaki, Yoshiteru et al., "Canonical NF-kB Activity, Dispensable forB Cell Development, Replaces BAFF-Receptor Signals and Promotes B Cell Proliferation upon Activation," Immunity, vol. 24:729-739 (2006). cited by applicant . Schnieke et al., Human Factor IX Transgenic Sheep Produced by Transfer of Nuclei from Transfected Fetal Fibroblasts, Science, Dec. 19, 1997, pp. 2130-2133, vol. 278, Issue 5346. cited by applicant . Scott, Christopher Thomas, "Mice with a human touch," Nature Biotechnology, vol. 25:1075-1077 (2007). cited by applicant . Response to Communication pursuant to Rules 70(2) and 70a(2) EPC and reference to Rule 39(1) EPC, EP Application No. 10186063.3, Oct. 17, 2011, 16 pages. cited by applicant . Response to Invitation to remedy deficiencies pursuant to Rule 30(3) EPC / Rule 163(3) EPC, EP Application No. 10186063.3, Jan. 27, 2011, 2 pages. cited by applicant . Retter, Marc W. et al., "Receptor Editing Occurs Frequently during Normal B Cell Development," J. Exp. Med., vol. 188(7):1231-1238 (1998). cited by applicant . Rickert, Robert C. et al., "B lymphocyte-specific, Cre-mediated mutagenesis in mice," Nucleic Acids Research, vol. 25(6)1317-1318 (1997). cited by applicant . Roberts and Szostak, RNA-peptide fusions for the in vitro selection of peptides and proteins, Proc. Natl. Acad. Sci. U.S.A., Nov. 1997, pp. 12297-12302, vol. 94. cited by applicant . Second Declaration of Peter Hudson, Jun. 2, 2015, 81 pages. cited by applicant . Rong et al., Tumorigenesis induced by coexpression of human hepatocyte growth factor and the human met protooncogene leads to high levels of expression of the ligand and receptor, Cell Growth Differ., Jul. 1993, pp. 563-569, vol. 4, No. 7. cited by applicant . Rong et al., Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor, Mol. Cell Biol., Nov. 1992, pp. 5152-5158, vol. 12, No. 11. cited by applicant . Simmons et al., Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies, J. Immunol. Methods, May 1, 2002, pp. 133-147, vol. 263. cited by applicant . Sirac et al., Role of the monoclonal kappa chain V domain and reversibility of renal damage in a transgenic model of acquired Fanconi syndrome, Blood, Jul. 15, 2006, pp. 536-543, vol. 108, No. 2. cited by applicant . Sjolander and Urbaniczky, Integrated fluid handling system for biomolecular interaction analysis, Anal. Chem., 1991, pp. 2338-2345, vol. 63, No. 20, Abstract only. cited by applicant . Smith, G.P., Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface. Science, Jun. 14, 1985, pp. 1315-1317, vol. 228, Issue 4705, Abstract only. cited by applicant . Smith-Gill et al., Contributions of immunoglobulin heavy and light chains to antibody specificity for lysozyme and two haptens, Journal of Immunology, Dec. 15, 1987, pp. 4135-4144, vol. 139, No. 12., Baltimore, MD, US. cited by applicant . Specification of International Application No. PCT/EP03/07690, "Recombinant Production of Mixtures of Antibodies", at least as early as Oct. 1, 2010, 122 pages. cited by applicant . Srinivas et al., Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus, BMC Dev. Biol., Mar. 27, 2001, vol. 1 :4. cited by applicant . Sharpe et al., Somatic hypermutation of immunoglobulin kappa may depend on sequences 3' of C kappa and occurs on passengertransgenes, The EMBO.Ioumal. 1991. pp. 2139-2145, vol. 10, No. 8. cited by applicant . Shvarts et al., A senescence rescue screen identifies BCL6 as an inhibitor of anti-proliferative p19(ARF)-p53 signaling, Genes Dev., Mar. 15, 2002, pp. 681-686, vol. 16(6). cited by applicant . Sidhu et al., Phage display for selection of novel binding peptides, Methods Enzymol., 2000 328:333 363. cited by applicant . Second Declaration of Robert Brink, Jun. 2, 2015, 38 pages. cited by applicant . Segal et al., Introduction: bispecific antibodies, Journal of Immunological Methods, 2001, pp. 1-6, vol. 248, Elsevier. cited by applicant . Seibler et al., Rapid generation of inducible mouse mutants, Nucleic Acids Res., Feb. 15, 2003, e12, vol. 31, No. 4. cited by applicant . Sequence Listing, at least as early as Oct. 1, 2010, 18 pages. cited by applicant . Sequence Listing, Reference No. P61909EP20, Jan. 27, 2011, 12 pages. cited by applicant . Response to communication pursuant Article 94(3) EPC, EP Application No. 09075279.1, Sep. 11, 2012, Reference No. P85231EP00, eleven pages. cited by applicant . Statement of Fact and Arguments in Support of Opposition dated Jul. 15, 2014 for EP 2 314 629 B1. cited by applicant . Statement of Facts and Arguments in support of Opposition, EP Application No. 09075279.1 and EP Patent No. 2147594, at least as early as Aug. 11, 2014, 46 pages. cited by applicant . Statement of Grounds and Particulars submitted in opposition to Australian Patent Application 2009263082, filed Sep. 22, 2014, 35 pages. cited by applicant . Stevens, Sean, "Human Antibody Discovery, Veloclmmune- A novel platform," Pharma Focus Asia, Issue 8, pp. 72-74 (2008). cited by applicant . Strelkauskas et al., Human Monoclonal Antibody: 2. Simultaneous Expression of IgG and IgM with Similar Binding Specificities by a Human Hybrid Clone, Hybridoma, 1987, pp. 479-487, vol. 6, No. 5, Mary Ann Lieber, Inc., Publishers. cited by applicant . Tada et al., Expression and characterization of a chimeric bispecific antibody against fibrin and against urokinase-type plasminogen activator, Journal of Biotechnology, 1994, pp. 157-174, vol. 33. cited by applicant . Verma et al., Antibody engineering: Comparison of bacterial, yeast, insect and mammalian expression systems, Journal of Immunological Methods, 1998, pp. 165-181, vol. 216. cited by applicant . Third Party Observation for application No. EP20090075279, Anonymous, at least as early as Sep. 5, 2013, seven pages. cited by applicant . Third Party Observations Against European Parent Application No. 09075279.1 in the Name of Merus BV, 3 pages, dated Jul. 1, 2013. cited by applicant . Third Party Observations for Application No. EP09075279.1, 6 pages, dated Oct. 25, 2012. cited by applicant . Third Party Observations Under Article 115 EPC Against European Parent Application No. 09075279.1 in the name of Merus B.V., dated Apr. 25, 2012. 6 pages. cited by applicant . Third Party Observations Under Article 115 EPC Against European Parent Application No. 09075279.1 in the name of Merus B.V., dated Oct. 25, 2012. 6 pages. cited by applicant . Thomas et al., Site-Directed Mutagenesis by Gene Targeting in Mouse Embryo-Derived Stem Cells, Cells, Nov. 6, 1987, pp. 503-512, vol. 51. cited by applicant . Throsby, Isolation and Characterization of Human Monoclonal Antibodies from Individuals Infected with West Nile Virus, J. Virol., Jul. 2006, pp. 6982-6992, vol. 80, No. 14. cited by applicant . Torres et al., "Chapter 10: LoxP-containing transgenes", Laboratory Protocols for Conditional Gene Targeting, 1997, pp. 42-53, Oxford University Press Inc., New York, USA. cited by applicant . U.S. Priority Document of U.S. Appl. No. 60/397,066, "Recombinant Production of Mixtures of Antibodies", submitted in International Application No. PCT/EP03/07690, Sep. 1, 2003, 140 pages. cited by applicant . Urlaub et al., Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity, PNAS, Jul. 1, 1980, pp. 4216-4220, vol. 77, No. 7. cited by applicant . V.O. communication to EPO, Executed Acknowledgement of receipt of EPO Form 2310 and 2043, EP Application No. 10186063.3 and EP Patent No. 2314629, Nov. 20, 2015, EPO Form 2936 08.10, one page. cited by applicant . Vajdos et al., Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis, J. Mol. Biol., Jul. 5, 2002, pp. 415-428, vol. 320, issue 2, Elsevier. cited by applicant . van den Beucken et al., Building novel binding ligands to B7.1 and B7.2 based on human antibody single variable light chain domains, J. Mol. Biol., Jul. 13, 2001, pp. 591-601, vol. 310, Issue 3, Abstract only. cited by applicant . van der Heijden et al., Structural and functional studies on a unique linear neutralizing antigenic site (G5) of the rabies virus glycoprotein, J. Gen. Virol., Aug. 1993, pp. 1539-1545, vol. 74, Issue 8. cited by applicant . Vaughan et al., "Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library", Nature Biotechnology, vol. 14, Mar. 1996, pp. 309-314. cited by applicant . Weiner, et al., Abstract, Fully human therapeutic monoclonal antibodies, Journal of Immunotherapy, Jan. 1, 2006, pp. 1-9, vol. 29, No. 1, Lippincott Williams & Wilkins, Hagerstown, MD, US. cited by applicant . Wen et al., Tricistronic viral vectors co-expressing interleukin-12 (1L-12) and CD80 (B7-1) for the immunotherapy of cancer: Preclinical studies in myeloma, Cancer Gene Therapy, 2001,pp. 361-370, vol. 8 No. 5. cited by applicant . Wildt et al., "Analysis of Heavy and Light Chain Pairings Indicates that Receptor Editing Shapes the Human Antibody Repertoire", Journal of Molecular Biology, vol. 285, 1999, pp. 895-901. cited by applicant . Wilmut et al., Basic techniques for transgenesis, Journals of Reproduction and Fertility, 1991, pp. 265-275, vol. 43, Journals of Reproduction & Fertility Ltd. cited by applicant . Wilmut et al., Viable offspring derived from fetal and adult mammalian cells, Nature, Feb. 27, 1997, pp. 810-813, vol. 385, Issue 6619. cited by applicant . Winter et al., Insertion of 2 kb of bacteriophage DNA between an immunoglobulin promoter and leader exon stops somatic hypermutation in a kappa trans gene, Molecular Immunology, Apr. 1997, pp. 359-366, vol. 34, No. 5. cited by applicant . Winter et al., Making antibodies by phage display technology, Annu. Rev. Immunol., Apr. 1994, pp. 433-455, vol. 12, Abstract only. cited by applicant . Xiang, Yougui et al., "The Downstream Transcriptional Enhancer, Ed, Positively Regulates Mouse Igk Gene Expression and Somatic Hypermutation," J. Immunol., vol. 180(10):6725-6732 (2008). cited by applicant . Xu et al, "Deletion of the Ig kappa light chain intronic enhancer/matrix attachment region impairs but does not abolish V kappa J kappa rearrangement," Immunity (1996) 4:377-385. cited by applicant . Taylor, Lisa D. et al., "A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins," Nucleic Acids Research, vol. 20(23):6287-6295 (1992). cited by applicant . Taylor, Lisa D. et al., "Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM," International Immunology, vol. 6(4):579-591 (1994). cited by applicant . Thiebe et al., The variable genes and gene families of the mouse immunoglobulin ? locus, European Journal of Immunology, Jul. 1999, pp. 2072-2081, vol. 29, Issue 7. cited by applicant . Third Party Observation for Application No. 2009263082, 25 pages, dated Oct. 21, 2013. cited by applicant . Szabo et al., Surface plasmon resonance and its use in biomolecular interaction analysis (BIA), Curr. Opin. Struct. Biol., Oct. 1995, pp. 699-705, vol. 5, Issue 5, Abstract only. cited by applicant . Tan et al., "Superhumanized" Antibodies: Reduction of Immunogenic Potential by Complementarity-Determining Region Grafting with Human Germline Sequences: Application to an Anti-CD281, J. Immunol., Jul. 15, 2002, pp. 1119-1125, vol. 169, No. 2. cited by applicant . Storb et al., Immunoglobulin transgenes as targets for somatic hypermutation, Int. J. Dev. Biol., 1998, pp. 977-982, vol. 42(7). cited by applicant . Storb, Ursula et al., "Transgenic Mice with mu and kappa Genes Encoding Antiphosphorylcholine Antibodies," J. Exp. Med., vol. 164:627-641 (1986). cited by applicant . Submission in opposition proceedings by Andrew Bentham, EP Application No. 09075279.1 and Patent No. 2147594, Nov. 17, 2015, two pages. cited by applicant . Yang, X.W. et al., "Homologous recombination based modification in Escherichia coil and germline transmission in transgenic mice of a bacterial artificial chromosome," Nat. Biotechnol., vol. 15(9):859-865 (1997). cited by applicant . Submission in opposition proceedings by Andrew Bentham, EP Application No. 09075279.1 and Patent No. 2147594, Jan. 29, 2016, two pages. cited by applicant . Summons to Attend Oral Proceedings, EP Patent No. 2147594, at least as early as Feb. 1, 2016, five pages. cited by applicant . Submission in opposition proceedings by Andrew Bentham, Letter providing alternated dates for Oral Proceedings, EP Application No. 09075279.1 and Patent No. 2147594, Feb. 15, 2016, one page. cited by applicant . Third Party Observations Against European Parent Application No. 09075279.1 in the name of Merus BV, at least as early as Sep. 5, 2013, four pages. cited by applicant . Zahn Zabel et al., Development of stable cell lines for production or regulated expression using matrix attachment regions, J. Biotechnology, Apr. 27, 2001, pp. 29-42, vol. 87, Issue 1. cited by applicant . Zhu et al., Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library, Cancer Res., Aug. 1998, pp. 3209-3214, vol. 58, No. 15. cited by applicant . Zhu et al., Remodeling domain interfaces to enhance heterodimer formation, Protein Science, Apr. 1997, pp. 781-788, vol. 6, Issue 4. cited by applicant . Zhu et. al., Inhibition of Tumor Growth and Metastasis by Targeting Tumor-Associated Angiogenesis with Antagonists to the Receptors of Vascular Endothelial Growth Factor, Invest. New Drugs, Aug. 1999, pp. 195-212, vol. 17, Issue 3, Abstract only. cited by applicant . Zou et al., Cre-loxP-mediated gene replacement: a mouse strain producing humanized antibodies, Current Biology, 1994, pp. 1099-1103, vol. 4. cited by applicant . ImMunoGeneTics Information System, for analysed sequence CHEB VK, http://www.imgt.org/IMGT vguesVvguest, at least as early as Apr. 25, 2012. cited by applicant . Inlay et al., Essential roles of the kappa light chain intronic enhancer and 3' enhancer in kappa rearrangement and demethylation, Nat Immunol., Apr. 22, 2002, pp. 463-468, vol. 3, Abstract only. cited by applicant . Inlay et al., Roles of the Ig kappa light chain intronic and 3' enhancers in Igk somatic hypermutation, J. Immunol., 2006, pp. 1146-1151, vol. 177(2). cited by applicant . International Preliminary Report on Patentability and Written Opinion for Application No. PCT/NL2009/050381, 11 pages, dated Jan. 5, 2011. cited by applicant . International Search Report for Application No. PCT/NL2009/050381, 5 pages, dated Dec. 7, 2009. cited by applicant . J A Kemp communication to EPO, Executed Acknowledgement of receipt of EPO Form 2310 and 2043, EP Application 10186063.3 and EP Patent No. 2314629, Nov. 25, 2015, EPO Form 2936 08.10, one page. cited by applicant . Jain et al., Engineering antibodies for clinical applications, Trends in Biotechnol., Jul. 2007, pp. 307-316, vol. 25, Issue 7. cited by applicant . Kong et al., A lambda 3' Enhancer Drives Active and Untemplated Somatic Hypermutation of a lambda1 Trans gene, The Journal ofImmunology, 1998, pp. 294-301, vol. 161. cited by applicant . Koochekpour et. al., Met and Hepatocyte Growth Factor/Scatter Factor Expression in Human Gliomas, Cancer Res., Dec. 1, 1997, pp. 5391-5398, vol. 57. cited by applicant . Kramer et al., A novel helper phage that improves phage display selection efficiency by preventing the amplification of phages without recombinant protein, Nucleic Acids Res., 2003, e59, vol. 31, No. 11. cited by applicant . Kunkel et al., Rapid and efficient site-specific mutagenesis without phenotypic selection, Methods in Enzymol., 1987, pp. 367-382, vol. 154. cited by applicant . Kwaks et al., Employing epigenetics to augment the expression of therapeutic proteins in mammalian cells, Trends in Biotechnology, Mar. 1, 2006, pp. 137-142, vol. 24, No. 3, Elsevier Publications, Cambridge, GB. cited by applicant . Kwaks et al., Identification of anti-repressor elements that confer high and stable protein production in mammalian cells, Nature Biotechnology, 2003, pp. 553-558, vol. 269. cited by applicant . Lang, A.B. et al, Immunotherapy with Human Monoclonal Antibodies, Journal of Immunology, Jul. 1993, pp. 466-472, vol. 151, No. 13. cited by applicant . Larrick et al., Producing proteins in transgenic plants and animals, Current Opinion in Biotechnology, Aug. 1, 2001, pp. 411-418, vol. 12, Issue 4. cited by applicant . Lazar et al., A molecular immunology approach to antibody humanization and functional optimization, Mol Immunol.,Mar. 2007, pp. 1986-1998, vol. 44, Issue 8. cited by applicant . Jakobovits et al., Analysis of homozygous mutant chimeric mice: deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production, Proc. Natl. Acad. Sci. U.S.A., Mar. 1993, pp. 2551-2555, vol. 90. cited by applicant . Jakobovits et al., From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice, Nature Biotechnology, Oct. 2007, pp. 1134-1143, vol. 25, No. 10. cited by applicant . Jakobovits et al., Germ-line transmission and expression of a human-derived yeast artificial chromosome, Nature, Mar. 18, 1993, pp. 255-258, vol. 362, Abstract only. cited by applicant . Jeffers et al., Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network, Mol. Cell. Biol., Mar. 1996, pp. 1115-1125, vol. 16, No. 3. cited by applicant . Jolly et al. Rapid methods for the analysis of immunoglobulin gene hypennutation: application to transgenic and gene targeted mice, Nucleic Acids Research, 1997, pp. 1913-1919, vol. 25, No. 10. cited by applicant . Jones et al., "High-Level Expression of Recombinant IgG in the Human Cell Line PER.C6", Biotechnology Progress, vol. 19, 2003, pp. 163-168. cited by applicant . Jones et al., Replacing the complementarity-determining regions in a human antibody with those from a mouse, Nature May 29, 1986, pp. 522-525, vol. 321, Abstract only. cited by applicant . Kabat, et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91 3242 Abstract only. cited by applicant . Kakitani et al., "A novel transgenic chimaeric mouse system for the rapid functional evaluation of genes encoding secreted proteins," Nucleic Acids Research (2005) 33(9):e85. cited by applicant . Kasprzyk et al., Therapy of an Animal Model of Human Gastric Cancer Using a Combination of Anti-erbB-2 Monoclonal Antibodies, Cancer Research, May 15, 1992, pp. 2271-2776, vol. 52. cited by applicant . Kaufman et al., Amplification and expression of sequences cotransfected with a modular dihydrofolate reductase complementary DNA gene, J. Mol. Biol., Aug. 25, 1982, pp. 601-621, vol. 159, Issue 4, Abstract only. cited by applicant . Klagsbrun et al., Vascular endothelial growth factor and its receptors, Cytokine Rev., Oct. 1996, pp. 259-270, vol. 7, Issue 3, Abstract only. cited by applicant . Kling, Jim, Big Pharma vies for mice, Nature Biotechnology, Jun. 1, 2007, pp. 613-614, vol. 25. cited by applicant . Klitz et al., New HLA haplotype frequency reference standards: High-resolution and large sample typing of HLA-DR DQ haplotypes in a sample of European Americans, Tissue Antigens, pp. 296-307, vol. 62, Issue 4, Abstract only. cited by applicant . Klohn, Peter-Christian et al., "IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics International Conferences and the 2012 Annual Meeting of the Antibody Society," mAbs, vol. 5(2):178-201 (2013). cited by applicant . Klotz et al., Somatic Hypermutation of a lambda, Transgene Under the Control of the lambda, Enhancer or the Heavy Chain Intron Enhancer, The Journal of Immunology, 1996. pp. 4458-4463. vol. 157. cited by applicant . Kohler and Milstein, Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, Aug. 7, 1975, pp. 495-497, vol. 256. cited by applicant . JA Kemp to The European Patent Office of Final Written Submissions for Oral Proceedings scheduled for Jun. 22, 2016 in Opposition to Merus B.V.'s EP 2 314 629 B1 dated May 20, 2016. cited by applicant . Janeway, The Development and Survival of Lymphocytes, Chapter 8, Immunobiology, 1999, pp. 275-290. cited by applicant . Hwang et al., Immunogenicity of engineered antibodies, Methods, May 2005, pp. 3-10, vol. 36, Issue 1. cited by applicant . Ignatovich et al., Dominance of intrinsic genetic factors in shaping the human immunoglobulin Vlambda repertoire, J. Mol. Biol., Nov. 26, 1999, pp. 457-465, vol. 294, Issue 2. cited by applicant . Hoogenboom et al., Selecting and screening recombinant antibody libraries, Nat. Biotechnol., Sep. 7, 2005, pp. 1105-1116, vol. 23, Abstract only. cited by applicant . Hoogenboom, Designing and optimizing library selection strategies for generating high-affinity antibodies, Trends Biotechnol., 1997, pp. 62-70, vol. 15, Issue 2, Abstract only. cited by applicant . Hoogenboom, et al., Natural and designer binding sites made by phage display technology, Immunol. Today, Aug. 1, 2000, pp. 371-378, vol. 21, Issue 8, Abstract only. cited by applicant . Hudziak et al., p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor, Mol. Cell. Biol., Mar. 1989, pp. 1165-1172, vol. 9. No. 3. cited by applicant . Huls, G., et al., Antitumor Immune Effector Mechanisms Recruited by Phage Display-derived Fully Human IgG1 and IgA1 Monoclonal Antibodies, Cancer Research, Nov. 15, 1999, pp. 5778-5784, vol. 59. cited by applicant . Judgement in Preliminary Relief Proceedings of Aug. 14, 2015 with English translation, Case No. C/09/480452/ KG ZA 15-9, 33 pages. cited by applicant . Hoogenboom et al., By-passing immunisation. Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro, J Mol Biol., Sep. 20, 1992, pp. 381-388, vol. 227, Issue 2, Abstract only. cited by applicant . Hoogenboom et al., Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains, Nucl. Acids Res., 1991, pp. 4133-4137, vol. 19, Issue 15. cited by applicant . Japan Patent Office, Final Notice of Reasons for Rejection, Japanese Patent Application No. 2011-516168,dated Jul. 28, 2014, six pages. cited by applicant . Japan Patent Office, Notice of Allowance, Japanese Patent Application No. 2011-516168, dated Apr. 13, 2015, four pages. cited by applicant . Sirac et al., Light chain inclusion permits terminal B cell differentation and does not necessarily result in autoreactivity, PNAS, May 16, 2006, pp. 7747-7752, vol. 103, No. 20. cited by applicant . Isenbruck Bosl Horschler LLP to European Patent Office, Documents filed by Proprietor, Response to the summons to attend oral proceedings scheduled for Oct. 28, 2016 and to the preliminary opinion of the Opposition Division dated Jan. 19, 2016, EP 2147594 / 09075279.1-1405, dated Aug. 26, 2016, 32 pages. cited by applicant . EPO Communication to J A Kemp, Submission in opposition proceedings made following summons to attend oral proceedings, Patent No. EP 2147594, Application No. EP09075279.1, dated Aug. 26, 2016, two pages. cited by applicant . Janeway et al., Chapter 3: Structure of the Antibody Molecule and the Immunoglobulin Genes, ImmunoBiology The Immune System in Health and Disease, Fourth Edition, 1999, pp. 90-108, Elsevier Science Ltd/Garland Publishing. cited by applicant . Declaration of Profressor Anthony DeFranco, European Patent No. 2147594 B1, European Patent Application No. 09075279.1, dated Aug. 24, 2016, 23 pages. cited by applicant . Declaration of Prof. Ton Logtenberg dated Sep. 15, 2015 filed in U.S Appl. No. 13/750,753, four pages. cited by applicant . Sequence Alignment and Declaration of Dr. John McWhirter, European Patent Application No. 09075289.1, European Patent No. 2147594 B1, dated Aug. 2, 2016, four pages. cited by applicant . Lefranc, Marie-Paule, Nomenclature of the Human Immunoglobulin Kappa (IGK) Genes, Exp Clin Immunogenet, 2001, pp. 161-174, vol. 18, Karger. cited by applicant . J A Kemp to European Patent Office, Final Written Submissions Oral Proceedings Scheduled for Oct. 28, 2016, Opposition to Merus N.V.'s EP2147594 dated Aug. 26, 2016, 40 pages. cited by applicant . Second Declaration of Ton Logtenberg Under 37 C.F.R. 1.132, U.S. Appl. No. 13/750,753 dated Dec. 18, 2015, ten pages. cited by applicant . Third Party Observation for application No. EP20120783456, Anonymous, Jun. 16, 2016, three pages. cited by applicant . Opposition Filed Against European Patent No. 2147594 (European Patent Application No. 09075279.1) in the Name of Merus N.V., Declaration of Professor Anthony DeFranco, dated Aug. 24, 2016, 23 pages. cited by applicant . Japan Patent Office, Notice of Reasons for Rejection, Japanese Patent Application No. 2011-516168, dated Oct. 15, 2013, four pages. cited by applicant . Japan Patent Office, Third Party Observation, Japanese Patent Application No. 2011-516168, May 9, 2014, 14 pages. cited by applicant . Third Party Observation for U.S. Appl. No. 15/140,321, filed Sep. 2, 2016, two pages. cited by applicant . Japan Patent Office, Opposition against Patent, JP Patent. No. 5749161, Jan. 15, 2016, 55 pages. cited by applicant . EPO Acknowledgement of receipt--Opposition proceedings in relation to EP09075279.1 dated Aug. 26, 2016, two pages. cited by applicant . Canadian Intellectual Property Office, Office Action, Application No. 2729095, dated Nov. 10, 2015, eight pages. cited by applicant . Borden Ladner Gervais LLP to Canadian Patent Office, Response to Official Action of Nov. 10, 2015, Application No. 2729095, dated May 10, 2016, 12 pages. cited by applicant . Third Party Opposition filed in Canadian Intellectual Property Office, Application No. 2729095, dated Sep. 16, 2015, 15 pages. cited by applicant . Borden Ladner Gervais LLP in the Canadian Patent Office, Voluntary Amendment, Application No. 2729095, dated May 12, 2016, two pages. cited by applicant . Japan Patent Office, Notification of Third Party Observation, Japanese Patent Application No. 2011-516168, May 20, 2014, one page. cited by applicant . Third Party citation for application No. 14163642.3, 3 pages, dated Jan. 29, 2016. cited by applicant . Shiga International Patent Office to Japan Patent Office, Amendments to claims made in response to notice of reasons for rejection, Japanese Patent Application No. 2011-516168, dated Jan. 5, 2015, three pages. cited by applicant . Shiga International Patent Office to Japan Patent Office, Amendments to claims made in response to notice of reasons for rejection, Japanese Patent Application No. 2011-516168, dated Jan. 14, 2014, three pages. cited by applicant . Japan Patent Office, Registration Fee Payment, Japanese Patent Application No. 2011-516168, dated May 13, 2015, one page. cited by applicant . Shiga International Patent Office to Japan Patent Office, Remarks in response to notice of reasons for rejection, Japanese Patent Application No. 2011-516168, dated Jan. 5, 2015, 16 pages. cited by applicant . Shiga International Patent Office to Japan Patent Office, Remarks in response to notice of reasons for rejection, Japanese Patent Application No. 2011-516168, dated Jan. 14, 2014, six pages. cited by applicant . Japan Patent Office, Certificate of Patent, Japanese Patent. No. 5749161, Japanese Application No. 2011-516168, dated May 22, 2015. cited by applicant . Japan Patent Office, As-Filed english language application, Japanese Patent Application No. 2015-097258, dated May 12, 2015, 218 pages. cited by applicant . Japan Patent Office, Request for Substantive Examination, Japanese Patent Application No. 2015-097258, dated Jun. 1, 2015, 1 page. cited by applicant . Japan Patent Office, As-Filed Application, Japanese Patent Application No. 2015-097258, dated May 13, 2015, 270 pages. cited by applicant . Japan Patent Office, Official Action, Japan Patent Application No. 2015-097258, dated Mar. 31, 2016, seven pages. cited by applicant . Canadian Patent Office, Completion Requirement, Submission of Sequence Listing , CA Application No. 2729095, dated Mar. 9, 2011, one page. cited by applicant . Canadian Intellectual Property Office to Blake Cassels & Graydon LLP, Protest Confirmation, Canadian Patent Application No. 2729095, dated Apr. 16, 2014, one page. cited by applicant . Canadian Intellectual Property Office, General Correspondence Form, CA Application No. 2729095, PCT Application No. PCT/NL2009/050381, Dec. 22, 2010, three pages. cited by applicant . Canadian Patent Office, Information Letter, Foreign and non-patent references, CA Applicaiton No. 2729095, Mar. 9, 2011, two pages. cited by applicant . Japan Patent Office, Acknowledgement of receipt, Japanese Patent Application No. 2015-097258, dated May 12, 2015, 1 page. cited by applicant . Canadian Intellectual Property Office to Borden Ladner Gervais LLP, Requisition by the Examiner, CA Application No. 2729095, Jun. 11, 2014, three pages. cited by applicant . Canadian Patent Office, Response to the Office Action dated Jun. 11, 2014, CA Application No. 2729095, Dec. 10, 2014, 24 pages. cited by applicant . Canadian Intellectual Property Office to Borden Ladner Gervais LLP, Requisition by the Examiner, CA Application No. 2729095, Apr. 16, 2013, seven pages. cited by applicant . Canadian Patent Office, Response to the Examiner's Report dated Apr. 16, 2013, CA Application No. 2729095, Oct. 15, 2013, 20 pages. cited by applicant . Canadian Patent Office, Voluntary Amendment , CA Application No. 2729095, dated Dec. 5, 2011, thirteen pages. cited by applicant . Canadian Intellectual Property Office to Borden Ladner Gervais LLP, Advisement of protest filed, CA Application No. 2729095, Nov. 2, 2015, one page. cited by applicant . Canadian Patent Office, Statement and Declaration Under Rule 37, CA Application No. 2729095, Dec. 22, 2010, one page. cited by applicant . Canadian Patent Office, Statement of Support , CA Application No. 2729095, Mar. 9, 2011, one page. cited by applicant . Ritchie et al., Allelic exclusion of control of endogenous immunoglobin gene rearrangement in kappa transgenic mice, Nature, Dec. 1984, pp. 517-520, vol. 312, Nature Publishing Group. cited by applicant . Atwell, S. et al, Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library, J Mol Biol, 1997, 270(1), 26-35. cited by applicant . Baeuerle, PA., Reinhard, C., Bispecific T-cell engaging antibodies for cancer therapy, Cancer Res., 2009, 69(12), 1941-4944. cited by applicant . Bendig, MM., The production of foreign proteins in mammalian cells, Genet Eng., 1988, (7):91-127. cited by applicant . Bogan, AA., Thorn KS., Anatomy of hot spots in protein interfaces, J Mol Biol., 1998, 280(1), 1-9. cited by applicant . Bostrom, J., et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site, Science, 2009, 323(5921), 1610-1614. cited by applicant . Capelle, MA et al., Spectroscopic characterization of antibodies adsorbed to aluminium adjuvants: correlation with antibody vaccine immunogenicity, 2005, Vaccine, 23(14), 1686-1694. cited by applicant . Carter, P. et al, Toward the production of bispecific antibody fragments for clinical applications, J Hematother, 1995, 4(5), 463-470. cited by applicant . Coligan JE, Commonly used detergents, Curr protoc Protein sci, 2001, Appendix 1. cited by applicant . Davies, J. et al., Antibody VH domains as Small Recognition Units, Biotechnology, 1995, 13(5), 475-479. cited by applicant . Davis, JH. et al, SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies, 2010, Protein Eng Des Sel., 23(4), 195-202. cited by applicant . de Kruif, J. et al, Generation of stable cell clones expressing mixtures of human antibodies, 2010, 106(5), 741-750. cited by applicant . de Vries, SJ. et al, The Haddock web server for data- driven biomolecular docking, 2010, 5(5):883-897. cited by applicant . Deisenhofer, Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution, 1981, 20(9), 2361-2370. cited by applicant . Demeule, B. Characterization of protein aggregation: the case of a therapeutic immunoglobulin, Biochim Biophys Acta, 2007, 1774(1),146-153. cited by applicant . Demeule, Detection and characterization of protein aggregates by fluorescence microscopy, 2007, Int J Pharm, 329(1-2):37-45. cited by applicant . Ellerson; JR: et al, Structure and function of immunoglobulin domains. III. Isolation and characterization of a fragment corresponding to the Cgamma2 homology region of human immunoglobin G1, J Immunol., 1976, 116(2), 510-517. cited by applicant . Farnan, D, Moreno GT, Multiproduct high-resolution monoclonal antibody charge variant separations by pH gradient ion-exchange chromatography, Anal Chem, 2009, 81(21), 8846-8857. cited by applicant . Gunasekaran, K. et al., Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG, JBC, 2010, 285(25), 19637-19646. cited by applicant . Hendsch, ZS. et al., Preferential heterodimer formation via undercompensated electrostatic interactions, J Am Chem Soc, 2001,123(6),1264-1265. cited by applicant . Idusogie, EE. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc, 2000, J Immunol., 164(8), 4178-4184. cited by applicant . Ionescu, RM. et al, Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies, 2008, J Pharm Sci., 2008, 97(4), 1414-1426. cited by applicant . Kabat, EA., Wu, TT, Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL genes, minigenes, and complementarity-determining regions to binding of antibody-combining sites, J Immunol., 1991,147(5), 1709-1719. cited by applicant . Kumar, R, Shieh, BH, The second PDZ domain of INAD is a type I domain involved in binding to eye protein kinase C. Mutational analysis and naturally occurring variants, J Biol Chem., 2001, 276(27), 24971-24977. cited by applicant . Lakowicz, Jr, Principles of fluorescence spectroscopy, 2nd edition, Kluwer Academic/Plenum Publisher, 2006. cited by applicant . Lee, B, Richards,FM: The interpretation of protein structures: estimation of static accessibility., J Mol Biol, 1971, 55(3), 379-400. cited by applicant . Marvin, JS. et al., Redesigning an antibody fragment for faster association with its antigen, Biochemistry, 2003,42(23), 7077-7083. cited by applicant . McPhee, F. et al., Engineering human immunodeficiency virus 1 protease heterodimers as macromolecular inhibitors of viral maturation, PNAS, 1996, 93(21),11477-11481. cited by applicant . Merus, Press Release (www.merus.nl), Jan. 7, 2013, 2 pages. cited by applicant . Merus, Press Release (www.merus.nl), Jun. 17, 2013, 3 pages. cited by applicant . Miller S., Protein-protein recognition and the association of immunoglobulin constant domains, J Mol Biol, 1990, 216 (4), 965-973. cited by applicant . Nieba, L. et al., Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment, Protein Eng., 1997, 10(4), 435-444. cited by applicant . Nohaile; MJ. et al., Altering dimerization specificity by changes in surface electrostatics, Proc Natl Acad Sci USA, 2001, 98(6), 3109-3114. cited by applicant . Padlan, EA, X-ray crystallography of antibodies, Adv Protein Chem, 1996, 49, 57-133. cited by applicant . Papadea, EA. and Check, IJ, Human immunoglobulin G and immunoglobulin G subclasses: biochemical, genetic, and clinical aspects, Crit Rev Clin Lab Sci, 1989, 27(1), 27-58. cited by applicant . Raffen, R. et al., Reengineering immunoglobulin domain interactions by introduction of charged residuesProtein Eng., 1998, 11(4), 303-309. cited by applicant . Ridgway, JB. et al., `Knobs-into-holes` engineering of antibody CH3 domains for heavy chain heterodimerization, Protein Eng, 1996, 9(7), 617-621. cited by applicant . Sal-Man, N. and Shai, Y., Arginine mutations within a transmembrane domain of Tar, an Escherichia coli aspartate receptor, can drive homodimer dissociation and heterodimer association in vivo, Biochem J, 2005, 385(Pt 1):29-36. cited by applicant . Schaefer, G. et al, A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies, Cancer Cell, 2011, 20(4), 472-486. cited by applicant . Schiffer, M. et al., Analysis of immunoglobulin domain interactions. Evidence for a dominant role of salt bridges, J Mol Biol, 1988, 203(3),799-802. cited by applicant . Selzer, T. et al., Rational design of faster associating and tighter binding protein complexes, Nat Struct Biol, 2000, 7(7), 537-541. cited by applicant . Sheinerman, FB. et al., Electrostatic aspects of protein- protein interactions, Curr Opin Struc Biol, 2000, 10(2),153-159. cited by applicant . Sinha, N. et al., Differences in electrostatic properties at antibody-antigen binding sites: implications for specificity and cross-reactivity, Biophys. J., 2002, 83(6), 2946-2968. cited by applicant . Sinha, N. and Smith-Gill, SJ., Electrostatics in protein binding and function, Curr Protein Pept Sci, 2002, 3(6),601-614. cited by applicant . Tahallah, N. et al, The effect of the source pressure on the abundance of ions of noncovalent protein assemblies in an electrospray ionization orthogonal time-of-flight instrument, Rapid Commun Mass Spectrom., 2001, 15(8):596-601. cited by applicant . Van Rhenen, A. et al., The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells, Blood, 2007, 110(7), 2659-2666. cited by applicant . Zhao, X., et.al., Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia, Haematologica, 2010, 95(1), 71-. cited by applicant . McGinnes, K., B-lineage colonies from normal, human bone marrow are initiated by B cells and their progenitors, Blood, 1991, 77(5), 961-970. cited by applicant . Mostoslavsky et al., "Asynchronous replication and allelic exclusion in the immune system," Nature (2001) 414:221-225. cited by applicant . Murakami, T. et al, Splenic CD19-CD35+B220+ cells function as an inducer of follicular dendritic cell network formation, Blood, 2007,110(4), 1215-1224. cited by applicant . Murphy, Chapter 6: Antigen Presentation to T Lymphocytes, Janeway's Immunobiology, Eighth Edition, 2012, 31 pages. cited by applicant . Nelson, Al. et al., Development trends for human monoclonal antibody therapeutics, Nat Rev Drug Discov, 2010, 9 (10), pp. 767-774. cited by applicant . Nikolic, T. et al, A subtraction of B220(+) cells in murine bone marrow and spleen does not belong to the B cell lineage but has dendritic cell characteristics, Eur J Immunol., 2002, 32(3), 686-692. cited by applicant . O'Brien, RL., Somatic hypermutation of an immunoglobulin transgene in kappa transgenic mice, Nature, 1987, 326 (6111), 405-409. cited by applicant . Opponent's submissions filed on Jan. 15, 2016 (oppo JP5749161). cited by applicant . Opponent's (REGN) submissions filed on Oct. 19, 2016 in--AU10. cited by applicant . Orban, PC. et al, Tissue- and site--specific DNA recombination in transgenic mice, Proc Natl Acad Sci U S A, 1992, 89 (15), 6861-6865. cited by applicant . Padlan et al., A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties, Mol. Immunot, 1991, pp. 489-498, vol. 28. cited by applicant . Phan, TG., High affinity germinal center B cells are actively selected into the plasma cell compartment, J Exp Med., 2006; 203(11); 2419-2424. cited by applicant . Retter, MW., Nemazee, D., Receptor editing: genetic reprogramming of autoreactive lymphocytes, Cell Biochem Biophys., 1999, 31(1), 81-88. cited by applicant . Roitt, Immunology, Moscow, 2000. cited by applicant . Shaffer, Al. Et al., In vivo occupancy of the kappa light chain enhancers in primary pro- and pre-B cells: a model for kappa locus activation, Immunity, 1997, 6(2), 131-143. cited by applicant . Singer et al., Genes & Genomes A Changing Perspective, University Science Books, Mill Valley, California, 1991, 134-145. cited by applicant . Smith, EJ. et al., A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeysSci Rep., 2015, 5: 17943. cited by applicant . Soriano, P., Generalized lacZ expression with the ROSA26 Cre reporter strain, Nat Genet. 1999;21(1), 70-71. cited by applicant . Submissions filed by applicant on Oct. 19, 2016 in--AU10. cited by applicant . Submissions filed by applicant on Jun. 9, 2016 in--AU10. cited by applicant . Weiner, et al., Fully human therapeutic monoclonal antibodies, Journal of Immunotherapy, Jan. 1, 2006, pp. 1-9, vol. 29, No. 1, Lippincott Williams & Wilkins. cited by applicant . Yang, SY. Et al, Control of gene conversion and somatic hypermutation by immunoglobulin promoter and enhancer sequences, J Exp Med., 2006, 203(13), 2919-2928. cited by applicant . Yarilin, Fundamentals of Immunology, Moscow, 1999. cited by applicant . Yoshio-Hoshino, N. et al., Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor, Cancer Res., 2007, 67(3), 871-875. cited by applicant . Zou, YR. et al, Generation of a mouse strain that produces immunoglobulin kappa chains with human constant regions, Science, 1993, 262(5137), 1271-1274. cited by applicant . Inlay et al., Essential roles of the kappa light chain intronic enhancer and 3' enhancer in kappa rearrangement and demethylation, Nat Immunol., Apr. 22, 2002, pp. 463-468, vol. 3. cited by applicant . Arnold, LW., et al., Development of B-1 cells: segregation of phosphatidyl choline- specific B cells to the B-1 population occurs after immunoglobulin gene expression, J Exp Med., 1994;179(5),1585-1595. cited by applicant . Attaelmannan, M., Understanding and identifying monoclonal gammopathies, Clin Chem., 2000, 46(8 Pt 2), 1230-1238. cited by applicant . Aucouturier et al., Monocloanl Ig L Chain and L Chain V Domain Fragment Crystallization in Myelloma-Associated Fanconi's Syndrome, and Aucouturier et al. Sequence alignment, the Journal of Immunology, 1993, 3561-3568. cited by applicant . Betz, AG. Elements regulating somatic hypermutation of an immunoglobulin kappa gene: critical role for the intron enhancer/matrix attachment region, Cell, 1994, 77(2), 239-248. cited by applicant . Cheong et al., Affinity Enhancement of Bispecific Antibody Against Two Different Epitopes in the Same Antigen, Biochemical and Biophysical Research Communications, vol. 173, No. 3, 1990, pp. 795-800. cited by applicant . Conrath K.E. et al., Emergence and evolution of functional heavy-chain antibodies in Camelidae.Development & Comparative Immunology., 2003, 27(2), 87-103. cited by applicant . Davies, J. Riechmann, L, Antibody VH domains as small recognition units, Biotechnology (N Y), 1995, 13(5), 475-479. cited by applicant . De Chiara 2009, Chapter 16 of Gene Knockout Protocols: 2nd Ed, vol. 530, Humana Press, 311-324. cited by applicant . Decision of UK High Court of Justice (REGN against Kymab Limited; Novo Nordisk) dated Feb. 2, 2016. cited by applicant . Decision of US District Court about U.S. Pat. No. 8,502,018, REGN vs. Menus B.V., dated Feb. 11, 2015. cited by applicant . Decl. Robert Brink (1st) Apr. 2015. cited by applicant . Decl. Robert Brink (2nd) Jun. 2015. cited by applicant . Decl. Robert Brink (4th), Oct. 19, 2016 (--AU10). cited by applicant . Decl. Anthony De Franco (1st) Dec. 2014. cited by applicant . Decl. Anthony De Franco (2nd) Oct. 2015. cited by applicant . Decl. Anthony De Franco (3rd) Apr. 10, 2016 (against--AU10). cited by applicant . Decl. Anthony De Franco (4th) Oct. 18, 2016 (against--AU10). cited by applicant . Decl. Anthony De Franco filed in Aug. 2016 (-EP). cited by applicant . Decl. Christopher Carl Goodnow (1st) Oct. 2015. cited by applicant . Decl. Christopher Carl Goodnow (2nd), Apr. 10, 2016 against--AU10. cited by applicant . Decl. Peter Hudson (1st) May 2015. cited by applicant . Decl. Peter Hudson (2nd) Jun. 2015. cited by applicant . Declaration of Prof. Ton Logtenberg dated Sep. 15, 2015 filed in U.S. Appl. No. 131/50,753, four pages. cited by applicant . Decl. John McWhirter incl. Sequence Alignment filed on Aug. 2, 2016. cited by applicant . Decl. David Tarlinton (2nd) Oct 2015. cited by applicant . Desmet et al., Fast and accurate side-chain topology and energy refinement (Faster) as a new method for protein structure optimization, Proteins, Jul. 1, 2002, pp. 31-43, vol. 48, Issue 1. cited by applicant . Desmet et al., Anchor profiles of HLA-specific peptides: Analysis by a novel affinity scoring method and experimental validation, Proteins, Jan. 1, 2005, pp. 53-69, vol. 58. cited by applicant . Fecteau, JF. et al., A new memory CD27- IgG+ B cell population in peripheral blood expressing VH genes with low frequency of somatic mutation, J Immunol., 2006, 177(6), 3728-3736. cited by applicant . Gen Bank Acc. No. DQ187586-1 2005. cited by applicant . Gen Bank Acc. No. X59315 (human Ig kappa LC variable region). cited by applicant . Matsuda, F. et al, The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus, J. Exp. Med., 1998, 188 (11), 2151-2162. cited by applicant . Green et al., Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs, Nat. Genet., 1994, pp. 13-21, vol. 7. cited by applicant . Hardy, R., Hayakawa, K., B cell development pathways, Annu Rev Immunol., 2001, 19, 595-621. cited by applicant . Hengstschlager, M. et al, a lambda 1 transgene under the control of a heavy chain promoter and enhancer does not undergo somatic hypermutation., Eur J Immuno1., 1994, 24(7), 1649-1656. cited by applicant . Hoogenboom et al., Selecting and screening recombinant antibody libraries, Nat. Biotechnol., Sep. 7, 2005, pp. 1105-1116, vol. 23. cited by applicant . Jakobovits A., The long-awaited magic bullets: therapeutic human monoclonal antibodies from transgenic mice, Expert Opinion Investigating Drugs, 1998, 7(4), 607-614. cited by applicant . McCafferty; Hoogenboom; Chiswell: Antibody engineering : a practical approach, 1996, Oxford University press. cited by applicant . Jones et al., Replacing the complementarity-determining regions in a human antibody with those from a mouse, Nature, May 29, 1986, pp. 522-525, vol. 321. cited by applicant . Kim, MS. et al., Comparative analyses of complex formation and binding sites between human tumor necrosis factor-alpha and its three antagonists elucidate their different neutralizing mechanisms, J Mol Biol., 2007, 374(5), 1374-1388. cited by applicant . Kitamura D., A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene, Nature, 1991, 350(6317), 423-426. cited by applicant . Klotz, EL. Storb, U, Somatic hypermutation of a lambda 2 transgene under the control of the lambda enhancer or the heavy chain intron enhancer, J Immunol, 1996, 157(10), 4458-4463. cited by applicant . Kontermann,RE, Dual targeting strategies with bispecific antibodies, 2012, mAbs 4(2), pp. 182-197. cited by applicant . Kroesen et al., Bispecific antibodies for treatment of cancer in experimental animal models and man, Department of Clinical Immunology, 1998 pp. 105-129. cited by applicant . Little, M., Recombinant antibodies for immunotherapy, chapter 7; 8; 2009, Cambridge Univ. Press. cited by applicant . Lonberg, N., Human antibodies from transgenic animals, Nat Biotechnol., 2005, 23(9), 1117-1125. cited by applicant . Lonberg, N., Fully human antibodies from transgenic mouse and phage display platforms, Curr Opin Immunol, 2008, 20(4), pp. 450-459. cited by applicant . Macdonald, LE. et al, Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes, Proc Natl Acad Sci USA, 2014, 111(14):5147-5152. cited by applicant . Mao, X. et al., Activation of EGFP expression by Cre-mediated excision in a new ROSA26 reporter mouse strain, Blood, 2001, 97(1), 324-6. cited by applicant . Communication of further notices of opposition, Aug. 23, 2016. cited by applicant . Acknowledgement of receipt, Jul. 13, 2016. cited by applicant . Murphy, Statement of, Exhibit Murphy 1, Mar. 18, 2015, Defendant's Exhibit DX145, Case No. 14-CV-1650 (KBF). cited by applicant . Declaration from Professor Allen Bradley in Respect of the opposition to EP2264163 filed by Kymab Limited, dated Jul. 7, 2016, with curriculum vitae. cited by applicant . Statement of Dr. Anne Corcoran dated Jul. 8, 2016 with listing of Literature Cited and curriculum vitae. cited by applicant . In The High Court of Justice, Chancery Division, Patents Court, Case No. HP-2013-000001/HP-2014-000001 dated Jan. 2, 2016, between Regeneron Pharmaceuticals Inc., Claimant and Kymab Limited and Novo Nordisk A/S, Defendants, Mr. Justice Henry Carr, Approved Judgment. cited by applicant . United States District Court Southern District of New York, Regeneron Pharmaceuticals, Inc., Plaintiff v. Merus B.V., Defendant, 14 Civ. 1650 (KBF) Opinion & Order (Claim Construction) dated Nov. 21, 2014. cited by applicant . United States District Court Southern District of New York, Regeneron Pharmaceuticals, Inc., Plaintiff v. Merus B.V., Defendant, 14 Civ. 1650 (KBF) Opinion & Order dated Nov. 2, 2015. cited by applicant . In The High Court of Justice, Chancery Division, Patents Court, Case No. HP-2013-000001/HP-2014-000001 dated Oct. 6, 2015, Expert Report of Adrian Francis Stewart, Report relates to a patent owned by Regeneron Pharmaceuticals, Inc., EP 1 360 287. cited by applicant . In The High Court of Justice, Chancery Division, Patents Court, Case No. HP-2013-000001/HP-2014-000001 dated Nov. 2, 2015, Second Expert Report of Adrian Francis Stewart, Report relates to a patent owned by Regeneron Pharmaceuticals, Inc., EP 1 360 287. cited by applicant . In The High Court of Justice, Chancery Division, Patents Court, Case No. HP-2013-000001/HP-2014-000001 dated Nov. 17, 2015, Third Expert Report of Adrian Francis Stewart, Report relates to a patent owned by Regeneron Pharmaceuticals, Inc., EP 1 360 287. cited by applicant . In The High Court of Justice, Chancery Division, Patents Court, Case No. HP-2013-000001/HP-2014-000001 dated Oct. 6, 2015, First Expert Report of Professor Sir Martin Evans FRS Ph.D., Report relates to a patent owned by Regeneron Pharmaceuticals, Inc., Report relates to patents owned by Regeneron Pharmaceuticals, Inc., EP 1 360 287 and 2 264 163. cited by applicant . Annex 1 to First Expert Report of Professor Sir Martin Evans FRS Ph.D., undated. cited by applicant . Annex 2 to First Expert Report of Professor Sir Martin Evans FRS Ph.D., undated. cited by applicant . In The High Court of Justice, Chancery Division, Patents Court, Case No. HP-2013-000001/HP-2014-000001 dated Nov. 3, 2015, Second Expert Report of Professor Sir Martin Evans FRS Ph.D., Report relates to patents owned by Regeneron Pharmaceuticals, Inc., EP 1 360 287 and 2 264 163. cited by applicant . In The High Court of Justice, Chancery Division, Patents Court, Case No. HP-2013-000001/HP-2014-000001 dated Nov. 12, 2015, Third Expert Report of Professor Sir Martin Evans FRS Ph.D., Report relates to patents owned by Regeneron Pharmaceuticals, Inc., EP 1 360 287 and 2 264 163. cited by applicant . In The High Court of Justice, Chancery Division, Patents Court, Case No. HP-2013-000001/HP-2014-000001 dated Nov. 3, 2015, Second Witness Statement of A. J. Murphy, Report relates to patent owned by Regeneron Pharmaceuticals, Inc., EP 1 360 287. cited by applicant . In The High Court of Justice, Chancery Division, Patents Court, Case No. HP-2013-000001/HP-2014-000001 dated Nov. 15, 2015, Third Witness Statement of Andrew Joseph Murphy, Report relates to patent owned by Regeneron Pharmaceuticals, Inc., EP 1 360 287. cited by applicant . In The High Court of Justice, Chancery Division, Patents Court, Case No. HP-2013-000001/HP-2014-000001 dated Oct. 6, 2015, Expert Report of Professor Jonathan Charles Howard, Report relates to patents owned by Regeneron Pharmaceuticals, Inc., EP 1 360 287 and 2 264 163. cited by applicant . In The High Court of Justice, Chancery Division, Patents Court, Case No. HP-2013-000001/HP-2014-000001 dated Nov. 3, 2015, Second Expert Report of Professor Jonathan Charles Howard, Report relates to patents owned by Regeneron Pharmaceuticals, Inc., EP 1 360 287 and 2 264 163. cited by applicant . In The High Court of Justice, Chancery Division, Patents Court, Case No. HP-2013-000001/HP-2014-000001 dated Oct. 6, 2015, First Expert Report of Professor Hiddie L Ploegh, Report relates to patents owned by Regeneron Pharmaceuticals, Inc., EP 1 360 287 and 2 264 163. cited by applicant . In the High Court of Justice, Chancery Division, Patents Court, Case No. HP-2013-000001/HP-2014-000001 dated Nov. 3, 2015, Second Expert Report of Professor Hiddie L Ploegh, Report relates to patents owned by Regeneron Pharmaceuticals, Inc., EP 1 360 287 and 2 264 163. cited by applicant . Andrew, Simon dated Mar. 2, 2011, 9 pages. cited by applicant . Notice of Opposition with statement and facts dated Oct. 14, 2015. cited by applicant . Abuin et al., Recycling Selectable Markers in Mouse Embryonic Stem Cells, Molecular and Cellular Biology, 6 pages, Apr. 1996, pp. 1851-1856, vol. 16. No. 4, American Society of Microbiology. cited by applicant . Askew et al., Site-Directed Point Mutations in Embryonic Stem Cells: a Gene-Targeting Tag- and Exchange Strategy, Molecular and Cellular Biology, 10 pages, Jul. 1993, pp. 4115-4124 vol. 13, No. 7, American Society of Microbiology. cited by applicant . Bagchi et al., CHD5 Is a Tumor Supp.ressor at Human 1p36, Cell, 17 pages,Feb. 9, 2007, pp. 459-475, vol. 128, No. 3, Elsevier Inc. cited by applicant . Blair et al., The Liberation of Embryonic Stem Cells, PLoS Genetics, 6 pages, Apr. 2011,pp. 1-6, vol. 7, No. 4. cited by applicant . Bolland et al., Antisense intergenic transcription in V (D) J recombination, Nature Immunology, 8 pages, Apr. 25, 2004, pp. 630-637, vol. 5, No. 6, Nature Publishing Group. cited by applicant . Bono et al., VH Gene Segments in the Mouse and Human Genomes, JMB, 3 pages, Sep. 3, 2004, pp. 131-143, vol. 342, No. 1, Elsevier Ltd . . . . cited by applicant . Bradley et al., Embryonic stem cells: proliferation and differentiation, Cell Biology, 6 pages, 1990, pp. 1013-1017, Current Biology Ltd . . . . cited by applicant . Bruggemann, Transgenic Animals: generation and use, 6 pages, 1997, pp. 397-402, OPA. cited by applicant . Chevillard et al., A Three-Megabase Yeast Artificial Chromosome Contig Spanning the C57BL Mouse Igh Locus, The Journal of Immunology, 8 pages, Jun. 1, 2002, pp. 5659-5666 vol. 168, No. 11 The American Association of Immunology. cited by applicant . Ceary et al , Disruption of an imprinted gene cluster by a targeted chromosomal translocation in mice, Nature Genetics, 5 pages, Aug. 20, 2001, pp. 78-82, vol. 29, No. 1, Nature Publishing Group. cited by applicant . Corcoran et al., The interleukin-7 receptor a chain transmits distinct signals for proliferation and differentiation during a lymphopoiesis, The EMBO Journal, 9 pages, Apr. 15, 1996, pp. 1924-1932, vol. 15, No. 8, Oxford University Press. cited by applicant . Davis et al., A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice, Genes & Development, 12 pages, Apr. 7, 1993, pp. 671-682, vol. 7, No. 4, Cold Spring Harbor Laboratory Press. cited by applicant . Deng et al., Reexamination of gene targeting frequency as a function of the extent of homology between the targeting vector and the target locus, Mol Cell Biol., Aug. 12, 1992, 3365-3371, vol. 12, No. 8, Medline. cited by applicant . Ebert et al., The Distal VH Gene Cluster of the Igh Locus Contains Distinct Regulatory Elements with Pax5 Transcription Fator-Dependent Activity in Pro-B Cells, Immunity Articles,13 pages, Feb. 25, 2011, pp. 175-187, vol. 34, No. 2, Elsevier, Inc . . . . cited by applicant . Fedorov et al., A comparison of the germline potential of differently aged ES cell lines and their transfected descendants, Transgenic Research, 9 pages, May 6, 1997, pp. 223-231, vol. 6, No. 3 Chapman & Hall. cited by applicant . Gu, et al., Independent Control of Immunoglobulin Switch Recombination at Individual Switch Regions Evidenced through Cre-loxP Mediated Gene Targeting, Cell, 10 pages, Jun. 18, 1993, pp. 1155-1164, vol. 73, No. 6, Cell Press. cited by applicant . Haines et al., Germline diversity of the expressed BALB/c VhJ558 gene family, Molecular Immunology, 10 pages, May 22, 2001, pp. 9-18 vol. 38, No. 1, Elsevier Science Ltd. . . . cited by applicant . Hansen et al., Large-scale gene trapp.ing in C57BL/6N mouse embryonic stem cells, Genome Research, 10 pages, 2008, pp. 1670-1679, vol. 18, Cold Spring Harbor Laboratory Press. cited by applicant . Herault et al., Engineering chromosomes in mice through targeted meiotic recombination (TAMERE), Nature Genetics, 4 pages, Dec. 20, 1998, pp. 381-384, vol. 20, Nature America Inc . . . . cited by applicant . Hong et al., Long targeting arms do not increase the efficiency of homologous recombination in the beta-globin locus of murine embryonic stem cells, Red Cells, 3 pages, Aug. 15, 2003, pp. 1531-1533, vol. 102, No. 4, The American Society of Hematology. cited by applicant . Huang et al., Association of telomere length with authentic pluripotency of ES/iPS cells, Cell Research, 13 pages, Feb. 2011, pp. 779-792, vol. 21, No. 5. cited by applicant . Johnston et al., Complete sequence assembly and characterization of the C57BL/6 mouse Ig heavy chain V region, The Journal of Immunology, 13 pages, Apr. 1, 2006, vol. 176, No. 7, The American Society of Immunology. cited by applicant . Joyner, 2007, previously submitted. cited by applicant . Karu et al., Recombinant Antibody Technology, ILAR Journal, 10 pages, 1995, pp. 132-141, vol. 37, No. 3, Oxford Journals. cited by applicant . Keane et al., Mouse genomic variation and its effect on phenotypes and gene regulation, Nature International Weekly Journal of Science, 6 pages, Sep. 15, 2011, pp. 289-294, vol. 477 Macmillan Publishers Limited. cited by applicant . Kuehn et al., A potential animal model for Lesch Nyhan syndrome through introduction of HPRT mutations into mice, Letters to Nature, 4 pages, Mar. 19, 1987, pp. 295-298, vol. 326, Nature Publishing Group. cited by applicant . Kuroiwa et al., Sequential targeting of the genes encoding immunoglobulin .mu. and prion protein in cattle, Nature Genetics, 5 pages, Jun. 6, 2004, pp. 775-780, vol. 36, No. 7, Nature Publishing Group. cited by applicant . Kwaks et al., 2003, previously submitted. cited by applicant . Lee et al., Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery, Nature Biotechnology, 8 days, Mar. 16, 2014, pp. 356-363, vol. 32, No. 4, Nature America Inc . . . . cited by applicant . Lewis et al., A common Human .beta. Globin Splicing Mutation Modeled in Mice, Blood Journal, 5 pages, Mar. 15, 1998, pp. 2152-2156, vol. 91, No. 6, The American Society of Hematology. cited by applicant . Liang et al., Extensive genomic copy number variation in embryonic stem cell, pnas, 4 pages, Nov. 11, 2008, pp. 17453-17456, vol. 105, No. 45, Genetic Society of America. cited by applicant . Lioudmila et al, Global Gene Expression profiling reveals similarities and differences among mouse pluripotent stem cells of different orgin and strains, Development Biology, 14 pages, Oct. 4, 2007, pp. 446-459, vol. 307, No. 2, NIH Public Access. cited by applicant . Liu, et al., Embryonic Lethality and Tumorigenesis Caused by Segmental Aneuploidy on Mouse Chromosome 11,14 pages, Nov. 1998, pp. 1155-1168, vol. 150, No. 3, The Genetic Society of America. cited by applicant . Liu, et al., Trisomy Eight in ES Cells Is a Common Potential Problem in Gene Targeting and Interferes With Germ Line Transmission, Development Dynamics, 7 pages, May 1997, pp. 85-91, vol. 209, No. 1, Wiley Liss, Inc. cited by applicant . MacDonald et al., 2014, previously submitted. cited by applicant . Matzuk et al., a- Inhibin is a tumor-supp.ressor gene with gonadal specificity in mice, Nature, 7 pages, Nov. 26, 1992, pp. 313-319, vol. 360, Nature Publishing Group. cited by applicant . McMahon et al., The Wnt-1 (int-1)Proto-Oncogene Is Required for Development of a Large Region of the Mouse Brain, Cell, 13 pages, Sep. 21, 1990, pp. 1073-1085, vol. 62, No. 6, Cell Press. cited by applicant . Miller, Ten years of gene targeting: targeted mouse mutants, from vector design to phenotype analysis, Mechanisms of Development, 19 pages, Jan. 21, 1999, pp. 3-21, vol. 82, No. 1-2, Elsevier Inc. cited by applicant . Murphy et al., 2014, previously submitted. cited by applicant . Nagy et al., Derivation of completely cell culture-derived mice from early-passage embryonic stem cells, Development Biology, 5 pages, Sep. 15, 1993, pp. 8424-8428, vol. 90, No. 18, Proc Natl Acad Sci U S A . . . . cited by applicant . Nakatani et al., Abnormal Behavior in a Chromosome Engineered Mouse Model for Human 15q11-13 Duplication Seen in Austin, Cell, 12 pages, Jun. 26, 2009, pp. 1235-1246, vol. 137, No. 7, Elsevier Inc. cited by applicant . Nobrega et al., Megabase deletions of gene deserts result in viable mice, Nature, 6 pages, Oct. 21, 2004, pp. 988-993 vol. 431, Nature Publishing Group. cited by applicant . Pawlitzky et al., Identification of a Candidate Regulatory Element within the 5' Flanking Region of the Mouse Igh Locus Defined by Pro-B Cell-Specific Hypersensitivity Associated with Binding of PU.1, Pax5, and E2A, The Journal of Immunology, 13 pages, Jun. 1, 2006, pp. 6839-6851, vol. 176, No. 11, The American Association of Immunology. cited by applicant . Perlot et al., Analysis of Mice Lacking DNasel Hypersensitive Sites at the 5' End of the IgH Locus, PLoS One, 11 pages, Nov. 15, 2010, pp. 1-10, vol. 5, No. 11. cited by applicant . Prosser et al., A resource of vectors and ES cells for targeted deletion of MicroRNAs in mice, Nature Biotechnology, 6 pages, Aug. 7, 2011, pp. 840-845, vol. 29, No. 9, Nature America Inc. cited by applicant . Ramirez-Solis et al., Chromosome engineering in mice, Nature, 5 pages, Dec. 14, 1995, pp. 720-724, vol. 378, Nature Publishing Group. cited by applicant . Reh et al., Gene Targeting by Homologous Recombination, eLS, 11 pages, Apr. 15, 2014, pp. 1-10, vol. 10, No. 2, John Wiley & Sons Ltd . . . . cited by applicant . Retter et al., Sequences and Characterization of the Ig Heavy Chain Constant and Partial Variable Region of the Mouse Strain 129S1, The Journal of Immunology, 9 pages, Aug. 15, 2007, pp. 2419-2427, vol. 179, No. 4, The American Association of Immunologists. cited by applicant . Ringrose et al., Quantitative comparison of DNA Looping in vitro and in vivo: chromatin increases effective DNA flexibility at short distances, The EMBO Journal, 12 pages, Dec. 1, 1999, pp. 6630-6641, vol. 18, No. 23, European Molecular Biology Organization. cited by applicant . Shen et al., A General Method to Modify BACs to Generate Large Recombinant DNA Fragments, Molecular Biotechnology, 6 pages, Nov. 3, 2005, pp. 181-186, vol. 31, No. 3, Humana Press Inc. cited by applicant . Skarnes et al., A conditional knock out resource for the genome--wide study of mouse gene function, Nature, 6 pages, Jun. 16, 2011, pp. 337-342, vol. 474, MacMillan Publishers. cited by applicant . Smith et al., A site-directed chromosomal translocation induced in embryonic stem cells by Cre-IoxP recombination, Nature Genetics, 10 pages, Apr. 1995, pp. 376-385, vol. 9, No. 4, Nature Publishing Group. cited by applicant . Stacy et al., Use of Double Replacement Gene Targeting to Replace the Murine a-Lactalbumin Gene with Its Human Counterpart in Embryonic Stem Cells and Mice, Molecular and Cellular Biology,8 pages, Feb. 1994, pp. 1009-1016, vol. 14, No. 2, American Society for Microbiology. cited by applicant . Storb et al., Ig gene expression and regulation in Ig transgenic mice, Immunoglobin Genes, 19 pages, 1995, pp. 345-363, Elsevier Ltd . . . . cited by applicant . Takahashi et al., Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors, Cell, 4 pages, Aug. 25, 2006, pp. 663-676, vol. 126, No. 4, Elsevier, Inc. cited by applicant . Taki et al., Targeted insertion of a Variable Region Gene into the Immunoglobulin Heavy Chain Locus, Science, 4 pages, Nov. 19, 1993, pp. 1268-1271, vol. 262, No. 5137. cited by applicant . Toyooka et al., Identification and characterization of subpopulations in undifferentiated ES Cell Culture, Development, 10 pages, Mar. 2008, pp. 909-918 vol. 135, No. 5. cited by applicant . Valenzuela et al., High Through put engineering of the mouse genome coupled with high resolution expression analysis, 13 pages, Nature Biotechnology, May 5, 2003, pp. 652-659, vol. 21, No. 6, Nature Publishing Group. cited by applicant . Wallace et al., Manipulating the mouse genome to engineer precise functional syntenic replacements with human sequence, Cell, 12 pages, Jan. 12, 2007, pp. 197-209, vol. 128, No. 1, Elsevier Inc . . . . cited by applicant . Wu et al., A protocol for constructing gene targeting vectors: generating knockout mice for the cadherin family and beyond, Natures Protocol, 20 pages, May 29, 2008, pp. 1056-1076, vol. 3, No. 6, Nature Publishing. cited by applicant . Yu et al., A mouse model of Down syndrome trisomic for all human chromosome 21 synthetic regions, Human Molecular Genetics, 12 pages May 12, 2010, pp. 1-12, Oxford University Press. cited by applicant . Zambrowicz et al., Disruption and sequence identification of 2,000 genes in mouse embryonic stem cells, Nature, 4 pages Apr. 9, 1998, pp. 608-611, vol. 392, Nature Macmillan Publishing. cited by applicant . Zheng et al., Engineering a mouse balancer chromosome, Nature Genetics, 4 pages, Aug. 1999, pp. 375-378, vol. 22, No. 4, Nature America Inc. cited by applicant . Opponents Initial Supplementary Submissions, Australia Oct. 5, 2016, 7 pages. cited by applicant . Letter with Fee, Australia, May 18, 2015, 1 page. cited by applicant . Acknowledgment of Receipt of Notice of Opposition from the APO, Jun. 23, 2014, 1 page. cited by applicant . Annexure PH-4 referred to in Peter Hudson Jun. 2, 2015 Declaration, 37 pages--Part 1. cited by applicant . Annexure PH-4 referred to in Peter Hudson Jun. 2, 2015 Declaration, 37 pages--Part 2. cited by applicant . Applicant response to post hearing submission, Australia, Sep. 16, 2016. cited by applicant . Section 27 Notice, Australia, Oct. 31, 2013, 25 pages. cited by applicant . Section 27 Notice, Australia, Mar. 18, 2014, 8 pages. cited by applicant . Applicant request for extension of time, Australia, May 18, 2015, 6 pages. cited by applicant . Lai et al., Mouse Cell Surface Antigens: Nomenclature and Immunophenotyping, The Journal of Immunology, 1998, 9 pages, pp. 3861-3868, The American Association of Immunologists. cited by applicant . Opponent Objects to the Allowability of the Ext, Australia, May 4, 2015, 3 pages. cited by applicant . Applicant Written Submission, Australia, Sep. 6, 2016, 49 pages. cited by applicant . Abedi, M.R. et al., Green, fluorescent protein as a scaffold for intracellular presentation of peptides, Nucleic Acids Res., 1998, 26(2), 623-630. cited by applicant . Akerstrom, B. et al., On the interaction between single chain Fv antibodies and bacterial immunoglobulin-binding proteins, J Immunol Methods., 1994, 177(1-2), 151-163. cited by applicant . Alber, T., Kawasaki, G., Nucleotide sequence of the triose phosphate isomerase gene of Saccharomyces cerevisiae, J Mol Appl Genet., 1982, 1(5), 419-434. cited by applicant . Ammerer, G., Expression of genes in yeast using the ADCI promoter, Methods Enzymol., 1983, 101, 192-201. cited by applicant . Antica, M. et al., Thymic stem cells in mouse bone marrow, Blood, 1994, 84(1), 111-117. cited by applicant . Appel RD, et al., A new generation of information retrieval tools for biologists: the example of the ExPASy WWW server, 1994, Trends Biochem. Sci., 19, 258-260. cited by applicant . Aranda, A., Pascual, A., Nuclear hormone receptors and gene expression, Physiol Rev., 2001, 81(3), 1269-1304. cited by applicant . Barbas, CF. et al., Assembly of combinatorial antibody libraries on phage surfaces: the gene III site, Proc Natl Acad Sci U S A, 1991, 88(18), 7978-7982. cited by applicant . Barnes, LM. et al, Characterization of the stability of recombinant protein production in the GS-NS0 expression system, Biotechnol Bioeng., 2001, 73(4), 261-270. cited by applicant . Bebbington, CR. et al, High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker, Biotechnology (N Y), 1992, 10(2), 169-175. cited by applicant . Bell, AC. et al., Insulators and boundaries: versatile regulatory elements in the eukaryotic genome, Science, 2001, 291 (5503), 447-450. cited by applicant . Bertagnolli, M., Herrmann, S., IL-7 supports the generation of cytotoxic T lymphocytes from thymocytes. Multiple lymphokines required for proliferation and cytotoxicity, J Immunol., 1990,145(6), 1706-1712. cited by applicant . Bertagnolli, MM. et al., IL-4- supported induction of cytolytic T lymphocytes requires IL-2 and IL-6, Cell Immunol., 1991, 133(2), 327-341. cited by applicant . Bertagnolli, MM. et al., IL-12 augments antigen-dependent proliferation of activated T lymphocytes, J Immunol., 1992, 149(12), 3778-3783. cited by applicant . Bhardwaj, N. et al., Influenza virus--infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+ T cells, J Clin Invest., 1994; 94(2), 797-807. cited by applicant . Binz, H.K. et al., Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins, J Mol Biol., 2003, 332(2), 489-503. cited by applicant . Bode et al. 2001, Int. J. Gene Ther. Mol. Biol. 6:33-46. cited by applicant . Boder, ET., Wittrup, KD., Yeast surface display for screening combinatorial polypeptide libraries, Nat Biotechnol., 1997, 15(6), 553-557. cited by applicant . Bowman, MR. et al., The cloning of CD70 and its identification as the ligand for CD27, J Immunol., 1994, 152(4), 1756-1761. cited by applicant . Brezinsky, SC. Et al., A simple method for enriching populations of transfected CHO cells for cells of higher specific productivity. J Immunol Methods, 2003, 277(1-2),141-155. cited by applicant . Brink MF, et al., Developing efficient strategies for the generation of transgenic cattle which produce biopharmaceuticals in milk, Theriogenology, 2000, 53(1), 139-148. cited by applicant . Broach; JR. et al., Transformation in yeast: development of a hybrid cloning vector and isolation of the CAN1 gene, Gene, 1979, 8(1), 121-133. cited by applicant . Chan, A., Mak, TW., Genomic organization of the T cell receptor, Cancer Detect Prev., 1989,14(2), 261-267. cited by applicant . Chesnut, J. et al., Selective isolation of transiently transfected cells from a mammalian cell population with vectors expressing a membrane anchored single-chain antibody, Journal of Immunological Methods, 1996 pp. 17-27. cited by applicant . Clackson, T. et al., Making antibody fragments using phage display libraries, Nature, 1991, 352(6336), 624-628. cited by applicant . Cockett MI, Bet al., High level expression of tissue inhibitor of metalloproteinases in Chinese hamster ovary cells using glutamate synthetase gene amplification, Biotechnology, 1990, 8(7), 662-667. cited by applicant . Corsaro, CM., Pearson, ML., Enhancing the efficiency of DNA--mediated gene transfer in mammalian cells, Somatic Cell Genet., 1981, 7(5), 603-616. cited by applicant . Darzynkiewicz, Z. et al., Features of apoptotic cells measured by flow cytometry, Cytometry, 1992,13(8), 795-808. cited by applicant . de Vries, P. et al., The effect of recombinant mast cell growth factor on purified murine hematopoietic stem cells, J Exp Med, 1991, 173(5), 1205-1211. cited by applicant . de Jong, G., Mammalian artificial chromosome pilot production facility: large-scale isolation of functional satellite DNA--based artificial chromosomes, Cytometry, 1999, 35(2), 129-133. cited by applicant . Declaration of Joel Martin filed May 18, 2016 in EP2314629B. cited by applicant . Desmyter, A. et al., Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme, Nat Struct Biol., 1996, 3(9), 803-811. cited by applicant . Dumoulin, M. et al., Single-domain antibody fragments with high conformational stability, Protein Sci., 2002, 11(3), 500-515. cited by applicant . Dumoulin, M. et al., A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme, Nature, 2003, 424(6950), 783-788. cited by applicant . Eren, R. et al., Preclinical evaluation of two human anti-hepatitis B virus (HBV) monoclonal antibodies in the HBV-trimera mouse model and in HBV chronic carrier chimpanzees, Hepatology, 2000, 32(3), 588-596. cited by applicant . Ezzell, C., Magic bullets fly again, Sci Am., 2001, 285(4), 34-41. cited by applicant . Feige, U. et. al., Anti-interleukin-1 and anti-tumor necrosis factor--alpha synergistically inhibit adjuvant arthritis in Lewis rats, Cell Mol Life Sci., 2000, 57(10), 1457-1470. cited by applicant . Fine, JS. et al., Interleukin-10 enhances gamma delta T cell development in the murine fetal thymus, Cell Immunol., 1994, 155(1), 111-122. cited by applicant . Fishwild DM, et al., High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice, Nat Biotechnol, 1996, 14(7), 845-851. cited by applicant . Frenken, LG. et al., Isolation of antigen specific llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae, J Biotechnol., 2000, 78(1), 11-21. cited by applicant . Frykman, S. et al, Quantitating secretion rates of individual cells: design of secretion assays, Biotechnol Bioeng., 1998,59(2), 214-226. cited by applicant . Galy, AH. et al., Delineation of T- progenitor cell activity within the CD34+ compartment of adult bone marrow, Blood, 1995, 85(10), 2770- 2778. cited by applicant . Gan, W. et al, Functional characterization of the internal ribosome entry site of elF4G mRNA, J Biol Chem., 1998, 273 (9), 5006-5012. cited by applicant . Garber, K. Biotech industry faces new bottleneck, Nat Biotechnol., 2001, 19(3), 184-185. cited by applicant . Garnick, RL., Peptide mapping for detecting variants in protein products, Dev Biol Stand., 1992, 76, 117-130. cited by applicant . Garrard, LJ. et al., Fab assembly and enrichment in a monovalent phage display system, Biotechnology (N Y), 1991, 9 (12), 1373-1377. cited by applicant . Gelpi, E., Biomedical and biochemical applications of liquid chromatography-mass spectrometry, J Chromatogr A, 1995, 703(1-2), 59-80, Abstract Only. cited by applicant . Ghetie, M-A., et al., Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells, Proc Natl Acad Sci U S A, 1997, 94(14), 7509-7514. cited by applicant . Gorczyca, W. et al., DNA strand breaks occurring during apoptosis--their early insitu detection by the terminal deoxynucleotidyl transferase and nick translation assays and prevention by serine protease inhibitors, Int J Oncol., 1992, 1(6), 639-648. cited by applicant . Gorczyca, W. et al., Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays, Cancer Res., 1993, 53(8), 1945-1951. cited by applicant . Gorczyca, W. et al., Induction of DNA strand breaks associated with apoptosis during treatment of leukemias, Leukemia, 1993, 7(5), 659-670. cited by applicant . Gorman, C., Bullock, C., Site--specific gene targeting for gene expression in eukaryotes, Curr Opin Biotechnol., 2000, 11(5), 455-460. cited by applicant . Graham, FL., van der Eb,AJ., A new technique for the assay of infectivity of human adenovirus 5 DNA, Virology, 1973, 52(2), 456-467. cited by applicant . Gram, H. et al., In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library, Proc Natl Acad Sci U S A, 1992, 89(8), 3576-3580. cited by applicant . Graslund, T. et al., Integrated strategy for selective expanded bed ion-exchange adsorption and site--specific protein processing using gene fusion technology, J Biotechnol., 2002, 96(1), 93-102. cited by applicant . Gray, F. et al., Secretion capture and report web: use of affinity derivatized agarose microdroplets for the selection of hybridoma cells, J Immunol Methods, 1995, 182(2), 155-163. cited by applicant . Greenberger, JS. et al., Demonstration of permanent factor--dependent multipotential (erythroid/neutrophil/basophil) hematopoietic progenitor cell lines, Proc Natl Acad Sci U S A, 1983, 80(10), 2931-2935. cited by applicant . Groeneveld EH., Burger Eh., Bone morphogenetic proteins in human bone regeneration, Eur J Endocrinol., 2000, 142 (1), 9-21. cited by applicant . Grosveld, F., Activation by locus control regions?, Curr Opin Genet Dev., 1999, 9(2),152-157. cited by applicant . Guery, JC, Adorini, L., Dendritic cells are the most efficient in presenting endogenous naturally processed self-epitopes to class II--restricted T cells, J Immunol., 1995, 154(2), 536-544. cited by applicant . Hamers-Casterman, C. et al., Naturally occurring antibodies devoid of light chains, Nature, 1993, 363(6428), 446-448. cited by applicant . Hanes, J. et al., Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display, Nat Biotechnol., 2000, 18(12), 1287-1292. cited by applicant . Hanes, J. et al., Selecting and evolving functional proteins in vitro by ribosome display, Methods Enzymol., 2000, 328, 404-430. cited by applicant . Harjunpaa, A., et al, Rituximab (anti- CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms, Scand J Immunol., 2000, 51(6), 634-641. cited by applicant . Hawkins, RE. et al., Selection of phage antibodies by binding affinity. Mimicking affinity maturation, J Mol Biol., 1992, 226(3), 889-896. cited by applicant . Hay, BN. et al., Bacteriophage cloning and Escherichia coli expression of a human IgM Fab, Hum Antibodies Hybridomas, 1992, 3(2), 81-85. cited by applicant . Hiatt A, et al., Production of antibodies in transgenic plants, Nature, 1989, 342(6245), 76-78. cited by applicant . Hitzeman, RA. et al., Isolation and characterization of the yeast 3- phosphoglycerokinase gene (PGK) by an immunological screening technique, J Biol Chem., 1980, 255(24), 12073-12080. cited by applicant . Holmes, P., Al-Rubeai, M., Improved cell line development by a high throughput affinity capture surface display technique to select for high secretors, J Immunol Methods, 1999, 230(1-2), 141-147. cited by applicant . Holt, L.J. et al., Domain antibodies: proteins for therapy, Trends Biotechnol., 2003, 21(11), 484-490. cited by applicant . Hooper, D., "Rabies Virus," In: Manual of Clinical Laboratory Immunology, Part II, 5 ed., N.R. Rose (Ed.), ASM Press, Wash. D.C. pp. 755-760, (1997). cited by applicant . Houshmand, H. et al., Use of bacteriophage T7 displayed peptides for determination of monoclonal antibody specificity and biosensor analysis of the binding reaction, Anal Biochem., 1999, 268(2), 363-370. cited by applicant . Houston, M.E., Jr. et al., Use of a conformationally restricted secondary structural element to display peptide libraries: 3 two- stranded alpha-helical coiled-coil stabilized by lactam bridges, J Mol Biol., 1996, 262(2), 270-282. cited by applicant . Huang, AY. et al., Role of bone marrow-derived cells in presenting MHC class I--restricted tumor antigens, Science, 1994, 264(5161), 961-965. cited by applicant . Huls, G. A., et al., A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments, Nat Biotechnol., 1999, 17(3), 276-281. cited by applicant . Huse, WD. et al., Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda, Science, 1989, 246(4935), 1275-1281. cited by applicant . Hynes, RO., Cell adhesion: old and new questions, Trends Cell Biol., 1999, 9(12), M33-37. cited by applicant . Inaba, K. et al., Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC--restricted T cells in situ, J Exp Med., 1990, 172(2), 631-640. cited by applicant . Inaba, M. et al., Distinct mechanisms of neonatal tolerance induced by dendritic cells and thymic B cells, J Exp Med., 1991, 173(3), 549-559. cited by applicant . Itoh, N. et al., The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis, Cell, 1991, 66(2), 233-243. cited by applicant . Jespers LS, et al., Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen, Biotechnology (N Y), 1994, 12(9), 899-903. cited by applicant . Johansson, BM. et al., Evidence for involvement of activin A and bone morphogenetic protein 4 in mammalian mesoderm and hematopoietic development, Mol Cell Biol., 1995, 15(1), 141-151. cited by applicant . Jonasson, P. et al., Genetic design for facilitated production and recovery of recombinant proteins in Escherichia coli, Biotechnol Appl Biochem., 2002, 35(Pt 2), 91-105. cited by applicant . Jones, D., et al., High-level expression of recombinant IgG in the human cell line PER.CX , Biotechnol Prog, 2003, 19 (1), 163-168. cited by applicant . Keller, G. et al., Hematopoietic commitment during embryonic stem cell differentiation in culture, Mol Cell Biol., 1993, 13(1), 473-486. cited by applicant . Kelley et al, Antigen Binding Thermodynamics and Antiproliferative Effects of Chimeric and Humanized anti-p185HER2 Anitbody Fab Fragments, 1992 Biochemistry 31:5435-5441. cited by applicant . Kim SJ, et al., Characterization of chimeric antibody producing CHO cells in the course of dihydrofolate reductase--mediated gene amplification and their stability in the absence of selective pressure, Biotechnol Bioeng., 1998, 58(1), 73-84. cited by applicant . Klagsbrun, M., D'Amore PA.,Vascular endothelial growth factor and its receptors, Cytokine Growth Factor Rev., 1996, 7(3), 259 270. cited by applicant . Kohler, G., Milstein, C., Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, 1975, 256(5517), 495-497. cited by applicant . Koide, A. et al., The fibronectin type III domain as a scaffold for novel binding proteins, J Mol Biol., 1998, 284(4), 1141-1151. cited by applicant . Koopman G, et al., Annexin V for Flow Cytometric Detection of Phosphatidylserine Expression on B Cells Undergoing Apoptosis, The Blood Journal, 1994, pp. 1415-1420. cited by applicant . Korndorfer, IP. et al., Crystallographic analysis of an "anticalin" with tailored specificity for fluorescein reveals high structural plasticity of the lipocalin loop region, Proteins, 2003, 53(1), 121-129. cited by applicant . Korndorfer, IP. et al., Structural mechanism of specific ligand recognition by a lipocalin tailored for the complexation of digoxigenin, J Mol Biol., 2003, 330(2), 385-396. cited by applicant . Kruse PF and Patterson MK (eds) Tissue Culture. Methods and Applications, 1973, Academic Press, New York, no pages provided. cited by applicant . Ku J. et al., Alternate protein frameworks for molecular recognition, Proc Natl Acad Sci U S A, 1995, 92(14), 6552-6556. cited by applicant . Kuhlman, B. et al, Design of a novel globular protein fold with atomic--level accuracy, Science, 2003, 302(5649), 1364-1368. cited by applicant . Letter of Protest filed by Regeneron against U.S. Appl. No. 15/158,543, filed Oct. 14, 2016. cited by applicant . Lobato MN., Rabbitts, TH., Intracellular antibodies and challenges facing their use as therapeutic agents, Trends Mol Med., 2003, 9(9), 390-396. cited by applicant . Lucas, BK. et al, High-level production of recombinant proteins in CHO cells using a dicistronic DHFR intron expression vector, Nucleic Acids Res., 1996, 24(9), 1774-1779. cited by applicant . Macatonia, SE et al, Primary stimulation by dendritic cells induces antiviral proliferative and cytotoxic T cell responses in vitro, J Exp Med., 1989,169(4), 1255-1264. cited by applicant . Macatonia, SE. et al., Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+T cells, J Immunol., 1995, 154(10), 5071-5079. cited by applicant . Macejak, DG., Sarnow, P., Internal initiation of translation mediated by the 5' leader of a cellular mRNA, Nature, 1991, 353(6339), 90-94. cited by applicant . Manen, D. et al., A sensitive reporter gene system using bacterial luciferase based on a series of plasmid cloning vectors compatible with derivatives of pBR322, Gene, 1997, 186(2), 197-200. cited by applicant . Marasco, WA., Intrabodies as antiviral agents, Curr Top Microbiol Immunol., 2001, 260, 247-270. cited by applicant . Marks, JD., Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization, Mov Disord., 2004, 19 Suppl 8, S101-108. cited by applicant . Massengale, WT et al., CD20--negative relapse of cutaneous B--cell lymphoma after anti-CD20 monoclonal antibody therapy, J Am Acad Dermatol, 2002, 46(3), 441- 443. cited by applicant . Mattheakis, LC. et al., An in vitro polysome display system for identifying ligands from very large peptide libraries, Proc Nati Acad Sci U S A, 1994, 91(19), 9022-9026. cited by applicant . Mayer, MP., A new set of useful cloning and expression vectors derived from pBlueScript, Gene, 1995, 163(1), 41-46. cited by applicant . McBurney, MW. et al., Evidence for repeat-induced gene silencing in cultured Mammalian cells: inactivation of tandem repeats of transfected genes, Exp Cell Res., 2002, 274(1), 1-8. cited by applicant . McClanahan, T. et al., Hematopoietic growth factor receptor genes as markers of lineage commitment during in vitro development of hematopoietic cells, Blood, 1993, 81(11), 2903-2915. cited by applicant . McConnell, S.J., Hoess, Rh., Tendamistat as a scaffold for conformationally constrained phage peptide libraries, J Mol Biol., 1995, 250(4), 460-470. cited by applicant . Muyldermans, S., Single domain camel antibodies: current status, J Biotechnol., 2001, 74(4), 277-302. cited by applicant . Nair, S. et al., Induction of primary, antiviral cytotoxic, and proliferative responses with antigens administered via dendritic cells, J Virol., 1993, 67(7), 4062-4069. cited by applicant . Nanbru, C. et al., Alternative translation of the proto-oncogene c--myc by an internal ribosome entry site, J Biol Chem., 1997, 272(51), 32061-32066. cited by applicant . Neumann, E., Gene transfer into mouse lyoma cells by electroporation in high electric fields, EMBO J.,1982, 1(7), 841-845. cited by applicant . Nord, K. et al., A combinatorial library of an alpha-helical bacterial receptor domain, Protein Eng., 1995, 8(6), 601-608. cited by applicant . Nord, K. et al., Recombinant human factor VIII-specific affinity ligands selected from phage-displayed combinatorial libraries of protein A, Eur J Biochem., 2001, 268(15), 4269-4277. cited by applicant . Office Action Response in U.S. Appl. No. 12/932,719 dated Aug. 10, 2013 filed in protest against U.S. App. No. 15/158,543. cited by applicant . Office Action Response in U.S. Appl. No. 12/932,719 dated Feb. 27, 2012 filed in protest against U.S. Appl. No. 15/158,543. cited by applicant . Office Action Response in U.S. Appl. No. 12/932,719 dated Nov. 6, 2014 filed in protest against U.S. Appl. No. 15/158,543. cited by applicant . Oh, SK., et al., Homeotic gene Antennapedia mRNA contains 5'--noncoding sequences that confer translational initiation by internal ribosome binding, Genes Dev., 1992, 6(9), 1643-1653. cited by applicant . Patel AK, Boyd, PN., An improved assay for antibody dependent cellular cytotoxicity based on time resolved fluorometry, J Immunol Methods, 1995, 184(1), 29-38. cited by applicant . PI?ckthun, A. et al, In vitro selection and evolution of proteins. In: Adv. Prot. Chem., F.M. Richards et al, Eds, Academic Press, San Diego, 2001, vol. 55, 367-403. cited by applicant . Porgador, A. et al., Bone marrow--generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes, J Exp Med., 1995, 182(1), 255-260. cited by applicant . Rebar, EJ. et al., Phage display methods for selecting zinc finger proteins with novel DNA-binding specificities, Methods Enzymol., 1996, 267, 129-149. cited by applicant . Rees, S. et al, Bicistronic vector for the creation of stable mammalian cell lines that predisposes all antibiotic-resistant cells to express recombinant protein, Biotechniques, 1996, 20(1), 102-4, 106, 108-10. cited by applicant . Reiter, Y. et al., An antibody single--domain phage display library of a native heavy chain variable region: isolation of functional single-domain VH molecules with a unique interface, J Mol Biol., 1999, 290(3), 685-698. cited by applicant . Repp, R. et al., Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI .times. anti-HER- 2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer, Br J Cancer, 2003,89(12), 2234-2243. cited by applicant . Riechmann, L., Winter, G., Novel folded protein domains generated by combinatorial shuffling of polypeptide segments, Proc Natl Acad Sci U S A, 2000, 97(18), 10068-10073. cited by applicant . Roitt, I.M. et al., Anti-idiotypes as surrogate antigens: structural considerations, Immunol Today, 1985, 6(9), 265-267. cited by applicant . Rosenberg A., e al., T7Select Phage Display System: A Powerful New Protein Display System Based on Bacteriophage T7, 1996, Innovations 6, 1-6. cited by applicant . Rottgen, P., Collins, J. et al., A human pancreatic secretory trypsin inhibitor presenting a hypervariable highly constrained epitope via monovalent phagemid display, Gene, 1995, 164(2), 243-250. cited by applicant . Sambrook, Fritsch and Maniatis, Molecular Cloning: A Laboratory Manual, 2nd edition, 1989. cited by applicant . Santini, C. et al., Efficient display of an HCV cDNA expression library as C-terminal fusion to the capsid protein D of bacteriophage lambda, J Mol Biol., 1998, 282(1), 125-135. cited by applicant . Schaffitzel, C. et al., Ribosome display: an in vitro method for selection and evolution of antibodies from libraries, J Immunol Methods, 1999, 231(1-2), 119-135. cited by applicant . Schaffitzel,C. et al., In vitro selection and evolution of protein--ligand interactions by ribosome display. In: Protein-Protein Interactions. A Molecular Cloning Manual, E. Golemis, Ed., Cold Spring Harbor Laboratory Press, New York, 2001, pp. 535-567. cited by applicant . Schlehuber et al., Tuning ligand affinity, specificity, and folding stability of an engineered lipocalin variant--a so-called "anticalin"--using a molecular random approach, Biophysical Chemistry 96 (2002) 213-228. cited by applicant . Schoonjans et al., A new model for intermediate molecular weight recombinant bispecific and trispecific antibodies by efficient heterodimerization of single chain variable domains through fusion to a Fab-chain, Biomolecular Engineering 17 (2001) 193-202. cited by applicant . Shields, RL, et al., High resolution mapping of the binding site on human IgGI for FcgRl, FcgRII, FcgRIII and FcRn and design of IgGI variants with improved binding to the FcgR, J Biol Chem., 2001, 276(9), 6591-6604. cited by applicant . Smith, CA., Rennick, DM., Characterization of a murine lymphokine distinct from interleukin 2 and interleukin 3 (IL-3) possessing a T-cell growth factor activity and a mast-cell growth factor activity that synergizes with IL-3, Proc Natl Acad Sci U S A, 1986, 83(6), 1857-1861. cited by applicant . Smith, GP. et al., Small binding proteins selected from a combinatorial repertoire of knottins displayed on phage, J Mol Biol., 1998, 27, 277(2), 317-332. cited by applicant . Spiridon CI, et al., Tartgeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo, Clin Cancer Res., 2002, 8(6), 1720-1730. cited by applicant . Stein, I., et al., Translation of vascular endothelial growth factor mRNA by internal ribosome entry: implications for translation under hypoxia, Mol Cell Biol., 1998, 18(6), 3112-3119. cited by applicant . Stijlemans, B. et al., Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm, J Biol Chem., 2004, 279(2), 1256-1261. cited by applicant . Stoneley, M., et al., C-Myc 5' untranslated region contains an internal ribosome entry segment, Oncogene, 1998 , 16 (3), 423-428. cited by applicant . Strelkauskas, AJ. Et al., Human monoclonal antibody: 2. Simultaneous expression of IgG and IgM with similar binding specificities by a human hybrid clone, Hybridoma, 1987, 6(5), 479-487. cited by applicant . Struhl, K. et al., High-frequency transformation of yeast: autonomous replication of hybrid DNA molecules, Proc Natl Acad Sci U S A, 1979, 76(3), 1035-1039. cited by applicant . (Page 1) EPO Form 2906 regarding Patent Application No. 10 186 063.3 dated Jul. 27, 2016, indicating the description needs to be brought in conformity with the claims, 1 page. cited by applicant . (Pages 2-3) EPO Document regarding Patent Application No. 10 186 0633 dated Jul. 27, 2016, Communication pursuant to Article 101(1) and Rule 81(2) to (3) EPC 2 pages. cited by applicant . (Page 4) The communication was printed for and notified to each of the representatives/parties, regarding EP Application 10186063.3, at least as early as Jul. 27, 2016, 1 page. cited by applicant . (Page 5-6) Letter from Isenbruck to the European Patent Office dated Jun. 20, 2016, indicating Ton Logtenberg will not be in attendance at the oral proceedings, 2 pages. cited by applicant . (Page 7) EPO Brief Communication regarding the Opposition against EP Application 10186063.3, dated Jun. 13, 2016, 1 page. cited by applicant . (Page 8) EPO Brief Communication regarding the Opposition against EP Application 10186063.3, dated Jun. 10, 2016, 1 page. cited by applicant . (Pages 9-61) Deed of Conversion and Amendment of the Articles of Association for Mews B.V. (new name: Merus N. V.), first in Dutch and then in English (Dutch version previously submitted without English translation). cited by applicant . (Page 62) EPO Payment of fees and expenses for EP Application 10186063.3 dated May 27, 2016, 1 page. cited by applicant . (Page 63-64) Letter dated May 27, 2016, accompanying the Deed of Conversion and Amendment, and Form 1010, 2 pages. cited by applicant . (Page 65) EPO Brief Communication regarding the Opposition against EP Application 10186063.3, dated May 26, 2016, 1 page. cited by applicant . (Page 66-70) Main Request with annotations, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages (previously submitted); (pp. 71-75) Auxiliary Request 1 with annotations, EP Patent. No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages (previously submitted); (pp. 76-80) Auxiliary Request 2, EP Patent. No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages (previously submitted). cited by applicant . (Pages 81-85) Auxiliary Request 3 with annotations, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages (previously submitted); (pp. 86-90) Auxiliary Request 4 with annotations, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages (previously submitted); (pp. 91-95) Auxiliary Request 5 with annotations, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages (previously submitted). cited by applicant . (Pages 96-100) Auxiliary Request 6 with annotations, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages (previously submitted); (pp. 101-107) Auxiliary Request 7 with annotations, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, seven pages (previously submitted); (pp. 108-114) Auxiliary Request 8 with annotations, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, seven pages (previously submitted). cited by applicant . (Pages 115-123) Auxiliary Request 9 with annotations, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, nine pages (previously submitted); (pp. 124-132) Auxiliary Request 10 with annotations, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, nine pages (previously submitted); (pp. 133-137) Auxiliary Request 11 with annotations, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages. cited by applicant . (Pages 138-142) Auxiliary Request 12 with annotations, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages (previously submitted); (pp. 143-147) Auxiliary Request 13 with annotations, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages; (pp. 148-152) Auxiliary Request 14 with annotations, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages. cited by applicant . (Pages 153-157) Auxiliary Request 1, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages. cited by applicant . (Pages 158-162) Auxiliary Request 2, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages; (previously submitted); (pp. 163-167) Auxiliary Request 4, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages (previously submitted); (pp. 173-177); Auxiliary Request 5, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages (previously submitted). cited by applicant . (Pages 178-182) Auxiliary Request 6, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages (previously submitted); (pp. 183-197) Auxiliary Request 7, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages (previously submitted); (pp. 188-192); Auxiliary Request 8, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages (previously submitted). cited by applicant . (Pages 193-197) Auxiliary Request 9, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages (previously submitted); (pp. 198-202) Auxiliary Request 10, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages (previously submitted); (pp. 203-205) Auxiliary Request 11, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, three pages (previously submitted). cited by applicant . (Pages 206-208); Auxiliary Request 12, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, three pages (previously submitted); (pp. 209-213); Auxiliary Request 13, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages (previously submitted); (pp. 214-218) Auxiliary Request 14, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages. cited by applicant . (Pages 219-225) Logtenberg, Prof. Ton Declaration of, CEO, Merus B.V., dated May 4, 2016, 7 pages (previously submitted); (pp. 226-251) Appeal Brief under 37 C.F.R. .sctn. 41.37 filed by Brenda Herschbach Jarrell, U.S. Appl. No. 13/948,818, filed Jul. 20, 2015, 26 pages with Claims Appendix (previously submitted). cited by applicant . (Pages 252-267) Response to the Summons to attend Oral Proceedings dated Nov. 29, 2015 and in preparation of the Hearing of Jun. 22, 2016, from Isenbruck Bosl Forschler LLP to European Patent Office dated May 20, 2016. cited by applicant . (Pages 268-272) Main Request with annotations, EP Patent No. 2314629B1, Reference No. M70120EPEIN FLZ, May 20, 2016, five pages (previously submitted); (pp. 273-279) EPO communication to Fritz Lahrtz of Isenbruck Bosl Hoschler LLP, Brief Communication regarding Oral proceedings on Jun. 22, 2016 at 10:00 in S2.1, EP Application No. 10186063.3 and EP Patent No. 2314629, Apr. 26, 2016, (previously submitted). cited by applicant . (Page 280) Correspondence from Dr. Fritz Lahrtz of Isenbruck Bosl Forschler LLP to the European Patent Office regarding the Oral Proceedings on Jun. 22, 2016, EP Application No. 10186063.3 and EP Patent No. 2314629, Feb. 16, 2016, one page (previously submitted); (p. 281) EPO communication to Fritz Lahrtz of Isenbruck Bosl Hoschler LLP, Communication of amended entries concerning the representative (R. 143(1)(h) EPC), EP Application No. 10186063.3 and EP Patent No. 2314629, Jan. 12, 2016, EPO Form 2548 08.13, one page (previsously submitted). cited by applicant . (Page 282) Correspondence from Dr. Fritz Lahrtz of Isenbruck Bosl Forschler LLP to the European Patent Office regarding change of correspondence, EP Application No. 10186063.3 and EP Patent No. 2314629, Jan. 8, 2016, one page (Previously submitted); (p. 283) EPO Acknowledgement of receip, Application No. 10186063.3, Dec. 17, 2015, one page; (previously submitted). cited by applicant . (Page 284-285) EPO Letter accompaning subsequently filed items, Document concerning representation filed by C. M. Jansen of V.O., EP Application No. 10186063.3, Dec. 17, 2015, two pages (previously submited); (pp. 286-287) EPO Communication to J A Kemp, Acknowledgement of receipt of EPO Forms 2310 and 2043, EP Application No. 10186063.3 and EP Patent No. 2314629, Nov. 19, 2015, EPO 2936 08.10, one page; (previously submitted). cited by applicant . (Pages 288-298) EPO Communication regarding opposition, EP Application No. 10186063.3, Nov. 19, 2015 EPO Form 2906 01.91TRI with Consolidated list o documents, 11 pages (previously submitted). cited by applicant . (Pages 299-301) EPO Communication regarding important information concerning oral proceedings, requesting information by Apr. 20, 2016, EPO Form 2043 02.09, three pages (previously submited). cited by applicant . (Page 302-303) EPO Communication in preparation for oral preceeding dated Jun. 22, 2016, EP Application No. 10186063.3, EPO Form 2040, two pages. cited by applicant . (Page 304-305) Summons to Attend Oral Proceedings, EP Application No. 10186063.3, dated Nov. 19, 2015, two pages. cited by applicant . (Page 306) EPO Communication of amended entries concerning the representative (R. 143(1)(h) EPC), EP Application No. 10186063.3 and EP Patent No. 2314629, Oct. 8, 2015, EPO Form 2548, 08.13, one page (previously submitted); (p. 307) Correspondence from C.M. Jansen of V.O. to European Patent Office regarding the Registration of the Association and change of addres, reference No. RvE/E100EPEP, Sep. 29, 2015, one page (previously submitted). cited by applicant . (Page 308) EPO Acknowledgement of Receipt of the submission by the proprietor, EP Application No. 10186063.3 and EP Patent No. 2314629, date of receipt Feb. 24, 2015, one page (previously submitted). cited by applicant . (Pages 309-310) EPO Communicaton regarding Submission in opposition proceedings, Reply of the patent proprietor to the notice(s) of opposition, EP Application No. 1018606.3 and Patent No. 2314629, Oct. 16, 2013, two pages. cited by applicant . (Pages 311-330) Reply to Communication under Rule 79(1) EPC, EP Application No. 10186063.3 and EP Patent No. 2314629, Feb. 24, 2015, 20 pages (previously submitted). cited by applicant . (Page 331) EPO Extension of time limit pursuant to Rule 132 EPC, EP Application No. 10186063.3 and EP Patent No. 2314629, Oct. 24, 2014, EPO Form 2944C, 06.12, one page. cited by applicant . (Page 332-335) EPO Communication regarding Submission in opposition proceedings, Request for extension of time, EP Application No. 10186063.3 and U.S. Patent No. 2314629, Oct. 16, 2014, four pages. cited by applicant . (Page 336) EPO Communication of a notice of opposition (R. 79(1) EPC), EP Application No. 10186063.3 and EP Patent No. 2314629, Aug. 22, 2014, EPO Form 2317A, 12.07, one page (previously submitted). cited by applicant . (Page 337) EPO Communication of a notice of opposition EP Application No. 10186063.3 and EP Patent No. 2314629 Jul. 21, 2014, EPO Form 2316, one page. cited by applicant . Roitt, et al., Really Essential Medical Immunology, pp. 23-35, 17 pages. cited by applicant . Takai, Y. et al., Requirement for three distinct lymphokines for the induction of cytotoxic T lymphocytes from thymocytes, J Immunol., 1986,137(11), 3494-3500. cited by applicant . Takai, Y. et al., B cell stimulatory factor-2 is involved in the differentiation of cytotoxic T lymphocytes, J Immunol., 1988, 140(2), 508-512. cited by applicant . Tanha, J. et al.,Selection by phage display of llama conventional V(H) fragments with heavy chain antibody V(H)H properties, J Immunol Methods, 2002, 263(1-2), 97-109. cited by applicant . Teaching of U.S. Appl. No. 12/589,181 (MeMo), submitted in U.S. Appl. No. 12/589,181, filed Jun. 20, 2012. cited by applicant . Thomassen ,Y. et al, Large-scale production of VHH antibody fragments by Saccharomyces cerevisiae, 2002, Enzyme Microb. Technol., 30, 273-278. cited by applicant . Thotakura, NR., Blithe, DL., Glycoprotein hormones: glycobiology of gonadotrophins, thyrotrophin and free alpha subunit, Glycobiology, 1995, 5(1), 3-10. cited by applicant . Toki, J. et al., Analyses of T-cell differentiation from hemopoietic stem cells in the GO phase by an in vitro method, Proc Natl Acad Sci U S A, 1991, 88(17), 7548-7551. cited by applicant . Transue, TR. et al., Camel single--domain antibody inhibits enzyme by mimicking carbohydrate substrate, Proteins, 1998, 32(4), 515-522. cited by applicant . Urlaub, G. et al., Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity, Proc Natl Acad Sci U S A, 1980, 77(7), 4216-4220. cited by applicant . Vagner, S., et al, Alternative translation of human fibroblast growth factor 2 mRNA occurs by internal entry of ribosomes, Mol Cell Biol., 1995, 15(1), 35-44. cited by applicant . Valenzuela, DM., High-throughput engineering of the mouse genome coupled with high-resolution expression analysis, Nat Biotechnol, 2003, 21(6), 652-659. cited by applicant . Van der Vuurst de Vries A, Logtenberg T, Dissecting the human peripheral B-cell compartment with phage display-derived antibodies, Immunology, 1999, 98(1), 55-62. cited by applicant . Wang, G. et al, A T cell--independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-gamma chain chimeric receptor gene recognizing a human ovarian cancer antigen, Nat Med., 1998, 4 (2), 168-172. cited by applicant . Weinberger, O. et al., Cellular interactions in the generation of cytolytic T lymphocyte responses: role of la-positive splenic adherent cells in presentation in H-2 antigen, Proc Natl Acad Sci U S A, 1980,77(10), 6091-6095. cited by applicant . Weinberger, O. et al, Cellular interactions in the generation of cytolytic T lymphocyte responses. Analysis of the helper T cell pathway, Eur J Immunol., 1981, 11(5), 405-411. cited by applicant . WHO Technical Series Report, 1994, vol. 848, p. 8. cited by applicant . Wigler, M. et al.,Biochemical transfer of single-copy eucaryotic genes using total cellular DNA as donor, Cell, 1978, 14 (3), 725-731. cited by applicant . Wilson TJ, Kola I., The LoxP/CRE system and genome modification, Methods Mol Biol., 2001, 158, 83-94. cited by applicant . Wright A, Morrison SL., Effect of glycosylation on antibody function: implications for genetic engineering, Trends Biotechnol., Jan. 1997;15(1):26-32. cited by applicant . Ye, X., et al., Ultrabithorax and Antennapedia 5' untranslated regions promote developmentally regulated internal translation initiation, Mol. Cell Biol., 1997, 17(3), 1714-17121. cited by applicant . Yelverton E, et al., Rabies virus glycoprotein analogs: biosynthesis in Escherichia coli, Science, 1983, 219(4585), 614-620. cited by applicant . Yoo EM et al., Structural requirements for polymeric immunoglobulin assembly and association with J chain, J Biol Chem., 1999, 274(47), 33771-33777. cited by applicant . Zacharchuk, CM. Et al., Programmed T lymphocyte death. Cell activation- and steroid-induced pathways are mutually antagonistic, J Immunol., 1990, 145(12), 4037-4045. cited by applicant . Zamai et al., Optimal detection of apoptosis by flow cytometry depends on cell morphology, Cytometry, 1993, 14(8), 891-897. cited by applicant . Zou, YR. et al. Cre-loxP-mediated gene replacement: a mouse strain producing humanized antibodies, Curr Biol, 1994 4(12), 1099-1103 cited by applicant . Jun. 20, 2016 Communication of the registration of a transfer or change of name and/or address, 2 pages. cited by applicant . Jun. 16, 2016 General enquiry, 1 page. cited by applicant . Jun. 15, 2016 Search started, 1 page. cited by applicant . May 30, 2016 Annexes in respect of a request for a change, 53 pages. cited by applicant . May 30, 2016 Payment of fees and costs, 1 page. cited by applicant . May 30, 2016 Request for change of name--applicant, 1 page. cited by applicant . Dec. 23, 2015 Communication of amended entries concerning the representative, 1 page. cited by applicant . Dec. 22, 2015 Request for change of applicant's representative, 2 pages. cited by applicant . Dec. 17, 2015 (Electronic) Receipt, 1 page. cited by applicant . Dec. 17, 2015 Letter accompanying subsequently filed items, 1 page. cited by applicant . Dec. 17, 2015 Request for change of applicant's representative, 1 page. cited by applicant . Oct. 8, 2015 Communication of amended entries concerning the representative, 1 page. cited by applicant . Sep. 29, 2015 Request for change of applicant's representative, 1 page. cited by applicant . Apr. 23, 2013 CDS Clean up--amended data concerning the representative for the applicant, 1 page. cited by applicant . Apr. 2, 2013 Document concerning representation, 3 pages. cited by applicant . Jan. 6, 2013 Notification of forthcoming publication, 2 pages. cited by applicant . Oct. 29, 2012 Non-scannable object, 1 page. cited by applicant . Oct. 29, 2012 Reply to the invitation to remedy deficiencies, 2 pages. cited by applicant . Oct. 29, 2012 Sequence listing, 76 pages. cited by applicant . Aug. 31, 2012 Deficiencies in sequence listing, 2 pages. cited by applicant . Aug. 20, 2012 (Electronic) Receipt, 1 page. cited by applicant . Aug. 20, 2012 (Partial) description filed in response to formal objections, 8 pages. cited by applicant . Aug. 20, 2012 Drawings, 79 pages. cited by applicant . Aug. 20, 2012 Letter accompanying subsequently filed items, 1 page. cited by applicant . Jul. 20, 2012 Deficiencies in application documents--annex B and C, 4 pages. cited by applicant . Jul. 9, 2012 Abstract, 1 page. cited by applicant . Jul. 9, 2012 Acknowledgement of receipt of electronic submission of the request for grant of a European patent, 2 pages. cited by applicant . Jul. 9, 2012 Claims, 6 pages. cited by applicant . Jul. 9, 2012 Description, 87 pages. cited by applicant . Jul. 9, 2012 Designation of inventor Daniel, 1 page. cited by applicant . Jul. 9, 2012 Designation of inventor Erwin, 1 page. cited by applicant . Jul. 9, 2012 Designation of inventor Ton, 1 page. cited by applicant . Jul. 9, 2012 Designation of inventor Mark, 1 page. cited by applicant . Jul. 9, 2012 Drawings, 72 pages. cited by applicant . Jul. 9, 2012 Request for grant of a European patent (divisional application), 6 pages. cited by applicant . Oct. 27, 2009 Priority document, 72 pages. cited by applicant . Aug. 8, 2016 Invitation to confirm maintenance of the application and to correct deficiencies in the Written Opinion/amend application, 2 pages. cited by applicant . Jul. 13, 2016 Refund of fees, 1 page. cited by applicant . Jun. 30, 2016 Communication regarding the transmission of the European search report, 1 page. cited by applicant . Jun. 30, 2016 European search opinion, 6 pages. cited by applicant . Jun. 30, 2016 European search report, 9 pages. cited by applicant . Jun. 30, 2016 Information on Search Strategy, 1 page. cited by applicant . Japan, Third Party Observation 2011-516168, 14 pages. cited by applicant . Japan, Argument, Jun. 21, 2016, 15 pages. cited by applicant . Japan, declaration of Ton Logtenberg, Sep. 15, 2015, 5 pages. cited by applicant . Japan, English translation and Opponents counter arguments, 25 pages. cited by applicant . Japan, Declaration of Peter Hudson, Jun. 17, 2016, 15 pages. cited by applicant . Japan, IMGT/LIGM-DB sequence, Jul. 26, 2016, 13 pages. cited by applicant . Japan, Information Sheet for Submitted Publications, 3 pages. cited by applicant . Japan, Notification 084747, 1 pages. cited by applicant . Japan, Opponents Counterargument 2016-700031, 19 pages. cited by applicant . Japan, Notice of Reasons for Revocation, Mar. 17, 2016, 8 pages. cited by applicant . Allen, Ligand-targeted therapeutics in anticancer therapy, Nat. Rev. Cancer, 2002, 2:750-783. cited by applicant . Folkman, Angiogenesis in cancer, vascular, rheumatoid and other disease, J. Nat. Med., 1995, pp. 27-31, vol. 1. cited by applicant . Gerstner et al., Sequence Plasticity in the Antigen-binding Site of a Therapeutic Anti-HER2 Antibody, J. Mol. Biol., Aug. 30, 2002, pp. 851-862, vol. 321, issue 5, Elsevier. cited by applicant . Gluzman, SV40-transformed simian cells support the replication of early SV40 mutants, Cell, Jan. 1981, pp. 175-182, vol. 23, Issue 1. cited by applicant . Hoogenboom et al., By-passing immunisation. Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro, J Mol Biol., Sep. 20, 1992, pp. 381-388, vol. 227, Issue 2. cited by applicant . Hoogenboom, Designing and optimizing library selection strategies for generating high-affinity antibodies, Trends Biotechnol., 1997, pp. 62-70, vol. 15, Issue 2. cited by applicant . Kaufman et al., Amplification and expression of sequences cotransfected with a modular dihydrofolate reductase complementary DNA gene, J. Mol. Biol., Aug. 25, 1982, pp. 601-621, vol. 159, Issue 4. cited by applicant . Bitter et al., Expression and Secretion Vectors for Yeast, in Methods in Enzymology, Ed. Wu & Grossman, Acad. Press. N.Y. 153:516 544 (1987). cited by applicant . Cherrington et al., New paradigms for the treatment of cancer: The role of anti-angiogenesis agents, Adv. Cancer. Res., 2000, pp. 1-38, vol. 79. cited by applicant . Zhu et. al., Inhibition of Tumor Growth and Metastasis by Targeting Tumor-Associated Angiogenesis with Antagonists to the Receptors of Vascular Endothelial Growth Factor, Invest. New Drugs, Aug. 1999, pp. 195-212, vol. 17, Issue 3. cited by applicant . EP, Instructions to the EPO to amend the application, Sep. 29, 2014, 7 pages. cited by applicant . Votice of Third Party Submission filed with the U.S. Patent Office on Aug. 29, 2016 in U.S. Appl. No. 15/140,321, 2 pages. cited by applicant . Concise Description of Relevance in Third Party Submission filed with the U.S. Patent Office on Aug. 29, 2016 in U.S. Appl. No. 15/140,321, 46 pages. cited by applicant . Concise Description of Relevance in Third Party Submission filed with the U.S. Patent Office on Aug. 29, 2016 in U.S. Appl. No. 15/140,321, 6 pages. cited by applicant . Third-Party Submission filed with the U.S. Patent Office on Aug. 29, 2016 in U.S. Appl. No. 15/140,321, 4 pages. cited by applicant . Documents listed in the Third-Party Submission include the following: U.S. Pat. No. 7,262,028 (previously submitted); Merchant et al., 1998 (previously submitted); Declaration of Dr. Joel Martin executed May 18, 2016 (previously submitted); U.S. Pat. No. 9,248,182 (previously submitted); WO 1998/050431 (previously submitted); Carter, 2001; WO 1999/045962 (previously submitted); Ritchie et al., 1984 (previously submitted); WO 02/066630 (previously submitted). cited by applicant . Canadian Intellectual Property Office--office action for Application No. 2,729,095 held by Merus B.V. dated Nov. 10, 2015 listing references considered: D8--Sirac et al., 2006 (previously submitted); D10--WO 2006/117699 (previously submitted); D12--WO 2004/106375 (previously submitted); D13--WO 02/066630 (previously submitted); D14--US 2007/0280945 (previously submitted). cited by applicant . D15-WO 2008/076379 (previously submitted); D16-WO 2008/054606 (previously submitted); D17--DeFrancesco et al., 2007 (listed separately below); D18--Scott, et al., 2007 (previously submitted); D19--Nagle, 2007 (previously submitted); Examination Search Report lists Family Members EP2147594B1 and AU2009263082B9. cited by applicant . DeFrancesco et al., Big Pharma vies for mice, Nature Biotechnology, 25/6, pp. 613-614, Jun. 2007. cited by applicant . Response to office action for Canadian Application No. 2,729,095 dated May 10, 2016, 12 pages. cited by applicant . Third-Party Opposition dated Sep. 16, 2015, for Canadian Application No. 2,729,095, and Protest and Submission of Prior Art, which lists the following documents D8, D9, D10, D11, D12, D13, D14, D15, D16, D17, D18, D19, D20. cited by applicant . The Third-Party Opposition of Sep. 16, 2015, indicates the following attachments: 1) Second Protest (13 pages); 2) D8--Sirac et al., 2006, 9 pages (previously submitted); 3) D9--US20060015957 (299 pages); 4) D10--WO 2006117699 (79 pages) (previously submitted); 5) D11--WO 2004009618 (186 pp.); 6) D12--WO 2004106375 (189 pages) (previously submitted); 7) D13--WO 20066630 (74 pages) (previously submitted). cited by applicant . 8) D14--US 20070280945 (71 pages) (previously submitted); 9) D15--WO2008076379 (37 pages) (previously submitted); 10) D16--WO 2008054606 (30 pages) (previously submitted); 11) D17--New in Brief 2007 (2 pages) (previously submitted); 12) D18--Scott et al., 2007 (3 pages.) (previously submitted); 13) D19--Nagle et al., 2007 (2 pages) (previously submitted) and 14) D20--Sirac et al., 2011 (15 pages) (previously submitted). cited by applicant . Voluntary Amendment filed by Borden Ladner Gervais LLP dated May 12, 2016 in Canadian Application No. 2,729,095, 2 pages. cited by applicant . Correspondence from the Canadian Intellectual Property Office in Canadian Application No. 2,729,095 to Borden Ladner Gervais LLP dated Apr. 16, 2014, advising that a protest has been filed by Blake Cassels & Graydon LLP, 1 page. cited by applicant . Correspondence from the Canadian Intellectual Property Office in Canadian Application No. 2,729,095 to Blake, Cassels & Graydon LLP dated Apr. 16, 2014, regarding filed protest, 1 page. cited by applicant . Protest and Submission of Prior Art submitted by Blake, Cassels & Graydon LLP dated Apr. 8, 2014, indicates the following attachments: 1) Protest and Submission of Prior Art (13 pages); 2) D8--Sirac et al., 2006, 9 pages (previously submitted); 3) D9--Aucouturier et al. (8 pages) (previously submitted); D10--GenBank M87478 (1 page) (previously submitted); D11--Sequence Alignment of GenBank (7 pages) (previously submitted); D12--de Wildt (7 pages) (previously submitted); D13--US 20060015957 (299 pages) (previously submitted); D14--WO 2004106375. cited by applicant . D17--WO 9850431 (70 pages) (previously submitted); D18--WO 02066630 (74 pages) (previously submitted); D19--JS 20070280945 (71 pages.) (previously submitted); D20--WO 2008076379 (37 pages) (previously submitted); D21--WO 2008054606 (30 pages) (previously submitted); D22--NIB 2007 (2 pages) (previously submitted); 23--Scott et al., 2007 (3 pages) (previously submitted); and D24--Nagle et al., 2007 (2 pages) (previously submitted). cited by applicant . Protest and Submission of Prior Art submitted by Blake, Cassels & Graydon LLP dated Sep. 16, 2015, indicates the following attachments: D8--Sirac et al., 2006, 9 pages (previously submitted); D9--US 20060015957 (299 pages) (previously submitted); D10--WO 2006117699 (previously submitted); D11--WO 2004009618 (previously submitted); D12--WO 2004106375 (previously submitted). cited by applicant . D13--WO 02066630 (previously submitted); D14--US 20070280945 (previously submitted); D15--WO 2008076379 (previously submitted); D16--WO 2008054606 (previously submitted); D17--News in Brief Article (previously submitted); D18--Scott, 2007 (previously submitted); D19, Nagle, 2007 (previously submitted); D20, Sirac et al., 2011. cited by applicant . Waterhouse et al., Combinatorial infection and in vivo recombination: strategy for making large phage antibody repertoires, Nucleic Acids Research 21(9), 1993, pp. 2265-2266. cited by applicant . Houldsworth et al., Comparative Genomic Hybridization: An Overview, American Journal of Pathology, vol. 145, Dec. 1994. cited by applicant . Jessen et al (1998) Modification of bacterial artificial chromosomes through Chi-stimulated homologous recombination and its application in zebrafish transgenesis. Proc. Natl. Acad. Sci. USA 95:5121-5126. cited by applicant . Muyrers et al., Rapid modification of bacterial artificial chromosomes by ET-recombination. Nucleic Acids Research, 1999, 27(6):1555-1557. cited by applicant . Narayanan et al., Efficient and precise engineering of a 200 kb beta-globin human/bacterial artificial chromosome in E. coli DH1OB using an inducible homologous recombination system, Gene Therapy, 1999, 6:442-447. cited by applicant . Soukharev et al., Segmental genomic replacement in embryonic stem cells by double lox targeting, Nucleic Acids Research, 1999, pp. e21, vol. 27, No. 18. cited by applicant . Appeal Briefs filed with the U.S. Appl. No. 13/948,818 at least as early as Jul. 17, 2015, available on the U.S. Patent Office website. cited by applicant . U.S. Appl. No. 60/244,665, filed Oct. 31, 2000, available on the U.S. Patent Office website. cited by applicant . Chu, 66 F.3d, 292--Case Summary and Opinion; United States Court of Appeals for the Federal Circuit, Sep. 14, 1995. cited by applicant . Moldenhauer et al., Bispecific antibodies from hybrid hybridoma, in R.E. Kontermann (ed): Bispecific antibodies, Berlin Heidelberg, Springer Verlag, 2011, pp. 29-46. cited by applicant . Staerz et al., Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity, Proc Natl Acad Sci U S A, 1986, vol. 83(5) pp. 1453-1457. cited by applicant . Description of relevance of Third Party Submission in U.S. Appl. No. 15/140,321 dated Feb. 10, 2017. cited by applicant . Description of relevance of Third Party Submission in U.S. Appl. No. 15/090,505 dated Feb. 24, 2017. cited by applicant . Materials from examination--submission in response to attend oral proceedings of a European Patent Application No. 09075279.1, Apr. 23, 2013. cited by applicant . Online Response of Regeneron Pharmaceuticals, Inc. for European Patent Application No. 12173456.0 dated Apr. 12, 2013. cited by applicant . Janeway's Immunobioloby, Murphy, Travers, Walport eds, Seventh Edition, 2008 (pp. 266-267). cited by applicant . Janeway's Immunobiology, Murphy, Travers, Walport eds, Seventh Edition, 2008 (pp. 144-155). cited by applicant . Mead G.P. et al., Poster, Detection of Bence Jones myeloma and monitoring of myeloma chemotherapy using immunoassays specific for free immunoglobulin light chains, Clinical Laboratory, 2003, vol. 49, No. 1-2, 2003, p. 25-27. cited by applicant . Roebroek, Anton J. et al., Mutant Lrp1 Knock-In mice generated by recombinase-mediated cassette exchange reveal differential importance of the NPXY motifs in the intracellular domain on LRP1 for normal fetal development, Molecular and Cellular Biology, 2006, vol. 26, No. 2, p. 605-616. cited by applicant . Shmerling, D. et al., Strong and ubiquitous expression of transgenes targeted into the beta-actin locus by Cre/lox cassette replacement, Genesis: The Journal of Genetics and Development, 2005, vol. 42, No. 4, p. 229-235. cited by applicant . Toledo, F, et al., RMCE-ASAP: a gene targeting method for ES and somatic cells to accelerate phenotype analyses, Nucleic Acids Research, 2006, vol. 34 No. 13, pp. e92-1. cited by applicant . Brief Communication regarding EP Application 10186063.3, dated Oct. 24, 2014, 1 page. cited by applicant . Communication of further notices of opposition pursuant to Rule 79(2) EPC, dated Aug. 22, 2014, 1 page. cited by applicant . Correspondence from S. van Doom of Vereenigde to the European Patent Office in response to the communication pursuant to Article 94(3) EPC, European Patent Application No. 09075279.1, Dec. 22, 2011, five pages. cited by applicant . Correspondence from S. van Doom to European Patent Office regarding request to hold application, EP Application No. 09075279.1, Sep. 3, 2013, one page. cited by applicant . Correspondence from S.T. van Doom of V.O. to European Patent Office in response to Communication under Rule 79 (1) EPC, EP Application No. 09075279.1 and Patent. No. 2147594, Apr. 2, 2015, 32 pages. cited by applicant . Correspondence from S.T. van Doom to European Patent Office regarding written submissions in response to the summons to attend oral proceedings dated Mar. 6, 2013, EP Application No. 09075279.1, Apr. 23, 2013, 15 pages. cited by applicant . Correspondence from S.T. van Doom of V.O. to European Patent Office regarding in vivo data, EP Application No. 09075279.1, Jun. 13, 2013, one page. cited by applicant . Correspondence from S.T. van Doom to European Patent Office regarding written submissions filed Apr. 23, 2013, EP Application No. 09075279.1, Apr. 24, 2013, one page. cited by applicant . Correspondence from T.J. Elmore of V.O. to European Patent Office regarding request for extension of time, EP Application No. 09075279.1 and Patent. No. 2147594, Oct. 16, 2014, one page. cited by applicant . Cvetkovic, B., et al., "Appropriate Tissue- and Cell-specific Expression of a Single Copy Human Angiotensinogen Transgene Specifically Targeted Upstream of the Hprt Locus by Homologous Recombination," Journal of Biological Chemistry 275(2):1073-1078, American Society for Biochemistry and Molecular Biology, United States (Jan. 2000 ). cited by applicant . Dammacco F., et al., "Immunoglobulin Secretion by Peripheral Blood and Bone Marrow B Cells in Patients With Multiple Myeloma. Studies by the Reverse Haemolytic Plaque Assay," Clinical & Experimental Immunology 57(3):743-751, Blackwell Scientific Publications, England (Sep. 1984). cited by applicant . David Power of J A Kemp communication to EPO, Executed Acknowledgement, EP Application No. 09075279.1 and EP Patent No. 2147594, Mar. 22, 2016, EPO Form 2936 08.10, one page. cited by applicant . Davies, N.P., et al., "Creation of Mice Expressing Human Antibody Light Chains by Introduction of a Yeast Artificial Chromosome Containing the Core Region of the Human Immunoglobulin Kappa Locus," Biotechnology 11(8):911-914, Nature Publishing Group (Aug. 1993). cited by applicant . De Graaf, M., et al., "Expression of scFvs and scFv Fusion Proteins in Eukaryotic Cells," Antibody Phage Display Methods and Protocals 178:379-387, Methods in Molecular Biology (2002). cited by applicant . De Haard, H.J., et al., "A Large Non-immunized Human Fab Fragment Phage Library That Permits Rapid Isolation and Kinetic Analysis of High Affinity Antibodies," Journal of Biological Chemistry 274(26):18218-18230, American Society for Biochemistry and Molecular Biology, United States (Jun. 1999). cited by applicant . De Kruif, J., et al., "Selection and Application of Human Single Chain Fv Antibody Fragments from a Semi-Synthetic Phage Antibody Display Library with Designed CDR3 Regions," Journal of Molecular Biology 248(1):97-105, Elsevier, England (Apr. 1995). cited by applicant . Decl. Andrew Murphy in the Matter of Australian Patent Application No. 2009263082 (the Opposed Application) in the name of Merus B.v. (the Applicant)--and--Opposition thereto by RegeneronPharmaceuticals, Inc. (the Opponent, Dated Dec. 19, 2014, 18 pages. cited by applicant . Declaration of Prof. Ton Logtenberg, CEO, Merus B.V., European Patent No. EP 2 314 629 B1, May 4, 2016, seven pages. cited by applicant . Deed of Conversion and Amendment of the Articles of Association for Merus BV (new name: Merus N.V.), May 19, 2016, 27 pages. cited by applicant . Deficiencies in application documents dated Jul. 20, 2012, EP12175544.1. cited by applicant . Description dated Jul. 9, 2012, EP12175544. cited by applicant . Designation of Inventor Bout Abraham, User Reference No. P61090EP20, at least as early as Oct. 1, 2010, 1 page. cited by applicant . Designation of Inventor Brus Ronald Hendrik Peter, User Reference No. P61090EP20, at least as early as Oct. 1, 2010, 1 page. cited by applicant . Designation of inventor Erwin Houtzager dated Jul. 9, 2012, EP12175544. cited by applicant . Designation of Inventor Logtenberg Ton, User Reference No. P61090EP20, at least as early as Oct. 1, 2010, 1 page. cited by applicant . Designation of inventor Mark Throsby dated Jul. 9, 2012, User Reference: P85261EP10, EP12175544. cited by applicant . Designation of inventor Pinto Rui Daniel dated Jul. 9, 2012, User Reference P85261EP10, EP12175544. cited by applicant . Designation of inventor Ton Logtenberg dated Jul. 9, 2012, User Reference: P85261EP10, EP12175544. cited by applicant . Designation of Inventor Van Berkel Patricius Hendrikus, User Reference No. P61090EP20, at least as early as Oct. 1, 2010, 1 page. cited by applicant . Desmet J., et al., "Computation of the Binding of Fully Flexible Peptides to Proteins With Flexible Side Chains," The FASEB Journal 11(2):164-172, The Federation, United States (Feb. 1997). cited by applicant . Desmet J., et al., "The Dead-end Elimination Theorem and Its Use in Protein Side-chain Positioning," Nature 356(6369):539-542, Nature Publishing Group, England (Apr. 1992). cited by applicant . Dietzschold, B., et al., "Delineation of Putative Mechanisms Involved in Antibody-Mediated Clearance of Rabies Virus From the Central Nervous System," Proceedings of the National Academy of Sciences of the United States of America 89(15):7252-7256, National Academy of Sciences, United States (Aug. 1992). cited by applicant . Dinnyes et al., "Somatic Cell Nuclear Transfer: Recent Progress and Challenges", Cloning and Stem Cells, vol. 4, No. 1, 2002, pp. 81-90. cited by applicant . Documents titled Oppostion to Merus B.V.'s EP 2 314 629 B1 Consolidated List of Documents filed by All Parties, listing of US patents and applications, foreign patents and non-patent literature, at least as early as Jun. 6, 2016, 1 page, (all documents on the Consolidated List have been or are being submitted on Information Disclosure Statements in the currently pending U.S. Patent Application). cited by applicant . Drawings, at least as early as Oct. 1, 2010, 33 pages. cited by applicant . Drawings continued dated Jul. 9, 2012, EP12175544. cited by applicant . Drawings dated Aug. 20, 2012, EP12175544.1. cited by applicant . Drew Murphy Statement dated Sep. 8, 2015, (5 page). cited by applicant . ECACC deposit, Deposit Ref. 96022940 dated Feb. 29, 1996. cited by applicant . ECACC deposit, Deposit Reference 03041601 dated Apr. 16, 2003. cited by applicant . Eggan, K., et al., "Hybrid Vigor, Fetal Overgrowth, and Viability of Mice Derived by Nuclear Cloning and Tetraploid Embryo Complementation," Proceedings of the National Academy of Sciences of the United States of America 98(11):6209-6214, National Academy of Sciences, United States (May 2001). cited by applicant . Eigenbrot, C., et al., "X-ray Structures of the Antigen-binding Domains From Three Variants of Humanized Anti-p185her2 Antibody 4d5 and Comparison With Molecular Modeling," Journal of Molecular Biology 229(4):969-995, Elsevier, England (Feb. 1993). cited by applicant . English translation of Deed of Conversion and Amendment of the Articles of Association for Merus BV (new name: Merus N.V.), May 19, 2016, 26 pages. cited by applicant . EP Acknowledgement of Receipt for EP Application No. 10186063.3, Sep. 6, 2013, 1 page. cited by applicant . EP Acknowledgement of Receipt for Request for Grant of EP Application No. 10186063.3, Oct. 1, 2010, 2 pages. cited by applicant . EPO Acknowledgement of receipt for EP Application 10186063.3, dated Jun. 6, 2016, 2 pages. cited by applicant . EPO Acknowledgement of receipt for EP Application 10186063.3, dated May 20, 2016, 2 pages. cited by applicant . EPO Acknowledgement of receipt for EP Application 10186063.3, dated Nov. 27, 2015, 1 page. cited by applicant . EPO Acknowledgement of receipt for EP Application 10186063.3 regarding submission in opposition proceedings, lated Nov. 27, 2015, 2 pages. cited by applicant . EPO Application No. 10186063.3, dated Jun. 6, 2016, Letter accompanying subsequently filed items, including the following: 1) comments on patentees subs., 2) consolidated document list, 3) Phelps, 4)Fussenegger, 5) Tada, and 6) Verma (non-patent literature documents previously submitted individually). cited by applicant . EPO Application No. 10186063.3, dated Jun. 6, 2016, Letter accompanying subsequently filed items, including the following: 1) Final Written Submissions for Oral Proceedings Scheduled for Jun. 22, 2016; 2) Huls; 3) Jones; 3) U.S. Pat. No. 9,248,182; 3) PCT Publication WO 02/18948 A2 ; PCT Publication WO 00/63403 ; (US Patent, PCT Publications and Non-patent literature documents previously submitted individually). cited by applicant . EPO Brief Communication regarding EP Application 10186063.3, dated Feb. 27, 2015, 1 page. cited by applicant . EPO Brief Communication regarding EP Application 10186063.3, dated Jan. 12, 2016, 1 page. cited by applicant . EPO Brief Communication regarding EP Application 10186063.3, dated Jun. 7, 2016, 1 page. cited by applicant . EPO Brief Communication regarding the Opposition against EP Application 10186063.3, dated Jun. 13, 2016 regarding Oral proceedings on Jun. 22, 2016, 1 page. cited by applicant . EPO Brief Communication regarding the Opposition against EP Application 10186063.3, dated Jun. 21, 2016 regarding Oral proceedings on Jun. 22, 2016, 1 page. cited by applicant . EPO Brief Communication regarding the Opposition against EP Application 10186063.3, dated May 31, 2016 regarding Oral proceedings on Jun. 22, 2016. cited by applicant . EPO Communication of amended entries concerning the representative, regarding EP Application 10186063.3, dated Jan. 12, 2016, 1 page. cited by applicant . EPO Communication, Payment of fees and expenses, EP Application No. 09075279.1, May 30, 2016, EPO Form 1010 03.15, one page. cited by applicant . EPO Communication regarding EP Application 10186063.3, dated Jun. 7, 2016, 3 page. cited by applicant . EPO Summons to attend oral proceedings pursuant to Rule 115(1) EPC, dated Nov. 19, 2015. cited by applicant . Kruif, D.J., et al., "Human Immunoglobulin Repertoires Against Tetanus Toxoid Contain a Large and Diverse Fraction of High-affinity Promiscuous V(H) Genes," Journal of Molecular Biology 387(3):548-558, Elsevier, England (Apr. 2009). cited by applicant . Kruif, J.D., et al., "Rapid Selection of Cell Subpopulation-Specific Human Monoclonal Antibodies from a Synthetic Phage Antibody Library," Proceedings of the National Academy of Sciences 92(9):3938-3942, National Academy of Sciences, United States (Apr. 1995). cited by applicant . McCafferty, et al., Antibody Engineering: A Practical Approach (Practical Approach Series), vol. 169, Irl Press (1996). cited by applicant . Nemazee, D.,, "Receptor Editing in B Cells," Advances in immunology 74:89-126, Academic Press, United States (2000). cited by applicant . Office Action dated Aug. 27, 2014, in U.S. Appl. No. 12/932,719 Hendrikus Van Berkel. et al., filed Mar. 4, 2011, 20 pages. cited by applicant . Office Action dated Mar. 11, 2014, in U.S. Appl. No. 12/932,719 Hendrikus Van Berkel. et al., filed Mar. 4, 2011, 14 pages. cited by applicant . Office Action dated May 2, 2012, in U.S. Appl. No. 12/932,719 Hendrikus Van Berkel. et al., filed Mar. 4, 2011, 11 pages. cited by applicant . Office Action dated May 5, 2015, in U.S. Appl. No. 12/932,719 Hendrikus Van Berkel. et al., filed Mar. 4, 2011, 15 pages. cited by applicant . Office Action dated May 9, 2013, in U.S. Appl. No. 12/932,719 Hendrikus Van Berkel. et al., filed Mar. 4, 2011, 11 pages. cited by applicant . Office Action dated Sep. 27, 2011, in U.S. Appl. No. 12/932,719 Hendrikus Van Berkel. et al., filed Mar. 4, 2011, 7 pages. cited by applicant . Office Action dated Aug. 21, 2017, in U.S. Appl. No. 15/090,505 Hendrikus Van Berkel. et al.,filed Apr. 4, 2016, 17 pages. cited by applicant . Office Action dated May 1, 2018, in United States Patent Application No. 15/090,505 Hendrikus Van Berkel. et al.,filed Apr. 4, 2016, 17 pages. cited by applicant . Office Action dated Feb. 15, 2018, in U.S. Appl. No. 15/855,258 Hendrikus Van Berkel. et al.,filed Dec. 27, 2017 19 pages. cited by applicant . US. Appl. No. 15/140,321, Method for Selecting a Single Cell Expressing a hetergeneous combination of antibodies, filed Apr. 27, 2016. cited by applicant . Beaudette-Zlatanova, B.C., et al., "B Cells and Dendritic Cells from VK8 Light Chain Transgenic Mice Activate MRL-lpr/gld CD4+ T Cells," J. Immunol 177:45-52, American Association of Immunologists, United States (2006). cited by applicant . Marvin, J.S., et al., Acta Pharmacologica Sinica, 16(6): 649-658, 2005. cited by examiner . Ngo, T.-H., et al, FEBS Letters, 416: 373-376, 1997. cited by examiner . Lang, A.B. et al, Journal of Immunology, 151(13): 466-472, 1993. cited by examiner . Huls, G., et al. Cancer Research, 59: 5778-5784, 1999. cited by examiner . Roholt et al, Antibodies of Limited Heterogeneity: L. Chains of a Single Mobility, Immunochemistry, Pergamon Press, 1970, vol. 7, pp. 329-340. cited by applicant . Morimoto et al., Abstract, High level expression of a human rabies virus-neutralizing monoclonal antibody by a rhabdovirus-based vector, J. Immunol. Methods, Jun. 2001, pp. 199-206, vol. 1, No. 252(1-2). cited by applicant . Arai et al., Abstract, Antibody responses induced by immunization with a Japanese rabies vaccine determined by neutralization test and enzyme-linked immunosorbert assay, Vaccine, Jun. 2002, pp. 2448-2453, vol. 7, No. 20(19-20). cited by applicant . Perrin et al., Abstract, In vitro rabies vaccine potency appraisal by ELISA: advant of the immunocapture method with a neutralizing anti-glycoprotein monoclonal antibody, Biologicals, Oct. 1990, pp. 321-330, vol. 18(4). cited by applicant . Boel et al., Functional human monoclonal antibodies of all isotypes constructed from phage display library-derived single-chain Fv antibody fragments, Journal of Immunological Methods, 2000, pp. 153-166, vol. 239. cited by applicant . Burioni et al., Nonneutralizing Human Antibody Fragments against Hepatitis C Virus E2 Glycoprotein Modulate Neutralization of Binding Activity of Human Recombinant Fabs, Abstract, Virology, Sep. 2001, pp. 29-35, vol. 288, No. 1. cited by applicant . Champion et al., Abstract, The development of monoclonal human rabies virus-neutralizing antibodies as a substitute for pooled human immune globulin in the prophylactic treatment of rabies virus exposure, Abstract, Journal of Immunological Methods, Feb. 2000, pp. 81-90, vol. 235, No. 1-2, Elsevier Science Publishers B.V., Amsterdam, NL. cited by applicant . Chen et al., Abstract, Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen, Journal of Molecular Biology, Nov. 5, 1999, pp. 865-881, vol. 293, No. 4. cited by applicant . De Kruif et al., Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library, Proc. Natl. Acad. Sci., USA, Apr. 1995, pp. 3938-3942, vol. 92. cited by applicant . Figini et al., In Vitro Assembly of Repertoires of Antibody Chains on the Surface of Phage by Renaturation, Journal of Molecular Biology, 1994, pp. 68-78, vol. 239. cited by applicant . Franconi et al., Functional expression in bacteria and plants of an scFv antibody fragment against tospoviruses, Immunotechnology, 1999, pp. 189-201, vol. 4. cited by applicant . French, et al., Cancer Research, 1991, pp. 2353-2361, vol. 51. cited by applicant . Friedenson et al., Immunoglobulin G Antibodies from an Individual Rabbit in Which Several Heavy Chain Variants Are Paired with One Light Chain Sequence, The Journal of Biological Chemistry, 1973, pp. 7073-7079, vol. 248, No. 20. cited by applicant . Holliger et al., "Diabodies": Small bivalent and bispecific antibody fragments, Proc. Natl. Acad. Sci., Jul. 1993, pp. 6444-6448, vol. 90. cited by applicant . Hoogenboom et al., Antibody phage display technology and its applications, Immunotechnology, 1998, pp. 1-20, vol. 4. cited by applicant . Huse et al., Purification of antibodies by affinity chromatography, Journal of Biochemical and Biophysical Methods, 2002, pp. 217-231, vol. 51. cited by applicant . Kang et al., Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces, Proc. Natl. Acad. Sci., May 1991, pp. 4363-4366, vol. 88. cited by applicant . Kortt et al., Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting, Biomol. Eng., Oct. 15, 2001, pp. 95-108, vol. 18, No. 3. cited by applicant . Krebs et al., High-throughput generation and engineering of recombinant human antibodies, Journal of Immunological Methods, 2001, pp. 67-84, vol. 254. cited by applicant . Kwaks et al., Identification of anti-repressor elements that confer high and stable protein production in mammalian cells, Nature Biotechnology, 2003, pp. 553-558, vol. 21. cited by applicant . Lekkerkerker, Phage antibodies against human dendritic cell subpopulations obtained by flow cytometry-based selection on freshly isolated cells, Journal of Immunological Methods, 1999, pp. 53-63, vol. 231. cited by applicant . Lindhofer et al., Preferential Species-Restricted Heavy/Light Chain Pairing in Rat/Mouse Quadromas, 1995, pp. 219-225, vol. 155. cited by applicant . Lu et al., Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy, Abstract, International Journal of Cancer, Jan. 20, 2002, pp. 393-399, vol. 97, No. 3. cited by applicant . Merchant et al., An efficient route to human bispecific IgG, Nature Biotechnology, Jul. 1998, pp. 677-681, vol. 16. cited by applicant . Morrison, Sherie L., Transfectomas Provide Novel Chimeric Antibodies, Science, Sep. 20, 1985, pp. 1202-1207, vol. 229. cited by applicant . Norderhaug et al., Balanced expression of single subunits in a multisubunit proteins, achieved by cell fusion of individual transfectants, European Journal of Biochemistry, 2002, pp. 3205-10, vol. 269. cited by applicant . Office Action for U.S. Appl. No. 11/490,545 dated Jul. 30, 2008. cited by applicant . Office Action for U.S. Appl. No. 11/490,545 dated Jan. 13, 2010. cited by applicant . Office Action for U.S. Appl. No. 11/490,545 dated Mar. 25, 2008. cited by applicant . Office Action for U.S. Appl. No. 11/490,545 dated May 29, 2009. cited by applicant . Pau et al, The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines, Vaccine, 2001, pp. 2716-2712, vol. 19. cited by applicant . PCT International Preliminary Examination Report, PCT/EP03/07690, dated Nov. 11, 2004. cited by applicant . PCT International Search Report, PCT/EP03/07690, dated Apr. 16, 2004. cited by applicant . PCT International Search Report, PCT/NL2004/000386 dated Nov. 23, 2004. cited by applicant . PCT International Search Report, PCT/NL2005/000036, dated Jan. 19, 2005. cited by applicant . Sidhu et al., Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions, Abstract, Journal of Molecular Biology, Apr. 23, 2004, pp. 299-310, vol. 338, No. 2. cited by applicant . Sugita, et al., Int. J. Cancer, 1986, pp. 351-357, vol. 37. cited by applicant . Vaughan et al., Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library, Nature Biotechnology, Mar. 1996, pp. 309-314, vol. 14. cited by applicant . Ward et al., Nature, 1989, pp. 544-546, vol. 341. cited by applicant . Warnaar et al., Hybridoma, 1994, pp. 519-526, vol. 13, No. 6. cited by applicant . Conrath et al., Camel Single-domain Antibodies as Modular Building Units in Bispecific and Bivalent Antibody Constructs, The Journal of Biological Chemistry, 2001, pp. 7346-7350, vol. 276, No. 10. cited by applicant . Nguyen et al., Heavy-chain only antibodies derived from dromedary are secreted and displayed by mouse B cells, Immunology, 2003, pp. 93-101, vol. 109. cited by applicant . Tanaka et al., De novo production of diverse intracellular antibody libraries, Nucleic Acids Research, 2003, e23, pp. 1-10, vol. 31, No. 5. cited by applicant . Lenz, et al.; Expression of heterobispecific antibodies by genes transfected into producer hybridoma cells,Gene; 87 Mar. 15, 1990, No. 2; pp. 213-218. cited by applicant . Muyldermans, Reviews in Molecular Biotechnology, 2001, pp. 277-302, vol. 72. cited by applicant . Schmitz et al., Phage Display: A Molecular Tool for the Generation of Antibodies--A Review, Placenta, 2000, pp. S106-S112, Supplement A, Trophoblast Research, vol. 14. cited by applicant . Friedenson, Bernard et al., "Immunoglobulin G Antibodies from an Individual Rabbit in Which Several Heavy Chain Variants are Paired with One Light Chain Sequence," The Journal of Biological Chemistry, Oct. 25, 1973, pp. 7073-7079, vol. 248, No. 20. cited by applicant . Notice of Allowance for U.S. Appl. No. 11/490,545, dated Jun. 15, 2012. cited by applicant . Flavell et al., Systemic Therapy with 3BIT, a Triple Combination Cocktail of Anti--CD19, -CD22, and -CD38--Saporin Immunotoxins, Is Curative of Human B-Cell Lymphoma in Severe Combined Immunodeficient Mice, Cancer Research, Nov. 1997, pp. 4824-4829, vol. 57. cited by applicant . Rojas et al. Phage antibody fragments library combining a single human light chain variable region with immune mouse heavy chain variable regions, Journal of Biotechnology. 2002, pp. 287-298, vol. 94. cited by applicant . European Search Report for European patent application No. 10189886.4 dated Nov. 20, 2012. cited by applicant . Logtenberg, Ton, Antibody cocktails: Next-Generation Biopharmaceuticals with Improved Potency, Trends in Biotechnology, 2007, pp. 390-394, vol. 25, No. 9, Science Direct. cited by applicant . Skerra, Arne, `Anticalins`: A New Class of Engineered Ligand-Binding Proteins with Antibody-Like Properties, 2001, Reviews in Molecular Biotechnology, pp. 257-275, vol. 74, Elsevier. cited by applicant . Communication from copending European patent application No. 05704566.8 dated Jun. 6, 2013. cited by applicant. |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.